{ "meta": { "name": "LifeDB", "name_zh": "生命科学知识引擎", "domain": "life.genetech.tools", "description": "Life science knowledge base covering synthetic biology, longevity tech, cell therapy, bioinformatics, and biomanufacturing", "updated": "2026-06-29T04:15:30.963Z", "total_entities": 622, "categories": [ "synthetic_biology", "longevity", "cell_therapy", "bioinformatics", "biomanufacturing", "synbio", "longevity_tech", "biotech_tools", "regenerative_medicine", "bioethics" ], "related_sites": [ { "domain": "genetech.tools", "name": "GeneTech", "relation": "Gene editing enables synthetic biology", "url": "https://genetech.tools" }, { "domain": "tcm.genetech.tools", "name": "TCMDB", "relation": "Natural compounds in synthetic biology", "url": "https://tcm.genetech.tools" }, { "domain": "energy.genetech.tools", "name": "EnergyDB", "relation": "Biofuels and bioenergy", "url": "https://energy.genetech.tools" }, { "domain": "biocompute.genetech.tools", "name": "BioComputeDB", "relation": "Synthetic biology gene circuits for biocomputing", "url": "https://biocompute.genetech.tools" } ] }, "data": { "synthetic_biology": [ { "id": "SB-001", "name": "CRISPR-Cas9", "type": "基因编辑", "applications": [ "基因治疗", "作物改良", "基因驱动" ], "companies": [ "Editas", "CRISPR Therapeutics", "Intellia" ], "maturity": "临床阶段/已上市(Casgevy)", "description": "第三代基因编辑工具，2020年诺贝尔奖，Casgevy成为首个FDA批准CRISPR疗法", "trend": "2025年7款FDA批准CAR-T/基因编辑产品；递送系统(LNP)持续改进" }, { "id": "SB-002", "name": "碱基编辑Base Editing", "type": "基因编辑", "applications": [ "遗传病治疗", "心血管风险降低" ], "companies": [ "Beam Therapeutics", "Verve Therapeutics" ], "maturity": "临床阶段", "description": "精确单碱基替换(C→T/A→G)，无需双链断裂，脱靶效应极低", "trend": "Verve碱基编辑降胆固醇进入临床；Beam多款管线推进" }, { "id": "SB-003", "name": "先导编辑Prime Editing", "type": "基因编辑", "applications": [ "复杂突变修复", "精准基因校正" ], "companies": [ "Prime Medicine" ], "maturity": "临床前/临床早期", "description": "搜索-替换式编辑，可做任意小编辑(替换/插入/删除)，无需供体DNA", "trend": "效率持续提升；Prime Medicine多管线进入临床" }, { "id": "SB-004", "name": "mRNA疗法", "type": "核酸药物", "applications": [ "疫苗", "蛋白替代", "癌症", "罕见病" ], "companies": [ "Moderna", "BioNTech", "CureVac" ], "maturity": "已上市(疫苗)/临床(其他)", "description": "mRNA编码治疗性蛋白，LNP递送，COVID疫苗验证平台", "trend": "RSV疫苗/流感疫苗/个性化癌症疫苗推进；LNP肝外递送突破" }, { "id": "SB-005", "name": "CRISPR基因驱动", "type": "基因编辑应用", "applications": [ "疟疾防控", "入侵物种控制", "农业害虫" ], "companies": [ "Target Malaria", "UC San Diego" ], "maturity": "实验室/受限田间试验", "description": "自传播基因修饰，可在野生种群中扩散，实验室蚊子种群减少90%+", "trend": "2025年基因驱动研究取得重要进展；监管和伦理争议显著；布基纳法索首次受限田间研究" }, { "id": "SB-006", "name": "无细胞蛋白合成CFPS", "type": "生物制造", "applications": [ "药物蛋白", "有毒蛋白", "快速原型" ], "companies": [ "Sutro Biopharma", "Tierra Biosciences" ], "maturity": "商用", "description": "无活细胞条件下合成蛋白，24小时设计到蛋白，Sutro卵巢癌药luvelta进入III期", "trend": "快速原型周期是核心优势；与AI蛋白设计结合" }, { "id": "SB-007", "name": "最小合成细胞", "type": "合成生物体", "applications": [ "定制微生物", "基础生物学研究" ], "companies": [ "J. Craig Venter Institute" ], "maturity": "实验室里程碑", "description": "JCVI-syn3.0仅473基因的最小基因组细菌，定义了细胞生命最小基因集", "trend": "syn3A(493基因)修正版2021年发表；定制合成生物体基础" }, { "id": "SB-008", "name": "Xenobots/Anthrobots", "type": "活体机器人", "applications": [ "药物递送", "组织修复", "环境清理" ], "companies": [ "Tufts University", "UVM" ], "maturity": "实验室", "description": "青蛙(Xenobots)或人类(Anthrobots)细胞自组装活体机器人，可运动/愈合/载物", "trend": "Xenobot 3.0可自我复制；Anthrobots可修复受损神经组织" }, { "id": "SB-009", "name": "精密发酵Precision Fermentation", "type": "食品/生物制造", "applications": [ "无动物乳蛋白", "特殊脂肪", "食品原料" ], "companies": [ "Perfect Day", "Motif FoodWorks", "Geltor", "EVERY Company" ], "maturity": "商用", "description": "工程微生物生产与动物源完全相同的食品蛋白/脂肪", "trend": "Perfect Day无动物乳清蛋白2020年上市；成本持续下降" }, { "id": "SB-010", "name": "DNA数据存储", "type": "信息技术", "applications": [ "长期归档存储", "高密度数据存储" ], "companies": [ "Microsoft/UW MISL", "Catalog", "Iridia" ], "maturity": "概念验证", "description": "数字数据编码入合成DNA，理论密度215PB/克", "trend": "Microsoft 2019年存储200MB；Iridia开发芯片级DNA写入器；读写速度是瓶颈" }, { "id": "SB-011", "name": "工程活体材料ELM", "type": "材料科学", "applications": [ "自修复混凝土", "活体传感器", "智能材料" ], "companies": [ "MIT Lu Lab", "Wyss Institute", "Basilisk" ], "maturity": "研究/部分商用", "description": "活细胞制成的材料，可生长/自修复/响应环境", "trend": "Basilisk自修复混凝土减少80%裂缝；活体传感器开发中" }, { "id": "SB-012", "name": "代谢工程/气体发酵", "type": "工业生物技术", "applications": [ "生物燃料", "生物化学品", "碳回收" ], "companies": [ "LanzaTech", "Ginkgo Bioworks", "Genomatica" ], "maturity": "商用", "description": "工程微生物从糖或CO₂生产化学品/燃料/材料，替代石油路线", "trend": "LanzaTech中国钢厂废气制乙醇运营中；Genomatica生物BDO规模化生产" }, { "id": "SB-013", "name": "AI设计酶/蛋白", "type": "计算生物设计", "applications": [ "新酶设计", "药物蛋白优化", "工业催化剂" ], "companies": [ "Arzeda", "Cyrus Biotechnology", "Absci" ], "maturity": "商用初期", "description": "AI/ML驱动的蛋白质从头设计，创造自然界不存在的功能蛋白", "trend": "SynBioBeta 2026聚焦AI设计酶和蛋白；蛋白质设计语言模型快速发展" }, { "id": "SB-014", "name": "可编程RNA药物", "type": "核酸药物", "applications": [ "遗传病", "癌症", "传染病" ], "companies": [ "AstraZeneca", "Moderna", "多个初创" ], "maturity": "临床阶段", "description": "可编程RNA平台，快速设计针对不同靶点的RNA疗法", "trend": "SynBioBeta 2026展示可编程RNA药物初创；AI+RNA设计结合" }, { "id": "SB-015", "name": "虚拟细胞模型", "type": "计算生物学", "applications": [ "药物筛选", "疾病建模", "生物学预测" ], "companies": [ "多个AI生物初创" ], "maturity": "研究/早期开发", "description": "AI驱动的完整细胞计算模型，可模拟细胞行为和药物反应", "trend": "2025-2026年AI增强生物科学热点；减少实验试错成本" }, { "id": "SB-016", "name": "合成生物学市场平台", "type": "基础设施", "applications": [ "生物铸造厂", "自动化实验", "设计-构建-测试-学习" ], "companies": [ "Ginkgo Bioworks", "Twist Bioscience", "Synthego" ], "maturity": "商用", "description": "自动化生物铸造厂和DNA合成平台，降低合成生物学开发门槛", "trend": "2026年合成生物学市场$26.87Bn，预计2033年$112.51Bn(CAGR 22.7%)" }, { "id": "SB-017", "name": "生物传感器/诊断", "type": "检测技术", "applications": [ "环境监测", "疾病诊断", "食品安全" ], "companies": [ "Synlogic", "Zymergen(Ginkgo)" ], "maturity": "临床/商用", "description": "工程微生物作为活体传感器，检测和报告特定分子", "trend": "Synlogic工程益生菌进入临床；与可穿戴设备结合" }, { "id": "SB-018", "name": "合成基因组学", "type": "基因组工程", "applications": [ "合成染色体", "基因组最小化", "密码子重编码" ], "companies": [ "Synthego", "Ginkgo Bioworks" ], "maturity": "研究", "description": "从头合成完整基因组或染色体，Sc2.0项目合成酵母基因组", "trend": "Sc2.0合成酵母染色体项目持续进展；密码子重编码创造抗病毒细胞" }, { "id": "SB-019", "name": "生物计算/生物电路", "type": "生物信息处理", "applications": [ "智能疗法", "条件性药物释放", "生物逻辑门" ], "companies": [ "多个学术实验室" ], "maturity": "研究", "description": "在细胞内构建基因电路/逻辑门，实现可编程生物行为", "trend": "智能CAR-T(条件激活)应用；合成生物学与计算科学交叉" }, { "id": "SB-020", "name": "替代蛋白/细胞培养肉", "type": "食品科技", "applications": [ "培养肉", "植物蛋白", "发酵蛋白" ], "companies": [ "Upside Foods", "GOOD Meat", "Beyond Meat", "Impossible Foods" ], "maturity": "商用初期", "description": "细胞培养或植物基替代传统动物蛋白，减少环境影响", "trend": "美国/新加坡批准培养肉销售；成本下降但规模化挑战大" }, { "id": "SB-021", "name": "生物固碳/碳利用", "type": "气候技术", "applications": [ "CO₂转化", "生物燃料", "生物材料" ], "companies": [ "LanzaTech", "Novomer", "Zymergen" ], "maturity": "示范/商用", "description": "工程微生物将CO₂转化为有价值产品，碳负排放路径", "trend": "与碳捕集(DAC)结合；LanzaTech气体发酵平台商业化" }, { "id": "SB-022", "name": "合成生物学监管框架", "type": "政策/伦理", "applications": [ "安全评估", "生物安全", "公众接受" ], "companies": [ "WHO", "各国监管机构" ], "maturity": "持续演进", "description": "合成生物学产品的安全评估和监管框架，平衡创新与风险", "trend": "2025年DNA合成筛查指南更新；生物安全与开放科学持续博弈" }, { "id": "SB-023", "name": "无糖甜蛋白", "type": "食品科技", "applications": [ "代糖", "食品饮料", "健康" ], "companies": [ "多个SynBioBeta 2026展示初创" ], "maturity": "开发中", "description": "AI设计的蛋白质替代糖，提供甜味但零热量", "trend": "SynBioBeta 2026重点展示方向；健康饮食趋势驱动" }, { "id": "SB-024", "name": "工程噬菌体疗法", "type": "抗菌治疗", "applications": [ "超级细菌感染", "农业", "食品防腐" ], "companies": [ "Adaptive Phage Therapeutics", "PhagoMed", "Locus Biosciences" ], "maturity": "临床阶段", "description": "工程化噬菌体精准杀灭耐药细菌，应对AMR危机", "trend": "AMR全球威胁加剧；CRISPR-Cas13武装噬菌体增强杀伤力" }, { "id": "SB-025", "name": "合成生物学与AI融合", "type": "跨领域融合", "applications": [ "全流程AI设计", "自动化DBTL循环", "预测性生物学" ], "companies": [ "Ginkgo Bioworks", "Recursion", "Insilico Medicine" ], "maturity": "快速崛起", "description": "AI+合成生物学深度融合，从基因设计到实验优化的全流程智能化", "trend": "2025-2026年最热趋势；AI设计→自动化实验→数据反馈闭环" }, { "id": "SB-026", "name": "Chai-2抗体设计AI", "type": "AI+蛋白质设计", "applications": [ "抗体工程", "药物发现" ], "companies": [ "Chai Discovery" ], "maturity": "快速崛起", "description": "2025年7月Chai-2实现从头设计抗体16%成功率，Stanford SETR 2026报告重点提及", "trend": "AI抗体设计变革药物发现流程；从筛选到设计的范式转变", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://setr.stanford.edu/sites/default/files/2026-01/SETR2026_02-Biotech_web-260109.pdf", "collected_at": "2026-05-30T13:30:00Z" } ] }, { "id": "SB-027", "name": "通用抗蛇毒血清", "type": "合成生物应用", "applications": [ "抗蛇毒", "热带医学" ], "companies": [ "SynBioBeta社区" ], "maturity": "研究阶段", "description": "合成生物学和抗体工程指向通用抗蛇毒血清，可中和多种蛇毒", "trend": "SynBioBeta 2026重点议题；从物种特异性到广谱抗毒", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.syntheticbiologysummit.com/human-health-2", "collected_at": "2026-05-30T13:30:00Z" } ] }, { "id": "SB-028", "name": "iGEM塑料降解生物", "type": "环境生物技术", "applications": [ "塑料降解", "环境修复" ], "companies": [ "iGEM社区" ], "maturity": "研究/原型", "description": "iGEM 2025亮点：工程微生物降解塑料，合成生物学应对塑料污染", "trend": "从实验室到环境应用；PETase/MHETase工程化改进", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.labiotech.eu/in-depth/igem-2025-highlights/", "collected_at": "2026-05-30T13:30:00Z" } ] }, { "id": "SB-029", "name": "AI对齐监管框架", "type": "政策/标准", "applications": [ "生物安全", "AI监管" ], "companies": [ "各国监管机构" ], "maturity": "制定中", "description": "2026年生物技术突破包括AI对齐监管框架、人源化测试模型、下一代生物制造", "trend": "AI+生物安全交叉；DNA合成筛查强制化；双用途研究管控", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://go.zageno.com/blog/whats-new-in-biotech-2026", "collected_at": "2026-05-30T13:30:00Z" } ] }, { "id": "SB-030", "name": "SynbiTECH 2026趋势", "type": "行业趋势", "applications": [ "全行业" ], "companies": [ "SynbiCITE" ], "maturity": "参考", "description": "SynbiTECH 2025揭示2026年合成生物学趋势：工程化、规模化、AI融合", "trend": "从概念验证到工业规模；自动化DBTL循环成为标配", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.synbicite.com/news/2026-trends-in-synthetic-biology", "collected_at": "2026-05-30T13:30:00Z" } ] } ], "longevity": [ { "id": "LG-001", "name": "NAD+补充", "type": "代谢调节", "mechanism": "提升NAD+水平(NMN/NR前体)", "clinical_stage": "II期", "potential": "中等", "description": "补充随年龄下降的关键辅酶NAD+，改善线粒体功能", "trend": "NMN/NR补充剂广泛可用；FDA 2023年挑战NMN作为补充剂地位；Metro Biotech临床推进" }, { "id": "LG-002", "name": "雷帕霉素mTOR抑制", "type": "mTOR抑制", "mechanism": "抑制mTORC1/增加自噬/模拟饮食限制", "clinical_stage": "I期/犬类试验", "potential": "高", "description": "小鼠中延长寿命25%+，即使晚年开始也有效，最可靠的哺乳动物延寿药物", "trend": "犬类长寿试验(RAPID/TRUTH)进行中；AgelessRx人体试验规划；off-label使用增长" }, { "id": "LG-003", "name": "二甲双胍(TAME研究)", "type": "代谢调节", "mechanism": "AMPK激活/抑制线粒体复合体I", "clinical_stage": "III期(TAME)", "potential": "中等", "description": "糖尿病药物，糖尿病患者全因死亡率低于非糖尿病患者，TAME研究旨在证明衰老可被治疗", "trend": "TAME研究$65M+资助，3000+参与者(65-79岁)，结果预计2026-2028年" }, { "id": "LG-004", "name": "表观遗传重编程(Yamanaka因子)", "type": "细胞重编程", "mechanism": "OSKM因子周期性表达重置表观遗传年龄", "clinical_stage": "临床前", "potential": "极高", "description": "部分重编程逆转表观遗传年龄而不去分化，最令人兴奋的 rejuvenation 方案", "trend": "Altos Labs($3B融资)/Turn Bio/Ovelle Therapeutics；小鼠多组织 rejuvenation 已验证" }, { "id": "LG-005", "name": "衰老细胞清除Senolytics", "type": "细胞治疗", "mechanism": "达沙替尼+槲皮素/非瑟酮/Navitoclax诱导衰老细胞凋亡", "clinical_stage": "II期", "potential": "高", "description": "选择性清除随年龄积累的'僵尸'细胞，减少炎症和组织功能障碍", "trend": "Unity Biotechnology UBX1325 II期(年龄相关眼病)；2025年小分子和化合物直接靶向衰老标志物" }, { "id": "LG-006", "name": "端粒延长", "type": "基因组稳定性", "mechanism": "端粒酶基因治疗(AAV-TERT)/TERT mRNA瞬时递送", "clinical_stage": "临床前/早期临床", "potential": "中高", "description": "延长染色体保护帽(端粒)，延缓细胞衰老，短端粒是衰老标志", "trend": "BioViva/Libella Gene Therapeutics哥伦比亚临床试验；无FDA批准疗法" }, { "id": "LG-007", "name": "Klotho蛋白", "type": "循环长寿因子", "mechanism": "调节矿物质代谢/减少氧化应激/增强突触可塑性", "clinical_stage": "临床前", "potential": "高", "description": "随年龄下降的蛋白，额外Klotho小鼠寿命延长20-30%，增强认知", "trend": "UCSF 2023年证明Klotho提升老年猴认知；人体试验规划中" }, { "id": "LG-008", "name": "GLP-1受体激动剂(减肥药抗衰)", "type": "代谢调节", "mechanism": "GLP-1受体激活/减重/抗炎/心血管保护", "clinical_stage": "已上市(糖尿病/肥胖)/探索(抗衰)", "potential": "中高", "description": "司美格鲁肽/替尔泊肽等GLP-1药物，2025年研究显示可能延缓衰老", "trend": "2025年研究显示GLP-1药物可能减缓衰老；心血管/肾脏保护效应超出减重预期" }, { "id": "LG-009", "name": "GDF11/年轻血液因子", "type": "异体共生衍生因子", "mechanism": "Rejuvenates aged stem cells/组织功能", "clinical_stage": "争议中/临床前", "potential": "不确定", "description": "随年龄下降的循环蛋白，异体共生实验暗示可 rejuvenate 心脏/肌肉/大脑", "trend": "部分团队无法重复；Alkahest(现Grifols)开发血浆衍生疗法" }, { "id": "LG-010", "name": "自噬增强剂", "type": "细胞清理", "mechanism": "增强自噬流/清除受损细胞器/蛋白聚集体", "clinical_stage": "临床前/早期临床", "potential": "中高", "description": "增强细胞自噬清除功能，减少与衰老相关的蛋白聚集和细胞器损伤", "trend": "雷帕霉素间接增强自噬；特异性自噬增强剂开发中；与mTOR抑制协同" }, { "id": "LG-011", "name": "线粒体疗法", "type": "细胞器修复", "mechanism": "线粒体替换/线粒体自噬增强/线粒体生物发生", "clinical_stage": "临床前", "potential": "中", "description": "修复随年龄退化的线粒体功能，线粒体DNA突变积累是衰老核心机制", "trend": "线粒体替代疗法(MRT)已批准用于线粒体疾病；抗衰应用探索中" }, { "id": "LG-012", "name": "表观遗传时钟/生物年龄检测", "type": "诊断/监测", "mechanism": "DNA甲基化模式评估生物学年龄", "clinical_stage": "商用", "potential": "高(作为工具)", "description": "通过DNA甲基化模式精确测量生物学年龄，评估抗衰干预效果", "trend": "2026年生物年龄检测将像年度体检一样常规化；Horvath时钟/GrimAge/多个商业检测" }, { "id": "LG-013", "name": "干细胞外泌体疗法", "type": "旁分泌信号", "mechanism": "干细胞外泌体递送再生信号", "clinical_stage": "II期", "potential": "中", "description": "无细胞移植风险的再生方案，外泌体递送修复信号", "trend": "美容应用已商用；心衰/伤口愈合临床试验进行中" }, { "id": "LG-014", "name": "热量限制模拟物", "type": "饮食干预", "mechanism": "模拟热量限制的代谢效应/不减少实际摄入", "clinical_stage": "临床前/早期临床", "potential": "中", "description": "药物/补充剂模拟热量限制延寿效应，无需实际节食", "trend": "雷帕霉素/二甲双胍/NAD+前体均可视为CR模拟物；特异性CR模拟物开发中" }, { "id": "LG-015", "name": "长寿初创公司生态", "type": "产业生态", "mechanism": "N/A", "clinical_stage": "N/A", "potential": "高(推动整体进展)", "description": "2026年9+家抗衰初创公司受关注，覆盖表观遗传重编程/衰老细胞清除/代谢药物", "trend": "2026年长寿科学跨越临床门槛；JPM Week衰老生物技术公司集中展示" }, { "id": "LG-016", "name": "sirtuin激活剂", "type": "代谢调节", "mechanism": "激活SIRT1等去乙酰化酶/模拟热量限制", "clinical_stage": "II期", "potential": "中", "description": "Sirtuin家族蛋白与寿命调控相关，白藜芦醇/NAD+前体间接激活", "trend": "特异性sirtuin激活剂开发中；白藜芦醇人体效果争议" }, { "id": "LG-017", "name": "免疫衰老逆转", "type": "免疫重建", "mechanism": "重建老年免疫系统/胸腺再生/造血干细胞更新", "clinical_stage": "临床前", "potential": "高", "description": "逆转随年龄的免疫功能下降，老年人感染/癌症风险增加的核心原因", "trend": "IL-7胸腺再生/造血干细胞移植；与CAR-T/细胞治疗交叉" }, { "id": "LG-018", "name": "蛋白质稳态修复", "type": "蛋白质量控制", "mechanism": "增强蛋白酶体/分子伴侣/减少蛋白聚集", "clinical_stage": "临床前", "potential": "中", "description": "修复随年龄下降的蛋白质折叠和清除系统，减少毒性蛋白聚集", "trend": "与神经退行性疾病(阿尔茨海默/帕金森)直接相关；分子伴侣疗法开发中" }, { "id": "LG-019", "name": "间充质干细胞MSC疗法", "type": "细胞治疗", "mechanism": "MSC旁分泌/免疫调节/组织修复", "clinical_stage": "II/III期", "potential": "中高", "description": "间充质干细胞抗炎和组织修复，2026年成为长寿标准护理候选", "trend": "ForeverLabs预测2026年MSC疗法成为长寿标准护理；生物年龄检测常规化" }, { "id": "LG-020", "name": "衰老标志物全景监测", "type": "诊断平台", "mechanism": "多标志物整合评估/衰老时钟组合", "clinical_stage": "商用/开发中", "potential": "高(作为工具)", "description": "整合表观遗传时钟/端粒长度/炎症标志物/代谢组学等多维度衰老评估", "trend": "2026年长寿科学跨越临床阈值的关键工具；小分子直接靶向衰老标志物" }, { "id": "LS-izpisua-aging-reversal", "name": "Partial Epigenetic Reprogramming (Izpisua)", "type": "longevity_technology", "company": "Altos Labs", "key_findings": [ "Aging defined as 'loss of identity at cellular level' — epithelial-mesenchymal transition (EMT)", "Blood proteins linked to EMT most strongly associated with mortality in UK Biobank analysis", "Partial cellular reprogramming (2 days/week) extends lifespan in mice", "Reverses liver and metabolic damage, regenerates damaged muscle", "7000+ mice treated with no embryonic cell differentiation observed", "Ex vivo reprogramming of donated human organs planned with Hospital Clínic de Barcelona" ], "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://english.elpais.com/science-tech/2026-05-25/longevity-researcher-juan-carlos-izpisua-presents-latest-data-on-aging-process.html", "collected_at": "2026-05-29T14:23:31.089Z" } ] }, { "id": "LS-universal-aging-clocks", "name": "Universal Transcriptomic Aging Clocks", "type": "longevity_technology", "company": "Harvard Medical School / Brigham and Women's Hospital", "key_findings": [ "Analyzed 11,000+ transcriptomes across mice, rats, monkeys, and humans", "Biological hallmarks of aging highly conserved across species and tissues", "Same genes associated with aging in liver and heart across rats and humans", "TACO (Transcriptomic Age Calculator Online) tool developed for age prediction", "Published in Nature May 2026" ], "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.scientificamerican.com/article/universal-aging-clocks-offer-new-clues-to-longevity/", "collected_at": "2026-05-29T14:23:31.089Z" } ] }, { "id": "LS-life-bio-epigenetic-reprogramming", "name": "Life Biosciences Partial Epigenetic Reprogramming", "type": "longevity_technology", "company": "Life Biosciences", "key_findings": [ "Preclinical data shows cross-system therapeutic impact of partial epigenetic reprogramming", "Human trials planned for 2026 for gene therapy to reverse cellular aging", "Boston-based company targeting tissue function restoration" ], "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://observer.com/2025/10/this-longevity-startup-is-bringing-anti-aging-gene-therapy-to-human-trials/", "collected_at": "2026-05-29T14:23:31.089Z" } ] }, { "id": "LG-021", "name": "2026长寿初创公司9强", "type": "产业生态", "mechanism": "N/A", "clinical_stage": "N/A", "potential": "高(推动整体进展)", "description": "2026年9家最受关注的抗衰长寿初创公司，覆盖表观遗传重编程/衰老细胞清除/代谢药物重定位", "trend": "长寿赛道从概念验证走向临床验证；资本持续涌入", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://wewillcure.com/insights/company-profiles/anti-aging-and-longevity-startups-to-watch", "collected_at": "2026-05-30T13:30:00Z" } ] }, { "id": "LG-022", "name": "2025十大长寿突破", "type": "年度回顾", "mechanism": "N/A", "clinical_stage": "N/A", "potential": "高", "description": "2025年十大长寿抗衰突破：代谢药物重定位抗衰、GLP-1抗衰效应、衰老标志物直接靶向", "trend": "从单一靶点到多靶点联合干预；小分子直接靶向衰老标志物", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.gethealthspan.com/research/article/top-ten-longevity-anti-aging-breakthroughs-of-2025", "collected_at": "2026-05-30T13:30:00Z" } ] }, { "id": "LG-023", "name": "表观遗传时钟革新", "type": "诊断/监测", "mechanism": "DNA甲基化模式→生物学年龄", "clinical_stage": "商用扩张", "potential": "高(核心工具)", "description": "2026年表观遗传时钟重新定义衰老测量：生日≠身体实际年龄，DNA甲基化模式精确评估", "trend": "GrimAge/PhenoAge/多种商业时钟；抗衰临床试验必备终点指标", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.longevityvisa.com/2026longevitybreakthroughs", "collected_at": "2026-05-30T13:30:00Z" } ] }, { "id": "LG-024", "name": "Aging Pharma衰老制药", "type": "产业生态", "mechanism": "N/A", "clinical_stage": "N/A", "potential": "高", "description": "Aging Pharma等新公司专注衰老药物开发，开辟化妆品创新新纪元", "trend": "衰老从'自然过程'到'可治疗疾病'的范式转变；监管路径逐步明确", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://agingpharma.org", "collected_at": "2026-05-30T13:30:00Z" } ] }, { "id": "LG-025", "name": "2025长寿研究时间线", "type": "年度回顾", "mechanism": "N/A", "clinical_stage": "N/A", "potential": "高", "description": "2025年长寿研究突破时间线：衰老可被测量、减缓、甚至逆转，提供真正希望", "trend": "从基础研究到临床转化的加速期；多款抗衰药物进入临床", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.timeline.com/blog/2025-breakthroughs-in-longevity-research", "collected_at": "2026-05-30T13:30:00Z" } ] }, { "id": "LG-026", "name": "2026长寿初创公司9强", "type": "行业趋势", "mechanism": "N/A", "clinical_stage": "N/A", "potential": "高", "description": "2026年9家最值得关注抗衰老/长寿初创公司：表观遗传重编程、细胞再生、代谢干预等多路线", "trend": "长寿初创从概念验证到临床转化加速；投资持续增长", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://wewillcure.com/insights/company-profiles/anti-aging-and-longevity-startups-to-watch", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "LG-027", "name": "2025十大长寿突破", "type": "年度回顾", "mechanism": "N/A", "clinical_stage": "N/A", "potential": "高", "description": "2025年十大长寿/抗衰老突破：代谢药物抗衰再定位、表观遗传时钟优化、GLP-1长寿关联等", "trend": "老药新用成为抗衰捷径；GLP-1类药物长寿证据增强", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.gethealthspan.com/research/article/top-ten-longevity-anti-aging-breakthroughs-of-2025", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "LG-028", "name": "2026长寿元年", "type": "行业趋势", "mechanism": "N/A", "clinical_stage": "N/A", "potential": "高", "description": "ForeverLabs称2026年为'长寿元年'：生物年龄检测像年度体检一样常规化，间充质干细胞疗法进展", "trend": "长寿从'抗衰老'到'健康寿命管理'范式转变；检测标准化", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.foreverlabs.com/articles/blog/2026-the-year-of-longevity-and-owning-your-biology", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "LG-029", "name": "11家抗衰老生物技术公司2026", "type": "行业趋势", "mechanism": "N/A", "clinical_stage": "N/A", "potential": "高", "description": "2026年11家领先抗衰老生物技术公司：从表观遗传重编程到细胞衰老清除，多路线并行", "trend": "抗衰从单一靶点到多靶点组合疗法；临床管线快速扩张", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.labiotech.eu/best-biotech/anti-aging-biotech-companies", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "LG-030", "name": "GLP-1长寿关联", "type": "代谢调节", "mechanism": "GLP-1受体激动→减重→降低全因死亡率", "clinical_stage": "IV期/真实世界", "potential": "高", "description": "2025年研究显示GLP-1类药物(Wegovy/Ozempic)与全因死亡率降低相关，4大抗衰途径之一", "trend": "GLP-1从糖尿病/肥胖药到长寿药的重定位；真实世界证据积累", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.foxnews.com/health/4-anti-aging-approaches-revealed-2025-may-help-americans-live-longer", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "LG-031", "name": "维生素D抗衰老证据", "type": "营养干预", "mechanism": "维生素D→减缓端粒缩短/抗炎/免疫调节", "clinical_stage": "流行病学/III期", "potential": "中等", "description": "2025年研究揭示维生素D可能减缓衰老过程，4大抗衰途径之一", "trend": "维生素D从骨骼健康到长寿干预的扩展；剂量和人群需优化", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.foxnews.com/health/4-anti-aging-approaches-revealed-2025-may-help-americans-live-longer", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "LG-032", "name": "冥想长寿关联", "type": "行为干预", "mechanism": "冥想→降低皮质醇/减缓端粒缩短/表观遗传改变", "clinical_stage": "临床研究", "potential": "中等", "description": "2025年研究显示冥想练习可能促进长寿，通过降低压力激素和减缓细胞衰老", "trend": "生活方式干预获得科学验证；与药物干预互补", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.foxnews.com/health/4-anti-aging-approaches-revealed-2025-may-help-americans-live-longer", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "LG-033", "name": "20大长寿趋势2026", "type": "行业趋势", "mechanism": "N/A", "clinical_stage": "N/A", "potential": "高", "description": "A4M 2026年20大长寿趋势：循证实践、先进技术整合、个性化长寿方案", "trend": "长寿从边缘到主流医疗；证据驱动取代营销驱动", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://blog.a4m.com/healthy-holistic-and-happening-now-a-look-at-longevity-trends-for-2026", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "LG-034", "name": "表观遗传时钟2.0", "type": "衰老生物标志物", "mechanism": "DNA甲基化模式→生物年龄评估", "clinical_stage": "商用/临床验证", "potential": "极高", "description": "表观遗传时钟重新定义衰老测量：生日≠身体实际年龄，DNA甲基化模式分析精确评估生物年龄", "trend": "从研究工具到临床标准；2026年多种时钟算法优化和验证", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.longevityvisa.com/2026longevitybreakthroughs", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "LG-035", "name": "ARDD 2026衰老药物大会", "type": "行业会议", "mechanism": "N/A", "clinical_stage": "N/A", "potential": "高", "description": "Aging Research & Drug Discovery (ARDD) 2026大会：推动健康衰老突破，开辟化妆品创新新纪元", "trend": "衰老从'自然过程'到'可治疗疾病'的范式转变；监管路径逐步明确", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://agingpharma.org", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "LG-036", "name": "部分重编程in vivo", "type": "表观遗传重编程", "mechanism": "OSKM因子瞬时表达→细胞年轻化→不丧失身份", "clinical_stage": "临床前/早期临床", "potential": "极高", "description": "体内部分重编程：短暂激活Yamanaka因子使细胞年轻化而不去分化，2025-2026年多项突破", "trend": "Turn Biotechniques/Altos Labs/Life Biosciences；2026年临床前数据密集发布", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "LG-037", "name": "衰老细胞清除Senolytics 2.0", "type": "细胞衰老清除", "mechanism": "选择性清除衰老细胞→减轻SASP炎症", "clinical_stage": "I/II期", "potential": "高", "description": "第二代衰老细胞清除疗法：更选择性/更安全/更长效，靶向特定组织衰老细胞", "trend": "Unity Biotechnology/Oisín Biotechnologies/Siwa Therapeutics；2026年临床数据读出", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "LG-038", "name": "长寿多组学整合", "type": "生物标志物", "mechanism": "基因组+表观组+蛋白质组+代谢组→综合衰老评估", "clinical_stage": "研究/商用", "potential": "高", "description": "多组学数据整合评估生物年龄和衰老速率，比单一标志物更准确预测健康结局", "trend": "AI驱动多组学衰老时钟；2026年个性化长寿方案基础", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "LG-039", "name": "NAD+前体临床进展", "type": "代谢调节", "mechanism": "NMN/NR→提升NAD+水平→改善线粒体功能", "clinical_stage": "II/III期", "potential": "中等", "description": "NAD+前体(NMN/NR)临床试验进展：Metro Biotech NMN药物推进，补充剂市场持续增长", "trend": "FDA对NMN补充剂立场反复；药物级NMN临床数据2026年读出", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "LG-040", "name": "间充质干细胞长寿疗法", "type": "细胞治疗", "mechanism": "MSC→免疫调节/抗炎/组织修复", "clinical_stage": "I/II期", "potential": "高", "description": "间充质干细胞(MSC)用于抗衰老和长寿：免疫调节、抗炎、组织修复多重机制", "trend": "ForeverLabs等推动MSC长寿应用；2026年临床数据积累", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "LG-041", "name": "Harvard WGS 2026衰老可逆声明", "type": "表观遗传重编程", "mechanism": "表观遗传重编程恢复细胞年轻态", "clinical_stage": "即将开始临床试验", "potential": "极高", "description": "Harvard科学家在WGS 2026宣布衰老可能很快可逆，表观遗传重编程疗法即将进入临床试验", "trend": "衰老逆转从理论到临床；表观遗传重编程是最有希望的路线", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.worldgovernmentssummit.org/media-hub/news/detail/ageing-could-soon-be-reversible", "collected_at": "2026-06-01T13:42:00Z" } ] }, { "id": "LG-042", "name": "NYT细胞 rejuvenation 2026", "type": "细胞 rejuvenation", "mechanism": "细胞 rejuvenation 治疗数百种疾病+逆转衰老", "clinical_stage": "早期临床", "potential": "极高", "description": "NYT 2026年4月报道：细胞 rejuvenation 有潜力治愈数百种疾病甚至逆转衰老", "trend": "细胞 rejuvenation 从实验室到临床；可能改变医学范式", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.nytimes.com/2026/04/27/magazine/cell-rejuventation-biotech-longevity", "collected_at": "2026-06-01T13:42:00Z" } ] }, { "id": "LG-043", "name": "Cambridge皮肤细胞逆转30年", "type": "表观遗传重编程", "mechanism": "Yamanaka因子部分重编程", "clinical_stage": "实验室", "potential": "高", "description": "Cambridge研究人员通过修饰Yamanaka因子将人类皮肤细胞生物年龄逆转约30年", "trend": "部分重编程避免完全去分化；精准控制重编程深度", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-01T13:42:00Z" } ] }, { "id": "LG-044", "name": "AFAR衰老研究顶级突破", "type": "综合", "mechanism": "多机制", "clinical_stage": "多阶段", "potential": "高", "description": "AFAR专家发现清除衰老细胞可延长寿命改善健康，即使晚期治疗也有效", "trend": "衰老细胞清除(senolytics)从动物到人体试验；联合用药策略", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.afar.org/top-breakthroughs-in-aging", "collected_at": "2026-06-01T13:42:00Z" } ] }, { "id": "LG-045", "name": "基因治疗延长小鼠寿命20%", "type": "基因治疗", "mechanism": "基因治疗延长寿命", "clinical_stage": "动物模型", "potential": "高", "description": "Liv Hospital报告：基因治疗突破在小鼠模型中延长寿命20%，为人类抗衰老开辟新途径", "trend": "基因治疗从遗传病到衰老；多靶点联合策略", "sources": [ { "source_type": "web", "source_credibility": "C", "article_url": "https://int.livhospital.com/anti-aging-breakthrough-the-newest-secrets", "collected_at": "2026-06-01T13:42:00Z" } ] }, { "id": "LG-046", "name": "9大抗衰老长寿初创公司2026", "type": "行业报告", "mechanism": "多机制", "clinical_stage": "多阶段", "potential": "高", "description": "Cure.评选2026年9大抗衰老长寿初创公司：表观遗传重编程/衰老细胞清除/代谢调节", "trend": "长寿初创公司从概念到临床数据；2026年关键数据读出年", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://wewillcure.com/insights/company-profiles/anti-aging-and-longevity-startups-to-watch-in-2026", "collected_at": "2026-06-01T13:42:00Z" } ] }, { "id": "LG-047", "name": "2025年10大长寿突破", "type": "年度回顾", "mechanism": "多机制", "clinical_stage": "多阶段", "potential": "高", "description": "Healthspan评选2025年10大长寿突破：代谢药物抗衰老再定位/衰老细胞清除/表观遗传重编程", "trend": "代谢药物(二甲双胍/SGLT2i)抗衰老临床数据积累；从延长寿命到延长健康寿命", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.gethealthspan.com/research/article/top-ten-longevity-anti-aging-breakthroughs", "collected_at": "2026-06-01T13:42:00Z" } ] }, { "id": "LG-048", "name": "2026年龄逆转5大创新", "type": "行业趋势", "mechanism": "多机制", "clinical_stage": "多阶段", "potential": "高", "description": "2026年5大年龄逆转创新：长寿科学近期突破汇总", "trend": "长寿科学从缓慢进展到加速突破；2026年可能是转折年", "sources": [ { "source_type": "web", "source_credibility": "C", "collected_at": "2026-06-01T13:42:00Z" } ] }, { "id": "LG-049", "name": "11大抗衰老生物技术公司2026", "type": "行业报告", "mechanism": "多机制", "clinical_stage": "多阶段", "potential": "高", "description": "Labiotech评选11大抗衰老生物技术公司：利用长寿技术延缓或停止衰老", "trend": "抗衰老公司从单一靶点到多靶点组合；投资从冷到热", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.labiotech.eu/best-biotech/anti-aging-biotech-companies", "collected_at": "2026-06-01T13:42:00Z" } ] }, { "id": "LG-050", "name": "ForeverLabs 2026长寿年", "type": "行业趋势", "mechanism": "MSC+生物年龄检测", "clinical_stage": "I/II期", "potential": "高", "description": "ForeverLabs: 2026年是长寿年，生物年龄检测像年度体检一样常规，MSC疗法推进", "trend": "生物年龄检测标准化；MSC长寿应用临床数据积累", "sources": [ { "source_type": "web", "source_credibility": "C", "article_url": "https://www.foreverlabs.com/articles/blog/2026-the-year-of-longevity-and-owning-your-biology", "collected_at": "2026-06-01T13:42:00Z" } ] }, { "id": "LG-051", "name": "Harvard科学家WGS 2026衰老可逆", "type": "学术声明", "mechanism": "表观遗传重编程", "clinical_stage": "临床前", "potential": "极高", "description": "哈佛科学家在世界政府峰会2026年声明：衰老可能很快可逆，消除所有癌症仅增加2.5年平均寿命", "trend": "衰老逆转从理论到实践；表观遗传重编程是核心路径", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.worldgovernmentssummit.org/media-hub/news/detail/ageing-could-soon-be-reversible-says-harvard-scientist-at-wgs-2026", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "LG-052", "name": "ARDD 2026衰老药物发现", "type": "学术会议", "mechanism": "多机制", "clinical_stage": "多阶段", "potential": "高", "description": "ARDD 2026(Aging Research & Drug Discovery): 开创健康衰老未来，推动长寿研究突破和化妆品创新", "trend": "长寿研究从延长寿命到健康寿命；药物发现加速", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://agingpharma.org", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "LG-053", "name": "LongevityFest 2026 A4M", "type": "行业会议", "mechanism": "多机制", "clinical_stage": "多阶段", "potential": "高", "description": "LongevityFest 2026 by A4M: 面向医疗专业人员和领导者，推进长寿医学/健康衰老/整合医学专业知识", "trend": "长寿医学从替代到主流；医疗专业人员培训需求增长", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.a4m.com/longevity-fest-2026.html", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "LG-054", "name": "NYT Altos Labs细胞 rejuvenation", "type": "深度报道", "mechanism": "细胞重编程", "clinical_stage": "临床前", "potential": "极高", "description": "NYT深度报道：Altos Labs细胞重编程研究可能治愈数百种疾病甚至逆转衰老，但长寿科学被过度炒作", "trend": "细胞重编程从炒作到务实；Altos Labs引领领域", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.nytimes.com/2026/04/27/magazine/cell-rejuventation-biotech-longevity-research-altos-labs.html", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "LG-055", "name": "2026年龄逆转5大真实创新", "type": "行业趋势", "mechanism": "多机制", "clinical_stage": "多阶段", "potential": "高", "description": "2026年5大年龄逆转真实创新：长寿科学近期突破汇总，从实验室到临床的进展", "trend": "年龄逆转从科幻到现实；多路线并行推进", "sources": [ { "source_type": "web", "source_credibility": "C", "article_url": "https://www.youtube.com/watch?v=qPEJ1khUN2w", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "LG-056", "name": "9大抗衰老长寿初创2026", "type": "初创公司", "mechanism": "多机制", "clinical_stage": "多阶段", "potential": "高", "description": "2026年9大抗衰老和长寿初创公司：表观遗传重编程/细胞疗法/代谢调节等多路线", "trend": "长寿初创公司融资活跃；表观遗传重编程最受关注", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://wewillcure.com/insights/company-profiles/anti-aging-and-longevity-startups-to-watch", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "LG-057", "name": "David Sinclair 2026年龄逆转预测", "type": "专家观点", "mechanism": "表观遗传重编程", "clinical_stage": "临床前", "potential": "极高", "description": "David Sinclair: 其实验室6周内将动物生物年龄逆转50-75%，预测2026年将是人类年龄逆转突破之年", "trend": "Sinclair实验室成果引人注目；从动物到人类仍有距离", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.reddit.com/r/Futurology/comments/1pfez5h/2026_is_soon_is_there_anything_to_be_optimistic", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "LG-058", "name": "2025十大长寿抗衰老突破", "type": "年度回顾", "mechanism": "多机制", "clinical_stage": "多阶段", "potential": "高", "description": "Healthspan盘点2025年十大长寿抗衰老突破：代谢药物重新定位用于抗衰老的研究和临床关注增强", "trend": "代谢药物抗衰老重新定位成为热点；从二甲双胍到新靶点", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.gethealthspan.com/research/article/top-ten-longevity-anti-aging-breakthroughs-of-2025", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "LG-059", "name": "长寿肽类研究2026全景", "type": "肽类疗法", "mechanism": "多肽机制", "clinical_stage": "临床前/临床", "potential": "高", "description": "Viking Labs 2026年长寿肽类研究全景：NAD+前体/衰老细胞清除剂/端粒酶激活剂/线粒体肽", "trend": "肽类长寿疗法从基础到临床；NAD+前体和senolytics领先", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://vikinglabs.co/research/peptides-longevity-research-2026", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "LG-060", "name": "表观遗传时钟标准化2026", "type": "生物标志物", "mechanism": "DNA甲基化", "clinical_stage": "商用", "potential": "高", "description": "表观遗传时钟标准化2026年进展：多种时钟算法(GrimAge/PhenoAge/DunedinPACE)精度提升，临床应用扩展", "trend": "生物年龄检测从研究到临床；标准化和监管框架建立", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "LG-061", "name": "Senolytics衰老细胞清除2026", "type": "药物疗法", "mechanism": "清除衰老细胞", "clinical_stage": "I/II期", "potential": "高", "description": "Senolytics衰老细胞清除疗法2026年进展：多种药物组合在动物模型中显示延寿效果，人体试验推进", "trend": "Senolytics从动物到人体；联合用药策略优化", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "LG-062", "name": "线粒体功能恢复疗法", "type": "代谢疗法", "mechanism": "线粒体生物发生", "clinical_stage": "临床前/临床", "potential": "中高", "description": "线粒体功能恢复疗法2026年进展：NAD+补充/线粒体移植/线粒体肽等多种策略改善线粒体功能", "trend": "线粒体从辅助靶点到核心靶点；多策略组合提升效果", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "LG-063", "name": "长寿投资市场2026", "type": "投资市场", "mechanism": "N/A", "clinical_stage": "N/A", "potential": "高", "description": "长寿投资市场2026年动态：Altos Labs/Calico/Retro Biosciences等获大额融资，长寿赛道投资热度持续", "trend": "长寿投资从早期到成长期；大型药企入场加速", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "LG-064", "name": "自噬激活剂2026进展", "type": "药物疗法", "mechanism": "激活自噬", "clinical_stage": "I/II期", "potential": "中高", "description": "自噬激活剂2026年进展：雷帕霉素类似物/天然自噬激活剂/组合策略在抗衰老中应用", "trend": "自噬从基础到转化；选择性自噬激活成为新方向", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "LG-065", "name": "肠道微生物与长寿2026", "type": "微生物组", "mechanism": "肠道菌群调节", "clinical_stage": "临床前/临床", "potential": "中", "description": "肠道微生物与长寿2026年进展：百岁老人菌群特征/菌群移植/益生菌干预研究", "trend": "肠道菌群从关联到因果；精准益生菌干预探索", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "LG-066", "name": "长寿监管框架2026", "type": "监管", "mechanism": "N/A", "clinical_stage": "N/A", "potential": "高", "description": "长寿监管框架2026年进展：FDA/EMA对衰老相关药物审批路径讨论，生物年龄作为临床终点探索", "trend": "监管从疾病到衰老；生物年龄作为终点获关注", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "LG-067", "name": "部分重编程in vivo 2026", "type": "重编程", "mechanism": "OSKM因子部分激活", "clinical_stage": "临床前", "potential": "极高", "description": "体内部分重编程2026年进展：OSKM因子短暂激活逆转衰老表型而不致瘤，动物模型效果显著", "trend": "部分重编程安全性改善；从小鼠到灵长类推进", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "LG-068", "name": "长寿生活方式干预2026", "type": "生活方式", "mechanism": "多机制", "clinical_stage": "商用", "potential": "中", "description": "长寿生活方式干预2026年进展：饮食限制模拟/运动处方/睡眠优化/压力管理综合方案", "trend": "生活方式干预从经验到循证；个性化长寿方案兴起", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "LG-070", "name": "科学家绘制50年人类衰老图谱", "type": "研究突破", "efficiency": "N/A", "cost": "N/A", "maturity": "研究前沿", "companies": [ "多研究机构" ], "description": "科学家绘制跨越50年的人类衰老图谱突破，为个性化抗衰老干预和靶向再生治疗提供基础", "trend": "衰老图谱从定性到定量；个性化长寿干预成为可能", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://targeting-longevity.com/news/breakthrough-scientists-map-human-aging-across-50-years", "collected_at": "2026-06-03T13:57:41.937Z" } ] }, { "id": "LG-073", "name": "2026长寿 owning your biology", "type": "行业趋势", "efficiency": "N/A", "cost": "N/A", "maturity": "行业趋势", "companies": [ "Forever Labs" ], "description": "Forever Labs: 2026年是长寿和掌控自己生物学之年，长寿从生物黑客走向主流标准", "trend": "长寿从边缘到主流；个性化长寿方案普及化", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.foreverlabs.com/articles/blog/2026-the-year-of-longevity-and-owning-your-biology", "collected_at": "2026-06-03T13:57:41.937Z" } ] }, { "id": "LG-074", "name": "BofA长寿科学AI加速", "type": "行业分析", "efficiency": "N/A", "cost": "N/A", "maturity": "参考", "companies": [ "Bank of America" ], "description": "Bank of America Breakthrough Technology Summit: AI加速长寿科学进步，重新定义衰老的含义", "trend": "AI成为长寿研究加速器；金融界关注长寿经济", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://business.bofa.com/en-us/content/breakthrough-technology/longevity-science-advances.html", "collected_at": "2026-06-03T13:57:41.937Z" } ] }, { "id": "LG-076", "name": "Top 10长寿突破2025", "type": "年度回顾", "efficiency": "N/A", "cost": "N/A", "maturity": "参考", "companies": [ "多研究机构" ], "description": "2025年十大长寿抗衰老突破：代谢药物重定位抗衰老研究增强，临床关注提升", "trend": "老药新用成为长寿研究热点；临床转化加速", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.gethealthspan.com/research/article/top-ten-longevity-anti-aging-breakthroughs-of-2025", "collected_at": "2026-06-03T13:57:41.937Z" } ] }, { "id": "LG-077", "name": "Harvard WGS 2026衰老可逆声明确认", "type": "表观遗传重编程", "mechanism": "表观遗传重编程恢复细胞年轻态", "clinical_stage": "即将开始临床试验", "potential": "极高", "description": "哈佛科学家在WGS 2026宣布衰老可能很快可逆，消除所有癌症仅增加2.5年平均寿命，衰老逆转才是根本", "trend": "衰老逆转从理论到临床；表观遗传重编程是最有希望的路线", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.worldgovernmentssummit.org/media-hub/news/detail/ageing-could-soon-be-reversible", "collected_at": "2026-06-04T14:05:26.379Z" } ] }, { "id": "LG-078", "name": "NYT细胞rejuvenation深度报道2026", "type": "深度报道", "mechanism": "细胞rejuvenation治疗数百种疾病+逆转衰老", "clinical_stage": "早期临床", "potential": "极高", "description": "NYT 2026年4月深度报道：细胞rejuvenation有潜力治愈数百种疾病甚至逆转衰老，但长寿科学被过度炒作", "trend": "细胞rejuvenation从实验室到临床；可能改变医学范式", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.nytimes.com/2026/04/27/magazine/cell-rejuventation-biotech-longevity", "collected_at": "2026-06-04T14:05:26.379Z" } ] }, { "id": "LG-080", "name": "Bank of America AI加速长寿科学", "type": "行业分析", "mechanism": "AI加速研究", "clinical_stage": "N/A", "potential": "高", "description": "Bank of America Breakthrough Technology Summit: AI加速长寿科学进步，重新定义衰老的含义", "trend": "AI成为长寿研究加速器；金融界关注长寿经济", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://business.bofa.com/en-us/content/breakthrough-technology/longevity-science-advances.html", "collected_at": "2026-06-04T14:05:26.379Z" } ] }, { "id": "LG-081", "name": "ARDD 2026衰老研究药物发现大会", "type": "行业会议", "mechanism": "全领域", "clinical_stage": "N/A", "potential": "参考", "description": "ARDD 2026大会：开创健康衰老未来，推动长寿研究突破，开启精准长寿医学新时代", "trend": "衰老研究从基础到转化；精准长寿医学兴起", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.agingdrugdiscovery.org", "collected_at": "2026-06-04T14:07:22.337Z" } ] }, { "id": "LG-082", "name": "LongevityFest 2026 A4M大会", "type": "行业会议", "mechanism": "全领域", "clinical_stage": "N/A", "potential": "参考", "description": "A4M LongevityFest 2026：面向医疗专业人员和领导者，推进长寿医学专业知识", "trend": "长寿医学从研究到临床实践；专业教育需求增长", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.a4m.com/longevityfest-2026.html", "collected_at": "2026-06-04T14:07:22.337Z" } ] }, { "id": "LG-082", "name": "FDA批准细胞rejuvenation疗法人体试验", "type": "监管突破", "mechanism": "表观遗传重编程", "clinical_stage": "I期临床", "potential": "极高", "description": "Nature Biotechnology报道：FDA批准细胞rejuvenation疗法人体试验，表观遗传重编程首次进入临床", "trend": "表观遗传重编程从动物到人体；FDA开绿灯", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.nature.com/articles/s41587-025-02623-5", "collected_at": "2026-06-04T14:09:22.606Z" } ] }, { "id": "LG-083", "name": "Life Biosciences ER-100 IND获批", "type": "监管突破", "mechanism": "表观遗传重编程ER-100", "clinical_stage": "I期临床", "potential": "极高", "description": "Life Biosciences 2026年1月获FDA IND批准ER-100：表观遗传治疗设计实现近乎完全的rejuvenating reset，逆转视力丧失", "trend": "表观遗传重编程首次人体试验；从视力丧失开始", "sources": [ { "source_type": "web", "source_credibility": "A", "collected_at": "2026-06-04T14:09:22.606Z" } ] }, { "id": "LG-084", "name": "FDA对rejuvenation态度转变", "type": "监管趋势", "mechanism": "N/A", "clinical_stage": "N/A", "potential": "高", "description": "Life Bio试验显示FDA对rejuvenation疗法态度正在转变，从保守到开放", "trend": "FDA从保守到开放；rejuvenation疗法监管路径清晰化", "sources": [ { "source_type": "web", "source_credibility": "A", "collected_at": "2026-06-04T14:09:22.606Z" } ] }, { "id": "LG-085", "name": "部分重编程表观遗传rejuvenation综述", "type": "学术综述", "mechanism": "部分重编程", "clinical_stage": "临床前", "potential": "极高", "description": "体内外研究证明部分重编程逆转衰老表型/增强组织修复的潜力，表观遗传rejuvenation前景综述", "trend": "部分重编程从概念到系统研究；安全性和有效性平衡", "sources": [ { "source_type": "web", "source_credibility": "A", "collected_at": "2026-06-04T14:09:22.606Z" } ] }, { "id": "LG-086", "name": "Harvard科学家WGS 2026: 衰老可逆", "type": "学术突破", "mechanism": "表观遗传重编程", "clinical_stage": "临床前", "potential": "极高", "description": "哈佛科学家在世界政府峰会2026宣布衰老可能很快可逆：消除所有癌症仅增加2.5年平均寿命，逆转衰老才是关键", "trend": "衰老逆转从理论到可能；消除癌症不如逆转衰老", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.worldgovernmentssummit.org/media-hub/news/detail/ageing-could-soon-be-reversible-says-harvard-scientist-at-wgs-2026", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "LG-087", "name": "NYT: 细胞rejuvenation疗法可能治愈数百种疾病", "type": "媒体报道", "mechanism": "细胞rejuvenation", "clinical_stage": "临床前", "potential": "极高", "description": "纽约时报深度报道：新疗法有潜力治愈数百种疾病甚至逆转衰老，Altos Labs等公司推动", "trend": "细胞rejuvenation从实验室到媒体主流；Altos Labs引领", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.nytimes.com/2026/04/27/magazine/cell-rejuventation-biotech-longevity-research-altos-labs.html", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "LG-088", "name": "2026年龄逆转5大真实创新", "type": "行业分析", "mechanism": "多机制", "clinical_stage": "多阶段", "potential": "高", "description": "Longevity Science News盘点2026年龄逆转5大真实创新：长寿科学最近几周突破令人难以置信", "trend": "年龄逆转从科幻到现实；多个创新同时突破", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.youtube.com/watch?v=qPEJ1khUN2w", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "LG-089", "name": "TIME: Steve Horvath谈衰老测量与逆转", "type": "专家访谈", "mechanism": "表观遗传时钟", "clinical_stage": "N/A", "potential": "高", "description": "TIME采访遗传学家Steve Horvath：表观遗传时钟发明者谈衰老测量和人类寿命延长可能性", "trend": "表观遗传时钟从发明到应用；衰老可测量是逆转前提", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://time.com/collections/future-of-living/7357365/steve-horvath-longevity-aging", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "LG-090", "name": "2026年9大抗衰老长寿初创公司", "type": "公司盘点", "mechanism": "多机制", "clinical_stage": "多阶段", "potential": "高", "description": "Cure盘点2026年9大抗衰老长寿初创公司：表观遗传重编程、senolytics、NAD+等方向", "trend": "长寿初创公司从概念到临床；多机制并行探索", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://wewillcure.com/insights/company-profiles/anti-aging-and-longevity-startups-to-watch", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "LG-091", "name": "Healthspan: 2025十大长寿抗衰老突破", "type": "年度回顾", "mechanism": "多机制", "clinical_stage": "多阶段", "potential": "高", "description": "Healthspan盘点2025十大长寿抗衰老突破：强调临床试验设计，从动物模型到转化飞跃", "trend": "长寿研究从动物到临床转化；试验设计更严谨", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.gethealthspan.com/research/article/top-ten-longevity-anti-aging-breakthroughs-of-2025", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "LG-092", "name": "Targeting Longevity世界大会2026柏林", "type": "行业会议", "mechanism": "N/A", "clinical_stage": "N/A", "potential": "N/A", "description": "Targeting Longevity世界大会2026(4月8-9日柏林)：世界线粒体学会组织，聚焦长寿靶点", "trend": "长寿从研究到靶向治疗；线粒体是关键靶点", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://targeting-longevity.com", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "LG-093", "name": "ForeverLabs: 2026长寿与掌控生物学之年", "type": "行业观点", "mechanism": "多机制", "clinical_stage": "多阶段", "potential": "高", "description": "ForeverLabs: 2026是长寿与掌控生物学之年，生物年龄检测将像年度体检一样常规", "trend": "生物年龄检测从研究到常规；长寿成为医疗标准", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.foreverlabs.com/articles/blog/2026-the-year-of-longevity-and-owning-your-biology", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "LG-094", "name": "Labiotech: 2026年11家抗衰老生物技术公司", "type": "公司盘点", "mechanism": "多机制", "clinical_stage": "多阶段", "potential": "高", "description": "Labiotech盘点2026年11家领先抗衰老生物技术公司：利用长寿技术延长寿命", "trend": "抗衰老公司从少数到群雄；多技术路线并行", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.labiotech.eu/best-biotech/anti-aging-biotech-companies", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "LG-095", "name": "Biohacker Alliance: 2026长寿科学实证指南", "type": "消费者指南", "mechanism": "多机制", "clinical_stage": "多阶段", "potential": "中-高", "description": "Biohacker Alliance 2026长寿科学指南：哪些机制驱动生物衰老、哪些干预有最强证据、如何构建长寿方案", "trend": "长寿科学从学术到消费者；实证指南降低信息门槛", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://biohackeralliance.com/insights/longevity-science-2026", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "LG-096", "name": "Altos Labs细胞rejuvenation 2026进展", "type": "公司进展", "mechanism": "部分重编程", "clinical_stage": "临床前", "potential": "极高", "description": "Altos Labs 2026年细胞rejuvenation进展：部分重编程技术从实验室向临床推进", "trend": "Altos Labs从科学到临床；部分重编程安全性改善", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.nytimes.com/2026/04/27/magazine/cell-rejuventation-biotech-longevity-research-altos-labs.html", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "LG-097", "name": "senolytics药物2026临床试验进展", "type": "药物开发", "mechanism": "senolytics", "clinical_stage": "临床I/II期", "potential": "高", "description": "2026年senolytics药物临床试验进展：清除衰老细胞的药物进入早期临床试验", "trend": "senolytics从概念到临床；清除衰老细胞是长寿关键策略", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "LG-098", "name": "NAD+补充剂2026临床证据更新", "type": "营养干预", "mechanism": "NAD+通路", "clinical_stage": "临床试验中", "potential": "中", "description": "2026年NAD+补充剂临床证据更新：NMN和NR的人体试验结果混合，部分指标改善", "trend": "NAD+补充剂从炒作到实证；临床结果喜忧参半", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "LG-099", "name": "间充质干细胞抗衰老2026进展", "type": "细胞疗法", "mechanism": "间充质干细胞", "clinical_stage": "临床前/早期临床", "potential": "中-高", "description": "2026年间充质干细胞抗衰老进展：Advanced Mesenchymal Stem Cell疗法从实验室到临床", "trend": "间充质干细胞从再生医学到抗衰老；临床转化加速", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.foreverlabs.com/articles/blog/2026-the-year-of-longevity-and-owning-your-biology", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "LG-100", "name": "表观遗传时钟2026新版本", "type": "诊断工具", "mechanism": "DNA甲基化", "clinical_stage": "商业化", "potential": "高", "description": "2026年表观遗传时钟新版本：更精准的生物年龄测量，多组织适用性提升", "trend": "表观遗传时钟持续迭代；精准度提升", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "LG-101", "name": "mTOR抑制剂抗衰老2026临床进展", "type": "药物开发", "mechanism": "mTOR通路", "clinical_stage": "临床试验中", "potential": "中-高", "description": "2026年mTOR抑制剂(如雷帕霉素类似物)抗衰老临床试验进展：低剂量长期方案探索", "trend": "mTOR抑制剂从免疫抑制到抗衰老；低剂量方案优化", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "LG-102", "name": "长寿生物标志物2026标准化进展", "type": "诊断标准", "mechanism": "多标志物", "clinical_stage": "标准化中", "potential": "高", "description": "2026年长寿生物标志物标准化进展：从研究工具到临床可用的生物年龄检测标准", "trend": "生物标志物从研究到临床标准；长寿医学规范化", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "LG-103", "name": "线粒体功能障碍与衰老2026新机制", "type": "基础研究", "mechanism": "线粒体", "clinical_stage": "基础研究", "potential": "高", "description": "2026年线粒体功能障碍与衰老新机制发现：线粒体质量控制、mtDNA突变等新靶点", "trend": "线粒体从旁观者到核心靶点；新机制指导干预策略", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "LG-104", "name": "肠道微生物与衰老2026关联研究", "type": "基础研究", "mechanism": "肠道微生物组", "clinical_stage": "基础研究", "potential": "中-高", "description": "2026年肠道微生物与衰老关联研究：特定菌群与生物年龄、炎症衰老的关系", "trend": "肠道微生物从消化到衰老调控；微生物组干预新方向", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "LG-105", "name": "长寿药物开发2026管线分析", "type": "行业分析", "mechanism": "多机制", "clinical_stage": "多阶段", "potential": "高", "description": "2026年长寿药物开发管线分析：从senolytics到重编程因子，多条路线并行推进", "trend": "长寿药物管线从稀疏到密集；多机制并行降低风险", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "LG-106", "name": "Life Biosciences ER-100首次人体注射", "type": "表观遗传重编程", "efficiency": "首次人体给药", "cost": "极高", "maturity": "临床I期", "companies": [ "Life Biosciences" ], "description": "2026年6月Life Biosciences宣布首位患者接受ER-100细胞重编程注射，这是史上首次逆转衰老相关变化的注射治疗，通过部分'重置'细胞生物学年龄实现", "trend": "首次逆转衰老人体注射是里程碑事件；表观遗传重编程从概念走向临床", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.businessinsider.com/first-ever-reverse-aging-treatment-injected-into-a-human-2026-6", "collected_at": "2026-06-16T22:31:38.000Z" } ] }, { "id": "LG-107", "name": "哈佛表观遗传重编程人体试验2026", "type": "衰老逆转", "efficiency": "即将开始", "cost": "极高", "maturity": "临床I期", "companies": [ "哈佛大学", "Life Biosciences" ], "description": "哈佛科学家在2026年世界政府峰会上宣布衰老可能很快可逆，表观遗传重编程疗法试验即将开始，旨在将细胞恢复到更年轻状态", "trend": "哈佛背书推动衰老逆转研究主流化；表观遗传重编程成为最前沿方向", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.worldgovernmentssummit.org/media-hub/news/detail/ageing-could-soon-be-reversible-says-harvard-scientist-at-wgs-2026", "collected_at": "2026-06-16T22:31:38.000Z" } ] }, { "id": "LG-108", "name": "Life Biosciences细胞 rejuvenation平台", "type": "细胞 rejuvenation", "efficiency": "临床推进", "cost": "极高", "maturity": "临床I期", "companies": [ "Life Biosciences" ], "description": "Life Biosciences开创表观遗传修复技术逆转衰老相关疾病，2026年计划开展人体试验测试基因疗法逆转细胞衰老并恢复组织功能", "trend": "细胞 rejuvenation 从抗衰研究走向临床应用；表观遗传修复成为核心策略", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://observer.com/2025/10/this-longevity-startup-is-bringing-anti-aging-gene-therapy-to-human-trials", "collected_at": "2026-06-16T22:31:38.000Z" }, { "source_type": "web", "source_credibility": "B", "article_url": "https://www.lifebiosciences.com", "collected_at": "2026-06-16T22:31:38.000Z" } ] }, { "name": "Rapamycin", "type": "Drug Compound", "mechanism": "Inhibits mTOR pathway to modulate cellular metabolism and autophagy, showing synergistic effects when combined with acarbose.", "target": "Aging-related pathways, Alzheimer's disease onset, and general age-related memory decline.", "status": "Clinically studied in animal models with demonstrated lifespan extension up to 36.6% in median lifespan.", "description": "Rapamycin is a well-researched drug compound known for its ability to extend lifespan and delay age-related diseases in mice. It works by inhibiting the mTOR pathway, which plays a crucial role in regulating cell growth and metabolism. Studies show that combining rapamycin with acarbose yields superior benefits compared to either drug alone. Its potential applications include treating neurodegenerative conditions and preserving heart function in aging populations.", "id": "LG-109" }, { "name": "Epigenetic Reprogramming", "type": "Biotechnological Technique", "mechanism": "Utilizes partial reprogramming to reverse multiple hallmarks of aging, including genomic instability and dysbiosis.", "target": "Aging cells and tissues, aiming to restore youthful epigenetic patterns.", "status": "Under active investigation with recent breakthroughs highlighted in 2025-2026 research.", "description": "Epigenetic reprogramming represents a cutting-edge approach to reversing the biological signs of aging by resetting cellular identity. This technique targets key aging markers such as genomic instability and microbial imbalance, offering potential regenerative benefits. Recent studies have demonstrated its efficacy in both laboratory settings and preliminary clinical trials. As part of the broader longevity science movement, it is considered one of the most promising innovations for extending healthspan.", "id": "LG-110" }, { "name": "Metformin", "type": "Drug Compound", "mechanism": "Activates AMPK pathway to improve metabolic regulation and reduce inflammation associated with aging.", "target": "Age-related metabolic disorders and general aging processes.", "status": "Widely used in diabetes treatment and increasingly explored for anti-aging applications.", "description": "Metformin is a commonly prescribed medication for type 2 diabetes that has gained attention for its potential anti-aging properties. By activating the AMPK pathway, it helps regulate energy balance and reduces inflammatory responses linked to aging. Clinical trials are ongoing to evaluate its effectiveness in extending lifespan and improving health outcomes in non-diabetic individuals. Its repurposing for longevity highlights the growing intersection between metabolic health and aging research.", "id": "LG-111" }, { "name": "NAD+ Precursors", "type": "Supplement Class", "mechanism": "Boosts cellular NAD+ levels to enhance mitochondrial function and support DNA repair mechanisms.", "target": "Cells experiencing age-related declines in NAD+ production.", "status": "Available as dietary supplements with ongoing research into optimal dosing and efficacy.", "description": "NAD+ precursors are compounds designed to increase levels of nicotinamide adenine dinucleotide (NAD+) in the body, a molecule critical for cellular health. As NAD+ levels naturally decline with age, supplementation aims to mitigate associated functional losses, particularly in mitochondria and DNA repair pathways. These supplements are widely accessible and form a cornerstone of many anti-aging regimens. Current research focuses on determining the most effective forms and doses for maximizing longevity benefits.", "id": "LG-112" }, { "name": "Sinclair Lab", "type": "Research Institution", "mechanism": "Focuses on nerve regeneration and reversal of aging symptoms through genetic and epigenetic interventions.", "target": "Humans and companion animals, aiming to develop scalable anti-aging therapies.", "status": "Actively conducting research with published findings on aging reversal strategies.", "description": "The Sinclair Lab, led by prominent aging researcher David Sinclair, is dedicated to understanding and reversing the biological processes of aging. Their work emphasizes nerve regeneration and the application of epigenetic modifications to restore youthful traits in cells. The lab explores therapeutic possibilities for both humans and pets, leveraging advancements in genetics and molecular biology. With significant contributions to the field, the Sinclair Lab remains at the forefront of longevity science innovation.", "id": "LG-113" }, { "id": "LG-114", "name": "哈佛化学重编程逆转衰老", "type": "表观遗传重编程", "applications": [ "衰老逆转", "再生医学" ], "companies": [ "Life Biosciences" ], "maturity": "实验室验证", "description": "哈佛医学院团队首次发表化学方法将细胞重编程至更年轻状态，发现可逆转衰老的小分子化合物", "trend": "化学重编程是表观遗传逆转的突破性路径" }, { "id": "LG-115", "name": "表观遗传重编程人体试验", "type": "表观遗传重编程", "applications": [ "衰老逆转" ], "companies": [ "Altos Labs", "Turn Biotechnologies" ], "maturity": "早期人体试验", "description": "表观遗传重编程技术接近首次人体试验，通过OSKM因子部分激活实现细胞 rejuvenation", "trend": "重编程从动物模型迈向人体" }, { "id": "LG-116", "name": "Senolytic药物开发", "type": "Senolytic", "applications": [ "清除衰老细胞", "抗衰老" ], "companies": [ "Unity Biotechnology", "Rubedo Life Sciences" ], "maturity": "II期临床", "description": "Senolytic药物选择性清除衰老细胞，2025-2026年多个候选药物进入II期临床试验", "trend": "清除衰老细胞是抗衰老最有希望的策略之一" }, { "id": "LG-117", "name": "2026抗衰老初创企业", "type": "长寿生态", "applications": [ "长寿治疗", "生物标志物" ], "companies": [ "Retro Biosciences", "NewLimit", "Hevolution" ], "maturity": "研发阶段", "description": "2026年最值得关注的抗衰老和长寿初创公司，涵盖表观遗传重编程、代谢干预和衰老生物标志物", "trend": "长寿赛道投资热度持续升温" }, { "id": "LG-118", "name": "小分子驱动的细胞重编程", "type": "小分子重编程", "applications": [ "衰老逆转", "细胞再生" ], "companies": [ "学术研究" ], "maturity": "实验室验证", "description": "研究发现小分子可驱动细胞重编程逆转衰老表型，通过重塑表观遗传和基因网络实现细胞年轻化", "trend": "小分子方法比基因疗法更易成药" }, { "id": "LG-119", "name": "衰老生物标志物标准化", "type": "生物标志物", "applications": [ "衰老评估", "临床试验终点" ], "companies": [ "Clock Foundation", "Elysia Health" ], "maturity": "商业化早期", "description": "衰老时钟和生物标志物标准化取得进展，为抗衰老临床试验提供可量化的疗效评估工具", "trend": "可靠的衰老标志物是抗衰老药物开发的基础" }, { "id": "LON-119", "name": "Dasatinib", "type": "Senolytic", "mechanism": "A tyrosine kinase inhibitor that selectively induces apoptosis in senescent cells by inhibiting pro-survival pathways, particularly involving BCL-2 family proteins.", "clinical_stage": "Phase 2" }, { "id": "LON-120", "name": "Quercetin", "type": "Senolytic", "mechanism": "A natural flavonoid that suppresses the pro-survival pathways of senescent cells, particularly by inhibiting PI3K/AKT and BCL-2, facilitating their removal by the immune system.", "clinical_stage": "Phase 2" }, { "id": "LON-121", "name": "Fisetin", "type": "Senolytic", "mechanism": "A flavonoid senolytic that selectively targets senescent cells by reducing the expression of anti-apoptotic proteins like BCL-xL and enhancing their clearance.", "clinical_stage": "Phase 2" }, { "id": "LON-122", "name": "Nicotinamide Mononucleotide (NMN)", "type": "NAD+ Booster", "mechanism": "A precursor to Nicotinamide Adenine Dinucleotide (NAD+), it replenishes NAD+ levels, supporting mitochondrial function, DNA repair, and sirtuin activity, which decline with age.", "clinical_stage": "Phase 2" }, { "id": "LON-123", "name": "Nicotinamide Riboside (NR)", "type": "NAD+ Booster", "mechanism": "Another NAD+ precursor that is efficiently converted to NAD+ in cells, enhancing cellular energy metabolism and activating sirtuins to promote healthy aging.", "clinical_stage": "Phase 2" }, { "id": "LON-124", "name": "Rapamycin", "type": "mTOR Inhibitor", "mechanism": "An inhibitor of the mechanistic target of rapamycin complex 1 (mTORC1), a central regulator of cell growth and metabolism. Inhibition extends lifespan by promoting autophagy and reducing protein synthesis.", "clinical_stage": "Phase 2" }, { "id": "LON-125", "name": "Everolimus", "type": "mTOR Inhibitor", "mechanism": "An analog of rapamycin with improved bioavailability, it inhibits mTORC1, leading to enhanced autophagy and potential lifespan extension in various models.", "clinical_stage": "Phase 2" }, { "id": "LON-126", "name": "Metformin", "type": "mTOR Inhibitor", "mechanism": "A first-line diabetes drug that indirectly inhibits mTOR signaling by activating AMPK, leading to reduced mTORC1 activity and improved metabolic health.", "clinical_stage": "Phase 3 (TAME trial)" }, { "id": "LON-127", "name": "Telomerase Activator (TA-65)", "type": "Telomerase", "mechanism": "A plant-derived compound that activates telomerase, the enzyme responsible for maintaining telomere length, potentially counteracting cellular senescence caused by telomere shortening.", "clinical_stage": "Phase 3" }, { "id": "LON-128", "name": "Oxidative Stress Reducer (MitoQ)", "type": "Mitochondrial Antioxidant", "mechanism": "A mitochondria-targeted antioxidant that reduces oxidative damage within the cell, preserving mitochondrial function and reducing age-related decline.", "clinical_stage": "Phase 2" }, { "id": "LON-129", "name": "Senolytic Combination (D+Q)", "type": "Senolytic", "mechanism": "A combination of Dasatinib and Quercetin, shown to effectively clear senescent cells in preclinical models and in early human trials for age-related conditions.", "clinical_stage": "Phase 2" }, { "id": "LON-130", "name": "NAD+ Precursor (NAD+)", "type": "NAD+ Booster", "mechanism": "Direct administration of NAD+ to increase cellular levels, though its efficacy is debated due to poor bioavailability; often used in conjunction with precursors.", "clinical_stage": "Phase 1" }, { "id": "LON-131", "name": "Spermidine", "type": "Autophagy Inducer", "mechanism": "A natural polyamine that induces autophagy, the process by which cells clear damaged components, thereby promoting cellular rejuvenation and longevity.", "clinical_stage": "Phase 2" }, { "id": "LON-132", "name": "Sirtuin Activator (Resveratrol)", "type": "Sirtuin Activator", "mechanism": "A polyphenol that activates SIRT1, a NAD+-dependent deacetylase involved in regulating stress resistance, metabolism, and aging pathways.", "clinical_stage": "Phase 2" }, { "id": "LON-133", "name": "FGF21 Analog", "type": "Metabolic Regulator", "mechanism": "An engineered version of Fibroblast Growth Factor 21, a hormone that improves metabolic health, enhances insulin sensitivity, and has shown lifespan extension in mice.", "clinical_stage": "Phase 2" }, { "id": "LON-134", "name": "Dasatinib", "type": "Senolytic", "mechanism": "A tyrosine kinase inhibitor that selectively induces apoptosis in senescent cells by inhibiting pro-survival pathways (e.g., BCL-2, PI3K) that are upregulated in these cells.", "clinical_stage": "Phase II" }, { "id": "LON-135", "name": "Quercetin", "type": "Senolytic", "mechanism": "A flavonoid that inhibits key anti-apoptotic pathways (e.g., BCL-xL, PI3K) in senescent cells, promoting their selective clearance.", "clinical_stage": "Phase II" }, { "id": "LON-136", "name": "Fisetin", "type": "Senolytic", "mechanism": "A flavonoid that reduces senescent cell burden by modulating pathways such as PI3K/AKT and reducing the expression of pro-survival proteins like BCL-xL and BCL-2.", "clinical_stage": "Phase II" }, { "id": "LON-137", "name": "NR (Nicotinamide Riboside)", "type": "NAD+ Booster", "mechanism": "A precursor to Nicotinamide Adenine Dinucleotide (NAD+), it boosts cellular NAD+ levels to support mitochondrial function, DNA repair, and sirtuin activity.", "clinical_stage": "Phase III" }, { "id": "LON-138", "name": "NMN (Nicotinamide Mononucleotide)", "type": "NAD+ Booster", "mechanism": "A direct precursor to NAD+, it increases intracellular NAD+ levels, enhancing energy metabolism, DNA repair, and activating sirtuins (e.g., SIRT1).", "clinical_stage": "Phase II" }, { "id": "LON-139", "name": "Rapamycin", "type": "mTOR Inhibitor", "mechanism": "An inhibitor of the mechanistic Target of Rapamycin (mTOR) complex 1 (mTORC1), it slows down anabolic processes and promotes autophagy, extending lifespan in model organisms.", "clinical_stage": "Phase II" }, { "id": "LON-140", "name": "Everolimus", "type": "mTOR Inhibitor", "mechanism": "An analog of rapamycin, it inhibits mTORC1 to reduce protein synthesis, induce autophagy, and potentially delay aging-related decline.", "clinical_stage": "Phase II" }, { "id": "LON-141", "name": "Metformin", "type": "mTOR Inhibitor", "mechanism": "An anti-diabetic drug that indirectly inhibits mTOR signaling via AMPK activation, reducing cellular growth and promoting metabolic health.", "clinical_stage": "Phase III" }, { "id": "LON-142", "name": "TAT-Beclin 1 Peptide", "type": "Senolytic", "mechanism": "A peptide that induces autophagy specifically in senescent cells by targeting the autophagy regulator Beclin 1, leading to their clearance.", "clinical_stage": "Preclinical" }, { "id": "LON-143", "name": "TA-65", "type": "Telomerase Activator", "mechanism": "A small-molecule activator of telomerase, it aims to lengthen telomeres (protective caps on chromosomes) to counteract cellular aging.", "clinical_stage": "Phase II" }, { "id": "LON-144", "name": "Urolithin A", "type": "Senolytic", "mechanism": "A metabolite produced by gut bacteria from pomegranates, it induces mitophagy (clearance of damaged mitochondria) and reduces inflammation associated with senescence.", "clinical_stage": "Phase II" }, { "id": "LON-145", "name": "Resveratrol", "type": "Sirtuin Activator", "mechanism": "A polyphenol that activates SIRT1, a NAD+-dependent deacetylase involved in DNA repair, metabolic regulation, and stress resistance.", "clinical_stage": "Phase II" }, { "id": "LON-146", "name": "ABT-263 (Navitoclax)", "type": "Senolytic", "mechanism": "A BCL-2/BCL-xL inhibitor that induces apoptosis in senescent cells by blocking their anti-apoptotic defenses.", "clinical_stage": "Phase I/II" }, { "id": "LON-147", "name": "Senolytic Cocktail (Dasatinib + Quercetin)", "type": "Senolytic", "mechanism": "A combination of dasatinib and quercetin that targets multiple pro-survival pathways in senescent cells for more effective clearance.", "clinical_stage": "Phase II" }, { "id": "LON-148", "name": "Spermidine", "type": "Autophagy Inducer", "mechanism": "A polyamine that induces autophagy, the process of cellular self-cleanup, which declines with age and is linked to longevity.", "clinical_stage": "Phase II" } ], "cell_therapy": [ { "id": "CT-001", "name": "CAR-T细胞治疗", "type": "免疫细胞治疗", "mechanism": "嵌合抗原受体T细胞靶向杀伤肿瘤", "clinical_stage": "已上市(血液瘤)/临床(实体瘤)", "potential": "极高(血液瘤)/高(实体瘤)", "description": "患者T细胞基因工程改造后回输，精准杀伤表达特定抗原的癌细胞", "trend": "截至2025年7款FDA批准CAR-T产品；2026年市场$4.83Bn→2033年$18.46Bn" }, { "id": "CT-002", "name": "CAR-NK细胞治疗", "type": "免疫细胞治疗", "mechanism": "嵌合抗原受体NK细胞杀伤肿瘤", "clinical_stage": "临床I/II期", "potential": "高", "description": "NK细胞CAR改造，无需HLA匹配，异体使用潜力大，CRS风险低", "trend": "Fate Therapeutics/NKarta/赛诺菲；现货型(off-the-shelf)产品开发" }, { "id": "CT-003", "name": "TCR-T细胞治疗", "type": "免疫细胞治疗", "mechanism": "T细胞受体工程靶向胞内抗原", "clinical_stage": "已上市(afamitresgene)/临床", "potential": "高", "description": "工程化T细胞受体识别MHC呈递的胞内抗原，可靶向CAR-T无法触及的靶点", "trend": "afamitresgene autoleucel获FDA批准(实体瘤)；实体瘤治疗突破" }, { "id": "CT-004", "name": "TIL肿瘤浸润淋巴细胞", "type": "免疫细胞治疗", "mechanism": "扩增肿瘤内天然T细胞回输", "clinical_stage": "已上市(Amtagvi)", "potential": "高", "description": "从患者肿瘤中提取天然识别肿瘤的T细胞，体外扩增后回输", "trend": "Iovance/Amtagvi 2024年获FDA批准(黑色素瘤)；实体瘤新选择" }, { "id": "CT-005", "name": "iPSC来源细胞治疗", "type": "干细胞治疗", "mechanism": "iPSC分化为功能细胞替代损伤组织", "clinical_stage": "已上市(日本)/临床", "potential": "极高", "description": "诱导多能干细胞分化为角膜/NK/心肌/神经等细胞用于治疗", "trend": "日本iPSC角膜细胞(2023)/NK细胞(2024)获批；全球大量临床试验" }, { "id": "CT-006", "name": "通用型CAR-T(异体)", "type": "免疫细胞治疗", "mechanism": "健康供者T细胞CAR改造/基因编辑消除排斥", "clinical_stage": "临床I/II期", "potential": "极高", "description": "现货型CAR-T产品，无需患者自体细胞，可大规模生产", "trend": "CRISPR编辑消除TCR/HLA；Allogene/Cellectis/Caribou Biosciences推进" }, { "id": "CT-007", "name": "CAR-巨噬细胞CAR-M", "type": "免疫细胞治疗", "mechanism": "巨噬细胞CAR改造吞噬肿瘤", "clinical_stage": "临床I期", "potential": "中高", "description": "工程化巨噬细胞可吞噬肿瘤并重塑肿瘤微环境，适合实体瘤", "trend": "Carisma Therapeutics领先；实体瘤微环境调控新策略" }, { "id": "CT-008", "name": "基因治疗(AAV递送)", "type": "基因治疗", "mechanism": "AAV载体递送功能基因替代缺陷基因", "clinical_stage": "已上市(多款)", "potential": "高", "description": "腺相关病毒载体递送治疗性基因，一次性治疗遗传病", "trend": "Hemgenix/Zolgensma/Casgevy已上市；AAV衣壳工程改进靶向性；免疫原性挑战" }, { "id": "CT-009", "name": "LNP递送基因编辑", "type": "基因治疗", "mechanism": "脂质纳米颗粒递送CRISPR/mRNA至靶器官", "clinical_stage": "临床I/II期", "potential": "极高", "description": "非病毒递送基因编辑工具，LNP可靶向肝脏，肝外递送突破中", "trend": "Intellia LNP-CRISPR肝脏靶向临床成功；肝外递送(肺/脑/肌肉)是前沿" }, { "id": "CT-010", "name": "CAR-T实体瘤策略", "type": "免疫细胞治疗", "mechanism": "多靶点/装甲CAR/微环境调控", "clinical_stage": "临床I/II期", "potential": "高", "description": "克服实体瘤微环境抑制的CAR-T策略：双靶点/分泌细胞因子/检查点阻断", "trend": "2026年CAR-T从血液瘤向实体瘤突破的关键年；数十款产品预计获批" }, { "id": "CT-011", "name": "间充质干细胞MSC", "type": "干细胞治疗", "mechanism": "旁分泌/免疫调节/组织修复", "clinical_stage": "II/III期(多适应症)", "potential": "中高", "description": "多能间充质干细胞抗炎和组织修复，移植物抗宿主病/骨关节炎等", "trend": "全球1000+临床试验；与长寿科技交叉；外泌体作为无细胞替代" }, { "id": "CT-012", "name": "3D生物打印组织/器官", "type": "组织工程", "mechanism": "逐层打印活细胞和生物材料构建功能组织", "clinical_stage": "临床(皮肤/软骨)/临床前(器官)", "potential": "极高(远期)", "description": "3D打印活体组织用于移植，最终目标是打印完整器官", "trend": "3D打印耳朵(2022)/皮肤已临床使用；完整器官仍需数年" }, { "id": "CT-013", "name": "体内CAR-T疗法", "type": "免疫细胞治疗", "mechanism": "LNP/AAV递送CAR基因在体内直接改造T细胞", "clinical_stage": "临床I期", "potential": "极高", "description": "无需体外培养T细胞，直接在体内将T细胞改造为CAR-T，大幅降低成本和等待时间", "trend": "2025年ASH年会最新进展；Interius Bio/Myeloid Therapeutics/Umoja Biopharma领先", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://link.springer.com/article/10.1007/s11605-025-09234-7", "collected_at": "2026-05-30T13:30:00Z" } ] }, { "id": "CT-014", "name": "现货型CAR-T(Off-the-Shelf)", "type": "免疫细胞治疗", "mechanism": "异体供体CAR-T/基因编辑消除GVHD", "clinical_stage": "临床I/II期", "potential": "极高", "description": "通用型CAR-T无需患者自体细胞，可即用即取，降低成本和等待时间", "trend": "2025-2026年临床进展显著但仍为研究性；CRISPR编辑消除TCR/MHC", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://globalrph.com/2026/04/car-t-cell-therapy-the-truth-about-off-the-shelf-treatments-in-2026", "collected_at": "2026-05-30T13:30:00Z" } ] }, { "id": "CT-015", "name": "CAR-T实体瘤突破2026", "type": "免疫细胞治疗", "mechanism": "双靶点/装甲CAR-T/肿瘤微环境调控", "clinical_stage": "临床I/II期", "potential": "极高", "description": "CAR-T从血液瘤向实体瘤突破的关键年，数十款产品预计获批", "trend": "2017-2025年6款自体CAR-T获FDA批准；2026年实体瘤突破窗口", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.linkedin.com/pulse/car-t-cell-therapy-2026-from-blood-cancers-solid-stefano-gaburro-phd-lvrjf", "collected_at": "2026-05-30T13:30:00Z" } ] }, { "id": "CT-016", "name": "CAR-T多发性骨髓瘤II期", "type": "免疫细胞治疗", "mechanism": "BCMA靶向CAR-T", "clinical_stage": "II期(ASH 2025)", "potential": "高", "description": "ASH 2025: CAR-T多发性骨髓瘤II期试验12个月PFS 79%，18个月PFS 66%，OS 95%/90%", "trend": "MD Anderson Cancer Center数据；长期生存数据支持CAR-T在骨髓瘤中的地位", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.mdanderson.org/newsroom/research-newsroom/ash-2025--car-t-cell-therapy-shows-promising-phase-ii-trial-results-in-multiple-myeloma.h00-159781968.html", "collected_at": "2026-05-30T13:30:00Z" } ] }, { "id": "CT-017", "name": "下一代CAR-T市场", "type": "市场趋势", "mechanism": "N/A", "clinical_stage": "N/A", "potential": "高", "description": "下一代CAR-T疗法市场预测：新靶点/新适应症/新制造工艺驱动增长", "trend": "自动化制造降低成本；新靶点(GPRC5D/SLAMF7)拓展适应症", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.towardshealthcare.com/insights/next-gen-car-t-therapy-market-sizing", "collected_at": "2026-05-30T13:30:00Z" } ] }, { "id": "CT-018", "name": "CRISPR临床试验2026更新", "type": "基因编辑治疗", "mechanism": "CRISPR-Cas9/碱基编辑/先导编辑", "clinical_stage": "多适应症临床", "potential": "极高", "description": "2026年CRISPR临床试验最新进展：Casgevy后更多基因编辑疗法进入临床", "trend": "IGI 2026更新：体内递送/碱基编辑/表观遗传编辑新方向", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://innovativegenomics.org/news/crispr-clinical-trials-2026", "collected_at": "2026-05-30T13:30:00Z" } ] }, { "id": "CT-019", "name": "现货型CAR-T(allogeneic)", "type": "免疫细胞治疗", "mechanism": "异体来源CAR-T细胞，即用型无需自体采集", "clinical_stage": "临床I/II期", "potential": "极高", "description": "现货型CAR-T：异体来源，无需患者自体细胞采集和培养，大幅降低成本和等待时间", "trend": "2025-2026年临床进展显著但仍处研究阶段；CRS/GvHD风险管控是关键", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://globalrph.com/2026/04/car-t-cell-therapy-the-truth-about-off-the-shelf-treatments-in-2026", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "CT-020", "name": "CAR-T多发性骨髓瘤II期", "type": "免疫细胞治疗", "mechanism": "BCMA靶向CAR-T", "clinical_stage": "II期", "potential": "高", "description": "ASH 2025：CAR-T多发性骨髓瘤II期试验12个月PFS 79%，18个月PFS 66%，OS 95%/90%", "trend": "多发性骨髓瘤CAR-T疗效数据持续改善；长期生存数据积累", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.mdanderson.org/newsroom/research-newsroom/ash-2025--car-t-cell-therapy-shows-promising-phase-ii-trial-results-in-multiple-myeloma.h00-159781968.html", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "CT-021", "name": "体内CAR-T(in vivo)", "type": "免疫细胞治疗", "mechanism": "体内递送CAR基因→T细胞原位改造", "clinical_stage": "临床I期", "potential": "极高", "description": "体内CAR-T：通过载体直接在体内将CAR基因递送至T细胞，无需体外培养，ASH 2025最新进展", "trend": "从体外到体内是CAR-T革命性转变；LNP/病毒载体递送技术突破", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://link.springer.com/article/10.1186/s40364-026-00938-8", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "CT-022", "name": "CAR-T实体瘤突破", "type": "免疫细胞治疗", "mechanism": "新靶点/新策略攻克实体瘤", "clinical_stage": "临床I/II期", "potential": "极高", "description": "2026年CAR-T从血液癌到实体瘤：新靶点(GPC3/CLDN18.2/MUC1)/新策略(双靶点/装甲CAR)", "trend": "实体瘤是CAR-T下一个前沿；6款自体CAR-T已获批(2017-2025)", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.linkedin.com/pulse/car-t-cell-therapy-2026-from-blood-cancers-solid-stefano-gaburro-phd-lvrjf", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "CT-023", "name": "AACR 2026 CAR-T早期研究", "type": "免疫细胞治疗", "mechanism": "高风险冒烟型多发性骨髓瘤CAR-T", "clinical_stage": "早期临床", "potential": "高", "description": "AACR 2026年会：CAR-T用于高风险冒烟型多发性骨髓瘤早期研究，AI诊断模型同步展示", "trend": "CAR-T从晚期治疗向早期干预扩展；AI辅助患者筛选", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.oncologynewscentral.com/oncology/early-studies-on-car-t-and-diagnostic-tools-among-highlights-at-aacr-2026", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "CT-024", "name": "CAR-T未来十年展望", "type": "行业趋势", "mechanism": "N/A", "clinical_stage": "N/A", "potential": "极高", "description": "BioInformant预测未来十年数十款CAR-T疗法将获批，覆盖多种血液癌和实体瘤", "trend": "从自体到异体/体内；从血液瘤到实体瘤；从末线到前线", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://bioinformant.com/car-t-cell-therapy-development", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "CT-025", "name": "CAR-T FDA里程碑(2017-2025)", "type": "行业回顾", "mechanism": "N/A", "clinical_stage": "已上市", "potential": "高", "description": "2017-2025年6款自体CAR-T产品获FDA批准：Kymriah/Yescarta/Tecartus/Breyanzi/Abecma/Carvykti", "trend": "CAR-T从突破性疗法到标准治疗；适应症从后线向前线推进", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://nonabio.com/car-t-cell-therapy-in-2025-breakthroughs-barriers-and-the-road-ahead", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "CT-026", "name": "TIL肿瘤浸润淋巴细胞疗法", "type": "免疫细胞治疗", "mechanism": "扩增肿瘤浸润T细胞→回输杀伤肿瘤", "clinical_stage": "已上市(Iovance)/临床", "potential": "高", "description": "从患者肿瘤中提取浸润淋巴细胞，体外扩增后回输，对实体瘤(黑色素瘤)有效", "trend": "Amtagvi(lifileucel)2024年获FDA批准；更多实体瘤适应症拓展", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "CT-027", "name": "TCR-T细胞治疗", "type": "免疫细胞治疗", "mechanism": "工程化T细胞受体识别胞内抗原", "clinical_stage": "已上市(Adaptimmune)/临床", "potential": "高", "description": "TCR-T识别细胞内抗原(MHC呈递)，可靶向CAR-T无法触及的胞内靶点", "trend": "Tecelra(afamitresgene autoleucel)2024年获FDA批准；实体瘤新选择", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "CT-028", "name": "CAR-M巨噬细胞治疗", "type": "免疫细胞治疗", "mechanism": "CAR修饰巨噬细胞吞噬肿瘤", "clinical_stage": "临床I期", "potential": "高", "description": "CAR修饰巨噬细胞，既可直接吞噬肿瘤，又可重塑肿瘤微环境，实体瘤潜力大", "trend": "Carisma Therapeutics领先；实体瘤微环境突破新策略", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "CT-029", "name": "KIR-CAR T细胞治疗", "type": "免疫细胞治疗", "mechanism": "KIR-CAR T细胞靶向杀伤肿瘤", "clinical_stage": "临床I期(AACR 2026)", "potential": "高", "description": "AACR 2026: KIR-CAR T细胞治疗在多发性骨髓瘤中安全，剂量递增疗效增加", "trend": "新型CAR设计突破传统scFv限制；KIR-CAR开辟新靶点空间", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://ecancer.org/en/news/28100-aacr-2026-new-kir-car-t-cell-therapy-shows-promise", "collected_at": "2026-06-01T13:42:00Z" } ] }, { "id": "CT-030", "name": "免化疗CAR-T疗法", "type": "免疫细胞治疗", "mechanism": "改良CAR-T免去预处理化疗", "clinical_stage": "临床早期", "potential": "高", "description": "Reuters 2026: 改良型CAR-T疗法可能让血液癌患者免受毒性预处理化疗", "trend": "CAR-T从高毒性到低毒性；免化疗预处理改善患者体验", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.reuters.com/business/healthcare-pharmaceuticals/new-car-t-cell-method", "collected_at": "2026-06-01T13:42:00Z" } ] }, { "id": "CT-031", "name": "FDA扩展CAR-T适应症", "type": "监管批准", "mechanism": "axi-cabtagene ciloleucel扩展", "clinical_stage": "已上市(新适应症)", "potential": "高", "description": "FDA扩展axi-cabtagene ciloleucel (axi-cel) CAR-T疗法适应症，覆盖罕见患者群体", "trend": "CAR-T从血液瘤到更广适应症；FDA加速审批路径", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://bloodcancerunited.org/resources/newsroom/fda-expands-car-t-approval-include-patients-with-rare", "collected_at": "2026-06-01T13:42:00Z" } ] }, { "id": "CT-032", "name": "CAR-T实体瘤进展2026", "type": "免疫细胞治疗", "mechanism": "CAR-T杀伤可检测肿瘤+免疫微环境调控", "clinical_stage": "临床I/II期", "potential": "高", "description": "CAR-T 2026年从血液瘤到实体瘤进展：杀伤可检测部分+免疫微环境调控", "trend": "实体瘤CAR-T从概念到早期临床；联合免疫检查点策略", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-01T13:42:00Z" } ] }, { "id": "CT-033", "name": "现货型CAR-T真相2026", "type": "免疫细胞治疗", "mechanism": "异体CAR-T(allogeneic)", "clinical_stage": "研究性", "potential": "高", "description": "2025-2026年现货型(off-the-shelf) CAR-T取得实质性临床进展但仍为研究性", "trend": "异体CAR-T从概念到临床数据；GVHD和持久性仍是挑战", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://globalrph.com/2026/04/car-t-cell-therapy-the-truth-about-off-the-shelf-treatments", "collected_at": "2026-06-01T13:42:00Z" } ] }, { "id": "CT-034", "name": "CAR-T未来十年发展策略", "type": "行业展望", "mechanism": "多策略", "clinical_stage": "多阶段", "potential": "极高", "description": "Bioinformant: 未来十年数十种CAR-T疗法可能获批，覆盖液体瘤和实体瘤", "trend": "CAR-T从7款到数十款；实体瘤突破是下一个里程碑", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://bioinformant.com/car-t-cell-therapy-development", "collected_at": "2026-06-01T13:42:00Z" } ] }, { "id": "CT-035", "name": "uPAR靶向CAR-T实体瘤突破", "type": "实体瘤CAR-T", "mechanism": "uPAR靶向CAR-T细胞", "clinical_stage": "临床前/早期临床", "potential": "极高", "description": "uPAR靶向CAR-T细胞缩小实体瘤并清除转移灶，为CAR-T治疗实体瘤提供新策略", "trend": "CAR-T从血液瘤到实体瘤突破；uPAR靶点前景广阔", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://medicalxpress.com/news/2026-03-upar-car-cells-shrank-solid.html", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "CT-036", "name": "WashU CAR-T FDA突破性疗法认定", "type": "T细胞血癌CAR-T", "mechanism": "创新CAR-T免疫疗法", "clinical_stage": "FDA突破性疗法认定", "potential": "极高", "description": "华盛顿大学医学院开发的侵袭性T细胞血癌CAR-T免疫疗法获FDA突破性疗法认定，加速审批路径", "trend": "CAR-T疗法审批加速；T细胞恶性肿瘤新选择", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://medicine.washu.edu/news/innovative-car-t-cell-therapy-receives-fda-breakthrough-therapy-designation", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "CT-037", "name": "AACR 2026 CAR-T早期研究亮点", "type": "学术会议", "mechanism": "多策略", "clinical_stage": "多阶段", "potential": "高", "description": "AACR 2026年会CAR-T早期研究亮点：高风险冒烟型多发性骨髓瘤CAR-T应用和AI诊断模型", "trend": "CAR-T适应症扩展到早期疾病；AI辅助CAR-T治疗决策", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.oncologynewscentral.com/oncology/early-studies-on-car-t-and-diagnostic-tools-among-highlights-at-aacr-2026", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "CT-038", "name": "iwCAR-T 2026国际研讨会", "type": "学术会议", "mechanism": "多策略", "clinical_stage": "多阶段", "potential": "高", "description": "iwCAR-T 2026: 年度国际CAR-T和细胞治疗研讨会，汇聚全球顶尖临床和转化研究人才", "trend": "CAR-T国际合作加强；从血液瘤到实体瘤策略讨论", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://iwcar-t.org/agenda", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "CT-039", "name": "CAR-T长期疗效Nature数据", "type": "临床数据", "mechanism": "CD19靶向CAR-T", "clinical_stage": "已上市", "potential": "高", "description": "Nature发表CAR-T长期疗效数据：CD19靶向CAR-T细胞可在B细胞恶性肿瘤中诱导长期缓解，长期毒性极小", "trend": "CAR-T长期疗效数据积累；安全性优于预期", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.nature.com/articles/s41571-023-00754-1", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "CT-040", "name": "CAR-T市场2026-2033预测", "type": "市场数据", "mechanism": "N/A", "clinical_stage": "N/A", "potential": "极高", "description": "全球CAR-T细胞治疗市场预计从2026年48.3亿美元增长到2033年184.6亿美元，CAGR 21.1%", "trend": "CAR-T市场持续高速增长；新适应症和通用型产品驱动", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.coherentmarketinsights.com/market-insight/car-t-cell-therapy-market-102", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "CT-041", "name": "CAR-T实体瘤免疫逃逸机制", "type": "机制研究", "mechanism": "免疫逃逸", "clinical_stage": "研究", "potential": "高", "description": "CAR-T治疗实体瘤免疫逃逸机制研究：CAR-T细胞杀伤可检测部分但剩余部分增殖(Lei et al., 2026)", "trend": "实体瘤免疫逃逸机制深入理解；联合策略克服逃逸", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.linkedin.com/pulse/car-t-cell-therapy-2026-from-blood-cancers-solid-stefano-gaburro-phd-lvrjf", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "CT-042", "name": "MSK CAR-T进展时间线", "type": "历史回顾", "mechanism": "多策略", "clinical_stage": "多阶段", "potential": "高", "description": "Memorial Sloan Kettering CAR-T进展时间线：从免疫细胞保护小鼠到7款FDA批准产品的完整历程", "trend": "CAR-T从实验室到临床的完整路径；未来十年数十种疗法可能获批", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.mskcc.org/timeline/car-t-timeline-progress", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "CT-043", "name": "通用型CAR-T(allogeneic)2026", "type": "异体CAR-T", "mechanism": "异体T细胞CAR改造", "clinical_stage": "I/II期", "potential": "极高", "description": "通用型(异体)CAR-T 2026年进展：现货型产品降低成本和等待时间，但GVHD和持久性挑战仍存", "trend": "异体CAR-T从概念到临床；成本和可及性改善", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "CT-044", "name": "CAR-NK细胞治疗2026进展", "type": "CAR-NK", "mechanism": "NK细胞CAR改造", "clinical_stage": "I/II期", "potential": "高", "description": "CAR-NK细胞治疗2026年进展：无需HLA匹配，异体使用潜力大，CRS风险低，实体瘤应用探索", "trend": "CAR-NK安全性优势明显；与CAR-T互补而非替代", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "CT-045", "name": "CAR-T联合免疫检查点抑制剂", "type": "联合疗法", "mechanism": "CAR-T+PD-1/CTLA-4抑制", "clinical_stage": "I/II期", "potential": "高", "description": "CAR-T联合免疫检查点抑制剂2026年进展：克服实体瘤免疫抑制微环境，提升CAR-T持久性和疗效", "trend": "联合疗法成为实体瘤CAR-T标准策略；免疫微环境调控", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "CT-046", "name": "CAR-T制造自动化2026", "type": "制造技术", "mechanism": "自动化生产", "clinical_stage": "N/A", "potential": "高", "description": "CAR-T制造自动化2026年进展：封闭式自动化生产系统降低成本和变异，缩短vein-to-vein时间", "trend": "CAR-T制造从手工到自动化；成本下降推动可及性", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "CT-047", "name": "TCR-T细胞治疗2026", "type": "TCR-T", "mechanism": "T细胞受体工程", "clinical_stage": "I/II期", "potential": "高", "description": "TCR-T细胞治疗2026年进展：识别细胞内抗原，拓展实体瘤治疗靶点范围", "trend": "TCR-T与CAR-T互补；细胞内靶点识别优势", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "CT-048", "name": "TIL肿瘤浸润淋巴细胞疗法", "type": "TIL疗法", "mechanism": "肿瘤浸润淋巴细胞扩增", "clinical_stage": "已上市(I期)", "potential": "高", "description": "TIL疗法2026年进展：Amtagvi(Lifileucel)获批后市场扩展，实体瘤治疗新选择", "trend": "TIL从黑色素瘤到其他实体瘤；制造工艺优化", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "CT-049", "name": "CAR-T安全性管理2026", "type": "安全管理", "mechanism": "CRS/ICANS管理", "clinical_stage": "已上市", "potential": "高", "description": "CAR-T安全性管理2026年进展：CRS和ICANS预测/预防/治疗策略优化，死亡率持续下降", "trend": "CAR-T安全性持续改善；早期干预和精准管理", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "CT-050", "name": "CRDWC 2026 CAR-T临床进展挑战", "type": "学术会议", "mechanism": "多策略", "clinical_stage": "多阶段", "potential": "高", "description": "CRDWC 2026年9月迈阿密：CAR-T细胞治疗临床进展与挑战专题，全球肿瘤专家和生物技术领袖", "trend": "CAR-T全球合作加强；临床挑战和解决方案讨论", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://cancerglobalconference.com/program/scientific-sessions/CAR-T-Cell-Therapy:-Clinical-Progress-and-Challenges", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "CT-051", "name": "KIR-CAR T实体瘤I期临床", "type": "免疫疗法", "efficiency": "N/A", "cost": "高", "maturity": "I期临床", "companies": [ "Penn Medicine" ], "description": "Penn Medicine首创KIR-CAR T细胞疗法I期临床试验，模仿自然杀伤细胞设计，限制T细胞毒性，针对实体瘤", "trend": "CAR-T从血液瘤到实体瘤突破；NK细胞设计策略降低毒性", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.pennmedicine.org/news/new-kir-car-t-cell-therapy-shows-promise-in-solid-cancers", "collected_at": "2026-06-03T13:57:41.937Z" } ] }, { "id": "CT-052", "name": "In vivo CAR-T体内制造", "type": "免疫疗法", "efficiency": "N/A", "cost": "潜在低", "maturity": "临床前", "companies": [ "Innovative Genomics Institute" ], "description": "IGI开发体内CAR-T疗法：在体内直接制造抗癌免疫细胞，小鼠实验杀死癌症，有望实现免化疗off-the-shelf治疗", "trend": "从体外到体内制造CAR-T；免化疗成为可能；off-the-shelf前景", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://innovativegenomics.org/news/in-vivo-car-t-cancer-fighting-immune-cells", "collected_at": "2026-06-03T13:57:41.937Z" } ] }, { "id": "CT-053", "name": "Mayo Clinic CAR-T实体瘤突破", "type": "免疫疗法", "efficiency": "N/A", "cost": "高", "maturity": "临床突破", "companies": [ "Mayo Clinic" ], "description": "Mayo Clinic跨学科合作实现CAR-T治疗实体瘤突破性进展", "trend": "跨学科合作推动CAR-T实体瘤突破；工程化改造是关键", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.mayoclinic.org/medical-professionals/cancer/news/major-advance-in-use-of-car-t-cell-therapy-to-treat-solid-tumors/mac-20588405", "collected_at": "2026-06-03T13:57:41.937Z" } ] }, { "id": "CT-054", "name": "City of Hope CAR-T胶质母细胞瘤", "type": "免疫疗法", "efficiency": "N/A", "cost": "高", "maturity": "临床研究", "companies": [ "City of Hope" ], "description": "City of Hope Christine Brown团队改造CAR-T治疗胶质母细胞瘤，为实体瘤CAR-T提供工程化改造经验", "trend": "脑瘤CAR-T从实验到临床；工程化改造策略多样化", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.cityofhope.org/research/research-news/edge-of-breakthrough/christine-brown", "collected_at": "2026-06-03T13:57:41.937Z" } ] }, { "id": "CT-055", "name": "Cancer Research UK CAR-T国际试验", "type": "免疫疗法", "efficiency": "N/A", "cost": "高", "maturity": "临床试验", "companies": [ "Cancer Research UK" ], "description": "Cancer Research UK 2026年4月启动突破性国际CAR-T临床试验，针对年轻人实体癌", "trend": "CAR-T临床试验从血液瘤扩展到实体瘤；国际合作加速", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://news.cancerresearchuk.org/2026/04/08/breakthrough-international-trial-launches-to-tackle-young-peoples-cancers", "collected_at": "2026-06-03T13:57:41.937Z" } ] }, { "id": "CT-056", "name": "TIM-3诱饵增强CAR-T", "type": "免疫疗法", "efficiency": "N/A", "cost": "高", "maturity": "临床前", "companies": [ "Avance Bio" ], "description": "TIM-3诱饵策略增强CAR-T疗效，目前聚焦血液癌但原理可适配实体瘤CAR-T", "trend": "免疫检查点诱饵策略增强CAR-T；从血液癌到实体瘤扩展", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.avancebio.com/breakthrough-in-car-t-cell-therapy-offers-hope-for-b-all-treatment", "collected_at": "2026-06-03T13:57:41.937Z" } ] }, { "id": "CT-057", "name": "Nature CAR-T当前挑战与未来方向", "type": "学术综述", "efficiency": "N/A", "cost": "N/A", "maturity": "参考", "companies": [ "多研究机构" ], "description": "Nature综述CAR-T当前挑战与未来方向：实体瘤尚未批准但其他T细胞疗法已获授权，新策略不断涌现", "trend": "CAR-T从血液瘤到实体瘤的攻坚；工程化/联合疗法/新型靶点", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.nature.com/articles/s41392-025-02269-w", "collected_at": "2026-06-03T13:57:41.937Z" } ] }, { "id": "CT-058", "name": "Penn Medicine KIR-CAR T实体瘤I期", "type": "免疫疗法", "mechanism": "KIR-CAR T细胞靶向杀伤实体瘤", "clinical_stage": "I期临床", "potential": "极高", "companies": [ "Penn Medicine" ], "description": "Penn Medicine首创KIR-CAR T细胞疗法I期临床试验，模仿自然杀伤细胞设计，限制T细胞毒性，针对实体瘤", "trend": "CAR-T从血液瘤到实体瘤突破；NK细胞设计策略降低毒性", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.pennmedicine.org/news/new-kir-car-t-cell-therapy-shows-promise-in-solid-cancers", "collected_at": "2026-06-04T14:05:26.379Z" } ] }, { "id": "CT-059", "name": "IGI体内CAR-T免化疗突破", "type": "免疫疗法", "mechanism": "体内直接制造CAR-T", "clinical_stage": "临床前", "potential": "极高", "companies": [ "Innovative Genomics Institute" ], "description": "IGI开发体内CAR-T疗法：在体内直接制造抗癌免疫细胞，小鼠实验杀死癌症，有望实现免化疗off-the-shelf治疗", "trend": "从体外到体内制造CAR-T；免化疗成为可能", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://innovativegenomics.org/news/in-vivo-car-t-cancer-fighting-immune-cells", "collected_at": "2026-06-04T14:05:26.379Z" } ] }, { "id": "CT-060", "name": "Mayo Clinic CAR-T实体瘤跨学科突破", "type": "免疫疗法", "mechanism": "跨学科合作CAR-T实体瘤", "clinical_stage": "临床突破", "potential": "极高", "companies": [ "Mayo Clinic" ], "description": "Mayo Clinic跨学科合作实现CAR-T治疗实体瘤突破性进展", "trend": "跨学科合作推动CAR-T实体瘤突破；工程化改造是关键", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.mayoclinic.org/medical-professionals/cancer/news/major-advance-in-use-of-car-t-cell-therapy-to-treat-solid-tumors/mac-20588405", "collected_at": "2026-06-04T14:05:26.379Z" } ] }, { "id": "CT-061", "name": "Cancer Research UK CAR-T国际试验启动", "type": "免疫疗法", "mechanism": "CAR-T治疗年轻人实体癌", "clinical_stage": "临床试验", "potential": "高", "companies": [ "Cancer Research UK" ], "description": "Cancer Research UK 2026年4月启动突破性国际CAR-T临床试验，针对年轻人实体癌", "trend": "CAR-T临床试验从血液瘤扩展到实体瘤；国际合作加速", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://news.cancerresearchuk.org/2026/04/08/breakthrough-international-trial-launches-to-tackle-young-peoples-cancers", "collected_at": "2026-06-04T14:05:26.379Z" } ] }, { "id": "CT-063", "name": "CAR-T全球多维分析Nature子刊", "type": "学术综述", "mechanism": "CAR-T", "clinical_stage": "综合分析", "potential": "参考", "companies": [ "多机构" ], "description": "Nature子刊发表CAR-T全球多维分析：血液恶性肿瘤取得实质性进展，实体瘤仍是挑战", "trend": "CAR-T血液瘤成熟/实体瘤突破中；全球研发格局分析", "sources": [ { "source_type": "web", "source_credibility": "A", "collected_at": "2026-06-04T14:07:22.337Z" } ] }, { "id": "CT-064", "name": "WashU CAR-T获FDA突破性疗法认定", "type": "监管突破", "mechanism": "CAR-T", "clinical_stage": "突破性疗法", "potential": "极高", "companies": [ "Washington University" ], "description": "Washington University CAR-T疗法获FDA突破性疗法认定，加速审批路径", "trend": "FDA加速CAR-T审批；突破性疗法认定增加", "sources": [ { "source_type": "web", "source_credibility": "A", "collected_at": "2026-06-04T14:07:22.337Z" } ] }, { "id": "CT-065", "name": "Reuters免化疗CAR-T报道", "type": "行业报道", "mechanism": "体内CAR-T", "clinical_stage": "临床前", "potential": "极高", "companies": [ "多公司" ], "description": "Reuters报道免化疗CAR-T疗法：在体内直接制造抗癌免疫细胞，无需化疗预处理", "trend": "免化疗是CAR-T终极目标；体内制造技术突破", "sources": [ { "source_type": "web", "source_credibility": "A", "collected_at": "2026-06-04T14:07:22.337Z" } ] }, { "id": "CT-065", "name": "基因驱动蚊子抑制疟疾患者来源寄生虫", "type": "基因驱动+免疫", "mechanism": "基因驱动蚊子+免疫", "clinical_stage": "临床前", "potential": "极高", "companies": [ "多研究机构" ], "description": "基因驱动蚊子抑制患者来源疟疾寄生虫：基因驱动技术引入野生蚊子遗传修饰，减少疟疾传播", "trend": "基因驱动从实验室到接近受控释放；疟疾防控新希望", "sources": [ { "source_type": "web", "source_credibility": "A", "collected_at": "2026-06-04T14:09:22.606Z" } ] }, { "id": "CT-066", "name": "uPAR靶向CAR-T缩小实体瘤并清除转移", "type": "实体瘤CAR-T", "mechanism": "uPAR靶向CAR-T", "clinical_stage": "临床前", "potential": "极高", "companies": [ "多研究机构" ], "description": "uPAR靶向CAR-T细胞缩小实体瘤并清除转移灶，突破CAR-T在实体瘤中的应用瓶颈", "trend": "CAR-T从血液癌到实体瘤突破；uPAR是新靶点", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://medicalxpress.com/news/2026-03-upar-car-cells-shrank-solid.html", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "CT-067", "name": "AACR 2026: CAR-T早期研究亮点", "type": "会议报告", "mechanism": "CAR-T", "clinical_stage": "早期临床", "potential": "高", "companies": [ "多机构" ], "description": "AACR 2026年会CAR-T早期研究亮点：高风险冒烟型多发性骨髓瘤CAR-T治疗、AI诊断模型", "trend": "CAR-T从晚期到早期疾病干预；AI辅助诊断", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.oncologynewscentral.com/oncology/early-studies-on-car-t-and-diagnostic-tools-among-highlights-at-aacr-2026", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "CT-068", "name": "Blood ICT: 扩大CAR-T可及性真实世界经验", "type": "临床研究", "mechanism": "CAR-T", "clinical_stage": "临床应用", "potential": "高", "companies": [ "多中心" ], "description": "Blood ICT发表扩大CAR-T可及性真实世界经验：从专科中心到更广泛医疗系统", "trend": "CAR-T从专科到普及；真实世界数据指导推广", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://ashpublications.org/bloodict/article/2/1/100026/557342/Broadening-CAR-T-access-lessons-from-real-world", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "CT-069", "name": "CAR-T细胞治疗市场4.83B→18.46B预测", "type": "市场数据", "mechanism": "CAR-T", "clinical_stage": "N/A", "potential": "N/A", "companies": [ "Coherent Market Insights" ], "description": "CAR-T细胞治疗市场2026年48.3亿美元，预计2033年达184.6亿美元，CAGR 21.1%", "trend": "CAR-T市场持续高速增长；适应症扩展驱动", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.coherentmarketinsights.com/market-insight/car-t-cell-therapy-market-102", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "CT-070", "name": "CAR-T 2026: 从血液癌到实体瘤", "type": "行业分析", "mechanism": "CAR-T", "clinical_stage": "多阶段", "potential": "极高", "companies": [ "多公司" ], "description": "CAR-T 2026年从血液癌到实体瘤：免疫抑制肿瘤微环境(TME)是主要挑战，新策略突破中", "trend": "CAR-T实体瘤是下一个前沿；TME调控是关键", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.linkedin.com/pulse/car-t-cell-therapy-2026-from-blood-cancers-solid-stefano-gaburro-phd-lvrjf", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "CT-071", "name": "CAR-T现状挑战与前景综述", "type": "学术综述", "mechanism": "CAR-T", "clinical_stage": "N/A", "potential": "高", "companies": [ "多机构" ], "description": "Wiley发表CAR-T现状挑战与前景综述：生物学基础、当前挑战和未来方向", "trend": "CAR-T从突破到优化；挑战和前景并存", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://onlinelibrary.wiley.com/doi/full/10.1002/mco2.70606", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "CT-072", "name": "BioInformant: CAR-T疗法开发未来策略", "type": "行业分析", "mechanism": "CAR-T", "clinical_stage": "多阶段", "potential": "高", "companies": [ "多公司" ], "description": "BioInformant分析CAR-T疗法开发未来策略：未来十年数十种CAR-T疗法可能获批", "trend": "CAR-T从少数到数十种；液体癌和实体瘤双线推进", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://bioinformant.com/car-t-cell-therapy-development", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "CT-073", "name": "CAR-T Summit 2026临床进展版", "type": "行业会议", "mechanism": "CAR-T", "clinical_stage": "N/A", "potential": "N/A", "companies": [ "多公司" ], "description": "CAR-T Cell Therapy Summit 2026临床进展第2版(9月21-23日)", "trend": "CAR-T年度峰会持续；临床进展是核心议题", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://cancerglobalconference.com/program/scientific-sessions/CAR-T-Cell-Therapy:-Clinical-Progress-and-Challenges", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "CT-074", "name": "MSK: CAR-T细胞进展时间线", "type": "历史回顾", "mechanism": "CAR-T", "clinical_stage": "N/A", "potential": "N/A", "companies": [ "MSK" ], "description": "Memorial Sloan Kettering CAR-T细胞进展时间线：从第二代CAR到临床突破", "trend": "CAR-T从概念到治愈；历史回顾显示加速趋势", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.mskcc.org/timeline/car-t-timeline-progress", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "CT-075", "name": "同种异体(off-the-shelf)CAR-T 2026进展", "type": "通用型CAR-T", "mechanism": "同种异体CAR-T", "clinical_stage": "临床I/II期", "potential": "极高", "companies": [ "多公司" ], "description": "2026年同种异体(off-the-shelf)CAR-T进展：从自体到通用型，降低成本和等待时间", "trend": "CAR-T从自体到通用型；成本和时间大幅降低", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "CT-076", "name": "CAR-T神经毒性2026管理策略", "type": "安全性", "mechanism": "CAR-T", "clinical_stage": "临床管理", "potential": "N/A", "companies": [ "多中心" ], "description": "2026年CAR-T神经毒性(ICANS)管理策略进展：早期识别、分级管理、新干预手段", "trend": "CAR-T安全性从被动到主动管理；神经毒性可控性提升", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "CT-077", "name": "CRISPR临床试验2026全景", "type": "基因编辑临床", "efficiency": "250+项试验", "cost": "高", "maturity": "临床推进", "companies": [ "CRISPR Therapeutics", "Vertex", "Intellia", "Editas" ], "description": "截至2026年初，全球约250项CRISPR基因编辑治疗临床试验正在进行，其中150+项处于活跃状态，覆盖血红蛋白病、癌症、自身免疫病等多领域", "trend": "CRISPR从实验室走向临床加速；血液病领域领先，实体瘤和HIV快速推进", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://crisprmedicinenews.com/clinical-trials", "collected_at": "2026-06-16T22:31:38.000Z" }, { "source_type": "web", "source_credibility": "A", "article_url": "https://innovativegenomics.org/news/crispr-clinical-trials-2026", "collected_at": "2026-06-16T22:31:38.000Z" } ] }, { "id": "CT-078", "name": "Christiana Care CRISPR头颈癌疗法", "type": "CRISPR癌症疗法", "efficiency": "I期临床试验", "cost": "高", "maturity": "临床I期", "companies": [ "Christiana Care Health System" ], "description": "2026年1月报道Christiana Care团队利用CRISPR基因编辑技术恢复化疗对耐药头颈癌肿瘤的疗效，为耐药癌症治疗提供新方案", "trend": "CRISPR用于克服化疗耐药性；实体瘤CRISPR疗法取得早期突破", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://news.christianacare.org/2026/01/gene-editing-breakthrough-offers-new-hope-for-head-and-neck-cancer-patients", "collected_at": "2026-06-16T22:31:38.000Z" } ] }, { "name": "CAR-T cell therapy", "type": "Therapy", "target": "Cancer (hematologic and solid tumors)", "companies": [], "status": "Clinical Trials", "description": "CAR-T cell therapy represents a significant advancement in cancer treatment, particularly for hematological malignancies. It involves genetically modifying a patient's own T cells to better recognize and attack cancer cells. The therapy has shown remarkable success in treating certain types of leukemia and lymphoma, though challenges remain in applying it to solid tumors.", "id": "CT-079" }, { "name": "UT MD Anderson", "type": "Institution", "target": "Novel CAR T cell therapy development", "companies": [], "status": "Clinical Studies", "description": "UT MD Anderson is a leading cancer research institution that has developed a novel CAR T cell therapy. This therapy is currently moving into clinical studies, indicating progress towards potential approval and wider use. The institution continues to innovate in the field of cell-based cancer treatments.", "id": "CT-080" }, { "name": "KIR-CAR T cell therapy", "type": "Therapy", "target": "Multiple solid cancers", "companies": [], "status": "Clinical Trials", "description": "KIR-CAR T cell therapy is an innovative type of CAR T cell therapy that has shown promise in treating multiple solid cancers. Early results indicate that it is safe and that efficacy increases with higher doses. This therapy represents a potential breakthrough in overcoming the limitations of traditional CAR-T approaches in solid tumor treatment.", "id": "CT-081" }, { "name": "CAR-NK cell therapy", "type": "Therapy", "target": "Solid tumors", "companies": [], "status": "Research", "description": "CAR-NK cell therapy is an emerging field focused on engineering next-generation therapies using Natural Killer (NK) cells. It aims to address the challenges associated with treating solid tumors, which have been difficult to manage with conventional CAR-T therapies. Research is ongoing to optimize the effectiveness and safety of these engineered NK cells.", "id": "CT-082" }, { "name": "Triple Threat CAR T-Cell Therapy", "type": "Therapy", "target": "CD19, CD20, CD22 antigens", "companies": [], "status": "Phase 1 Clinical Trial", "description": "Triple Threat CAR T-Cell Therapy is a novel approach that targets three different antigens (CD19, CD20, and CD22) overexpressed in B-cell malignancies. Currently in Phase 1 clinical trials at KU Cancer Center, this therapy aims to improve treatment outcomes by simultaneously attacking multiple cancer cell markers. The multi-target strategy could potentially reduce the likelihood of cancer cells evading treatment.", "id": "CT-083" }, { "name": "Nanoparticle-Enhanced CAR-T/NK Combination Therapy", "type": "Combined CAR-T and NK Cell Therapy", "target": "CD19-targeted cells with IL-15 delivery support", "technology": "Lipid nanoparticles (LNPs) delivering IL-15 to enhance NK and CAR-T cell activity", "status": "Clinical trial NCT05341409 ongoing", "description": "This clinical trial assesses a combined therapeutic approach involving CD19-targeted CAR-T therapy alongside IL-15 delivery via lipid nanoparticles (LNPs). The IL-15 is designed to support and enhance the activity of both NK cells and CAR-T cells. Published in PMC, this nanoparticle-enhanced strategy represents an emerging technique to improve cellular immunotherapy outcomes through synergistic cell support mechanisms.", "id": "CT-084" }, { "name": "Novel CAR T Cell Therapy (UT MD Anderson)", "type": "CAR-T Cell Therapy", "target": "Cancer cells (specific targets not detailed in snippet)", "technology": "Novel CAR T cell engineering developed by UT MD Anderson researchers", "status": "Moved into clinical studies as of May 15, 2026", "description": "Researchers at UT MD Anderson have developed a novel CAR T cell therapy that has progressed into clinical studies. Announced in a news release on May 15, 2026, this therapy represents new innovations in CAR T cell engineering from the MD Anderson team. While specific targets were not detailed in the provided information, the advancement into clinical trials indicates promising preclinical results.", "id": "CT-085" }, { "name": "Next-Generation CAR-NK Cell Therapy", "type": "CAR-NK Cell Therapy", "target": "Solid tumors", "technology": "Engineered CAR-NK cells with next-generation modifications", "status": "Under active research and review for solid tumor applications", "description": "CAR-NK cell therapy represents an emerging approach focusing on engineering natural killer cells with chimeric antigen receptors for improved anti-tumor activity. Current reviews discuss trends and concepts in next-generation CAR-NK therapies, particularly their application in treating solid tumors which remain challenging for conventional cell therapies. This approach leverages the unique properties of NK cells while enhancing their targeting specificity through CAR engineering.", "id": "CT-086" }, { "id": "CT-087", "name": "A2B543 CAR-T Fast Track", "type": "CAR-T", "target": "HLA-A*02", "maturity": "Fast Track", "companies": [ "A2Bio" ], "description": "FDA 2026年4月授予A2B543自体CAR-T细胞疗法快速通道资格，用于治疗胚系杂合HLA-A*02成人患者", "trend": "CAR-T向实体瘤和罕见靶点扩展" }, { "id": "CT-088", "name": "soficabtagene geleucel 突破性认定", "type": "CAR-T", "target": "T-Cell Lymphoma", "maturity": "突破性疗法", "companies": [ "Allogene" ], "description": "FDA授予soficabtagene geleucel突破性疗法认定，治疗复发/难治性T细胞淋巴瘤患者", "trend": "异体CAR-T取得突破性进展" }, { "id": "CT-089", "name": "WU-CART-007 突破性认定", "type": "CAR-T", "target": "R/R T-ALL", "maturity": "突破性疗法", "companies": [ "Wugen" ], "description": "FDA授予Wugen的WU-CART-007突破性疗法认定，治疗复发/难治性T细胞急性淋巴细胞白血病", "trend": "CAR-T覆盖更多血液肿瘤亚型" }, { "id": "CT-090", "name": "11款自体CAR-T获批", "type": "CAR-T", "target": "血液肿瘤", "maturity": "已上市", "companies": [ "Novartis", "Gilead/Kite", "BMS", "Janssen", "百济神州" ], "description": "截至2025年已有11款自体CAR-T细胞疗法获批上市，覆盖多种血液肿瘤适应症", "trend": "CAR-T从前沿疗法走向标准治疗" }, { "id": "CT-091", "name": "ASCO 2025 实体瘤CAR-T I期进展", "type": "CAR-T", "target": "实体瘤", "maturity": "I期临床", "companies": [ "多家中美药企" ], "description": "2025 ASCO会议报告了多项CAR-T治疗实体瘤的I期临床试验进展，展示CAR-T在实体瘤中的潜力", "trend": "实体瘤CAR-T是下一个重大突破方向" }, { "id": "CELL-92", "name": "Kymriah (tisagenlecleucel)", "type": "CAR-T", "mechanism": "Autologous T-cells engineered with a chimeric antigen receptor (CAR) targeting CD19 on B-cells.", "clinical_stage": "Approved" }, { "id": "CELL-93", "name": "Yescarta (axicabtagene ciloleucel)", "type": "CAR-T", "mechanism": "Autologous CAR-T cells targeting CD19 for the treatment of B-cell lymphomas.", "clinical_stage": "Approved" }, { "id": "CELL-94", "name": "Breyanzi (lisocabtagene maraleucel)", "type": "CAR-T", "mechanism": "CD19-directed CAR-T cell therapy with a defined 4-1BB co-stimulatory domain.", "clinical_stage": "Approved" }, { "id": "CELL-95", "name": "Abecma (idecabtagene vicleucel)", "type": "CAR-T", "mechanism": "BCMA-directed CAR-T cell therapy for patients with multiple myeloma.", "clinical_stage": "Approved" }, { "id": "CELL-96", "name": "Tecartus (brexucabtagene autoleucel)", "type": "CAR-T", "mechanism": "CD19-targeting CAR-T cell therapy for B-cell malignancies, including mantle cell lymphoma.", "clinical_stage": "Approved" }, { "id": "CELL-97", "name": "CAR-TCR-Hi-1", "type": "CAR-T", "mechanism": "Next-generation CAR-T with enhanced persistence and reduced exhaustion through cytokine modulation.", "clinical_stage": "Phase II" }, { "id": "CELL-98", "name": "Allogeneic iPSC-Derived NK Cells", "type": "NK cell", "mechanism": "Off-the-shelf natural killer cells derived from induced pluripotent stem cells (iPSCs).", "clinical_stage": "Phase I" }, { "id": "CELL-99", "name": "NK-92 (Hank's formulation)", "type": "NK cell", "mechanism": "Cytokine-induced killer (CIK) cells derived from the NK-92 cell line, engineered for enhanced tumor targeting.", "clinical_stage": "Phase II" }, { "id": "CELL-100", "name": "CAR-NK Cells (CD19-targeted)", "type": "NK cell", "mechanism": "Allogeneic CAR-NK cells engineered to target CD19 on B-cell malignancies.", "clinical_stage": "Phase I" }, { "id": "CELL-101", "name": "Mesenchymal Stem Cells (MSCs) for GvHD", "type": "Stem cell", "mechanism": "Allogeneic MSCs that modulate the immune response to treat graft-versus-host disease (GvHD).", "clinical_stage": "Phase III" }, { "id": "CELL-102", "name": "Hematopoietic Stem Cell Transplant (HSCT)", "type": "Stem cell", "mechanism": "Autologous or allogeneic HSCT to reconstitute a patient's hematopoietic system after high-dose chemotherapy.", "clinical_stage": "Approved" }, { "id": "CELL-103", "name": "Vγ9Vδ2 T Cell Therapy", "type": "Gamma delta T", "mechanism": "Ex vivo expanded Vγ9Vδ2 T cells that recognize phosphoantigens on stressed or tumor cells.", "clinical_stage": "Phase I/II" }, { "id": "CELL-104", "name": "Tumor-Infiltrating Lymphocytes (TIL) Therapy", "type": "TIL", "mechanism": "Autologous T cells isolated from a patient's tumor, expanded ex vivo, and reinfused to target tumor antigens.", "clinical_stage": "Phase II" }, { "id": "CELL-105", "name": "CAR-Treg Cells", "type": "CAR-T", "mechanism": "Engineered regulatory T cells (Tregs) with a CAR to target specific autoantigens for autoimmune diseases.", "clinical_stage": "Phase I" }, { "id": "CELL-106", "name": "Dual-Specific CAR-T (CD19/CD20)", "type": "CAR-T", "mechanism": "CAR-T cells engineered with two CARs to target both CD19 and CD20 antigens, reducing antigen escape.", "clinical_stage": "Preclinical" }, { "id": "CELL-107", "name": "Kymriah (tisagenlecleucel)", "type": "CAR-T", "mechanism": "CD19-directed CAR-T therapy for B-cell malignancies", "clinical_stage": "Approved" }, { "id": "CELL-108", "name": "Yescarta (axicabtagene ciloleucel)", "type": "CAR-T", "mechanism": "CD19-directed CAR-T therapy for B-cell lymphomas", "clinical_stage": "Approved" }, { "id": "CELL-109", "name": "Breyanzi (lisocabtagene maraleucel)", "type": "CAR-T", "mechanism": "CD19-directed CAR-T therapy for B-cell lymphomas", "clinical_stage": "Approved" }, { "id": "CELL-110", "name": "Abecma (idecabtagene vicleucel)", "type": "CAR-T", "mechanism": "BCMA-directed CAR-T therapy for multiple myeloma", "clinical_stage": "Approved" }, { "id": "CELL-111", "name": "Tecartus (brexucabtagene autoleucel)", "type": "CAR-T", "mechanism": "CD19-directed CAR-T therapy for B-cell malignancies", "clinical_stage": "Approved" }, { "id": "CELL-112", "name": "CAR-19 T-cell Therapy", "type": "CAR-T", "mechanism": "Next-generation CD19-targeting CAR with safety switch", "clinical_stage": "Phase III" }, { "id": "CELL-113", "name": "Mesenchymal Stem Cell Therapy (MSC-100)", "type": "Stem Cell", "mechanism": "Allogeneic MSCs for modulating inflammation and promoting tissue repair", "clinical_stage": "Phase II" }, { "id": "CELL-114", "name": "Induced Pluripotent Stem Cell-Derived Cardiomyocytes (iPSC-CM)", "type": "Stem Cell", "mechanism": "Patient-specific cardiomyocytes for regenerative therapy of heart failure", "clinical_stage": "Phase I/II" }, { "id": "CELL-115", "name": "NK-92 Cell Therapy (haNK)", "type": "NK Cell", "mechanism": "Engineered NK-92 cells expressing IL-2 and anti-EGFR scFv for solid tumors", "clinical_stage": "Phase I" }, { "id": "CELL-116", "name": "Allogeneic NK Cell Therapy (FT516)", "type": "NK Cell", "mechanism": "iPSC-derived, off-the-shelf NK cells with enhanced cytokine support", "clinical_stage": "Phase II" }, { "id": "CELL-117", "name": "Tumor-Infiltrating Lymphocyte Therapy (LN-145)", "type": "TIL", "mechanism": "Autologous TILs expanded ex vivo and reinfused for solid tumors", "clinical_stage": "Phase II" }, { "id": "CELL-118", "name": "Gamma Delta T-Cell Therapy (GD2-CAR γδ T)", "type": "Gamma Delta T", "mechanism": "Engineered γδ T-cells with GD2-specific CAR for neuroblastoma", "clinical_stage": "Phase I" }, { "id": "CELL-119", "name": "iPSC-Derived Hematopoietic Stem Cells (iPSC-HSC)", "type": "Stem Cell", "mechanism": "Universal donor iPSC-HSCs for hematopoietic reconstitution", "clinical_stage": "Phase I" }, { "id": "CELL-120", "name": "Natural Killer Cell Therapy (SNK01)", "type": "NK Cell", "mechanism": "Cryopreserved allogeneic NK cells with enhanced ADCC activity", "clinical_stage": "Phase II" }, { "id": "CELL-121", "name": "Gamma Delta T-Cell Therapy (Vδ2 T-cell Expansion)", "type": "Gamma Delta T", "mechanism": "Ex vivo expanded Vδ2 T-cells for targeting phosphoantigens in cancer", "clinical_stage": "Phase I/II" } ], "bioinformatics": [ { "id": "BINF-001", "name": "单细胞多组学Single-Cell Multi-Omics", "type": "分析平台", "description": "同时测量单个细胞的多个分子层(基因组/表观组/转录组/蛋白质组)，揭示细胞异质性", "application": "癌症异质性/免疫细胞图谱/发育生物学/药物耐药", "tool": "10x Genomics Multiome/Parse Biosciences/BD Rhapsody", "trend": "空间+单细胞融合；百万细胞级实验成为常规" }, { "id": "BINF-002", "name": "长读长测序PacBio/Oxford Nanopore", "type": "测序技术", "description": "单次读取>10000碱基，解析重复区域/结构变异/表观修饰", "application": "完整基因组组装/结构变异检测/直接RNA测序/甲基化检测", "tool": "PacBio Revio/Oxford Nanopore PromethION", "trend": "成本快速下降；人类泛基因组参考使用长读长；$100基因组目标接近" }, { "id": "BINF-003", "name": "AI驱动药物发现", "type": "计算药物设计", "description": "ML预测药物-靶点相互作用/优化先导化合物/设计新分子，大幅缩短药物开发时间", "application": "从头药物设计/虚拟筛选/ADMET预测/临床试验优化", "tool": "Insilico Medicine/Recursion/Exscientia/Absci", "trend": "AI设计分子进入临床；Recursion/NVIDIA合作加速；生成式AI药物设计" }, { "id": "BINF-004", "name": "AlphaFold/蛋白质结构预测", "type": "蛋白质结构预测", "description": "DeepMind AI从氨基酸序列预测3D蛋白结构，AlphaFold3预测蛋白-配体/DNA/RNA相互作用", "application": "药物设计/酶工程/疾病突变理解", "tool": "Google DeepMind/Isomorphic Labs", "trend": "AlphaFold3 2024年发布；蛋白质-蛋白质/蛋白质-药物相互作用预测" }, { "id": "BINF-005", "name": "空间转录组学Spatial Transcriptomics", "type": "分析工具", "description": "保留组织空间位置测量基因表达，揭示细胞邻域和组织结构", "application": "癌症微环境/脑细胞图谱/发育生物学", "tool": "10x Genomics Visium/Xenium/Vizgen MERFISH/NanoString CosMx", "trend": "亚细胞分辨率；与单细胞数据整合分析；Nature Methods年度技术" }, { "id": "BINF-006", "name": "蛋白质组学Mass Spectrometry", "type": "蛋白质分析", "description": "质谱大规模鉴定和定量蛋白质，补充基因组/转录组信息", "application": "生物标志物发现/药物靶点验证/翻译后修饰分析", "tool": "Thermo Fisher Orbitrap/Bruker timsTOF/Somalogic SomaScan", "trend": "单细胞蛋白质组学突破；SomaScan 7000+蛋白检测；与基因组学整合" }, { "id": "BINF-007", "name": "基因组组装与泛基因组", "type": "基因组学", "description": "完整基因组组装和人类泛基因组参考，代表全球遗传多样性", "application": "结构变异检测/群体遗传学/精准医学", "tool": "T2T Consortium/HPRC/PacBio+HiC+Ont", "trend": "T2T完整人类基因组2022年发布；人类泛基因组参考(HPRC)2023年发布；350+个体组装" }, { "id": "BINF-008", "name": "生物信息学流程与云平台", "type": "计算基础设施", "description": "可重复的生物信息学分析流程和云计算平台", "application": "基因组分析/RNA-seq/变异调用/多组学整合", "tool": "Nextflow/Snakemake/Terra/DNAnexus/BaseSpace", "trend": "FAIR原则推动；容器化(Docker/Singularity)标准化；云端分析成为主流" }, { "id": "BINF-009", "name": "AI/LLM在生物学中的应用", "type": "AI for Biology", "description": "大语言模型和AI在生物学文本挖掘/知识图谱/实验设计中的应用", "application": "文献挖掘/假设生成/实验设计优化/蛋白质语言模型", "tool": "ESMFold/ProtGPT2/BioGPT/GeneGPT", "trend": "蛋白质语言模型(ESM-2/3)预测结构和功能；LLM辅助实验设计" }, { "id": "BINF-010", "name": "表观基因组学Epigenomics", "type": "表观遗传分析", "description": "全基因组DNA甲基化/组蛋白修饰/染色质可及性分析", "application": "衰老时钟/癌症表观遗传/发育重编程/环境暴露", "tool": "ATAC-seq/ChIP-seq/Bisulfite-seq/Nanopore直接甲基化检测", "trend": "表观遗传时钟(GrimAge/PhenoAge)用于衰老评估；单细胞表观组学" }, { "id": "BINF-011", "name": "代谢组学Metabolomics", "type": "代谢分析", "description": "大规模检测和定量生物样本中的代谢物", "application": "疾病诊断/药物代谢/营养学/微生物组", "tool": "Metabolon/Agilent/Bruker/Mass Spectrometry+NMR", "trend": "与基因组学/蛋白质组学整合；精准营养学应用；微生物组代谢" }, { "id": "BINF-012", "name": "微生物组分析Microbiome", "type": "微生物组学", "description": "16S/宏基因组/宏转录组分析微生物群落", "application": "肠道健康/免疫调节/药物代谢/农业", "tool": "QIIME2/MetaPhlAn/HUMAnN/Shotgun metagenomics", "trend": "肠-脑轴研究热点；粪菌移植(FMT)规范化；合成生物学改造微生物组" }, { "id": "BINF-013", "name": "AI蛋白质结构预测AlphaFold3+", "type": "AI+结构生物学", "description": "AlphaFold3预测蛋白质-配体/DNA/RNA相互作用；2026年AI蛋白质设计从预测到创造", "application": "药物设计/酶工程/理解疾病突变", "tool": "AlphaFold3/ESMFold/RoseTTAFold2/Chai-2", "trend": "从结构预测到蛋白质设计；Chai-2抗体设计16%成功率；ESM3生成全新蛋白质" }, { "id": "BINF-014", "name": "空间多组学Spatial Multi-Omics", "type": "分析平台", "description": "空间转录组+空间蛋白质组+空间表观组融合，同时保留空间位置和多个分子层信息", "application": "肿瘤微环境/脑细胞图谱/发育生物学", "tool": "10x Genomics Xenium/Vizgen MERFISH/NanoString CosMx", "trend": "2026年空间组学从单模态到多模态融合；亚细胞分辨率成为标配" }, { "id": "BINF-015", "name": "AI驱动的基因组解读", "type": "AI+基因组学", "description": "AI模型自动解读基因组变异的临床意义，加速精准诊断", "application": "罕见病诊断/癌症基因组/药物基因组学", "tool": "DeepVariant/GATK/临床AI解读平台", "trend": "从人工解读到AI辅助解读；VUS(意义不明变异)率显著降低" }, { "id": "BINF-016", "name": "数字孪生人体模型", "type": "计算模型", "description": "基于多组学数据构建个体化数字孪生，模拟疾病进展和药物反应", "application": "药物筛选/个性化治疗/临床试验模拟", "tool": "Aitia/Dana-Farber/计算系统生物学平台", "trend": "从群体统计到个体化预测；与AI/ML深度整合" }, { "id": "BINF-017", "name": "长读长单细胞测序", "type": "测序技术", "description": "长读长测序与单细胞技术结合，同时获得转录本异构体和细胞身份信息", "application": "可变剪接/融合基因/等位基因特异性表达", "tool": "PacBio MAS-Seq/Oxford Nanopore单细胞", "trend": "2026年单细胞长读长从概念到常规；揭示短读长遗漏的转录组复杂性" }, { "id": "BINF-018", "name": "AI蛋白质结构预测AlphaFold3", "type": "AI工具", "description": "AlphaFold3预测蛋白质-配体/蛋白质-核酸复合物结构，扩展到药物设计应用", "application": "药物设计/蛋白质工程/靶点发现", "tool": "DeepMind AlphaFold3", "trend": "从结构预测到药物设计全流程；2026年与实验验证闭环" }, { "id": "BINF-019", "name": "AI基因组解读", "type": "AI工具", "description": "AI自动解读基因组变异的临床意义，从VUS(意义不明变异)到明确诊断", "application": "罕见病诊断/癌症基因组/药物基因组学", "tool": "DeepVariant/GATK/AI解读平台", "trend": "AI解读准确率接近专家水平；2026年临床部署加速" }, { "id": "BINF-020", "name": "空间转录组学Spatial Transcriptomics", "type": "分析平台", "description": "保留组织空间位置信息的转录组分析，揭示细胞在组织中的空间关系", "application": "肿瘤微环境/发育生物学/脑科学", "tool": "10x Visium/MERFISH/Vizgen/Resolve Biosciences", "trend": "2026年空间组学从研究到临床病理；与单细胞数据融合" }, { "id": "BINF-021", "name": "多模态生物AI", "type": "AI工具", "description": "整合基因组/蛋白质组/影像/临床数据的多模态AI模型，实现跨尺度生物预测", "application": "药物发现/精准医学/临床试验优化", "tool": "Google DeepMind/Recursion/Insilico Medicine", "trend": "从单模态到多模态融合；2026年药物发现AI平台成熟化" }, { "id": "BINF-022", "name": "联邦学习基因组分析", "type": "隐私计算", "description": "联邦学习实现多机构基因组数据联合分析，保护数据隐私", "application": "多中心临床研究/罕见病/药物基因组学", "tool": "NVIDIA FLARE/OpenFL/TensorFlow Federated", "trend": "数据隐私法规推动；2026年跨国基因组协作项目采用" }, { "id": "BINF-023", "name": "蛋白质组学质谱4D", "type": "分析平台", "description": "timsTOF等4D质谱技术实现更高通量/灵敏度蛋白质组分析", "application": "生物标志物发现/精准医学/药物靶点验证", "tool": "Bruker timsTOF/Thermo Orbitrap", "trend": "2026年单细胞蛋白质组学突破；与基因组数据整合" }, { "id": "BINF-024", "name": "临床NLP电子病历挖掘", "type": "AI工具", "description": "自然语言处理挖掘电子病历中的临床信息，辅助研究和诊断", "application": "临床研究/药物警戒/患者队列识别", "tool": "GPT-4/Med-PaLM/ClinicalBERT", "trend": "LLM驱动的临床NLP 2026年快速成熟；从研究到临床部署" }, { "id": "BINF-025", "name": "表观基因组图谱", "type": "分析平台", "description": "全基因组表观修饰(DNA甲基化/组蛋白修饰/染色质开放性)系统分析", "application": "衰老研究/癌症表观遗传/发育生物学", "tool": "ENCODE/Roadmap/IHEC", "trend": "表观遗传时钟与疾病预测；2026年临床表观基因组学起步" }, { "id": "BINF-026", "name": "微生物组分析平台", "type": "分析平台", "description": "宏基因组/宏转录组分析肠道/皮肤/环境微生物组，揭示微生物-宿主互作", "application": "肠道健康/免疫疾病/药物代谢", "tool": "QIIME2/MetaPhlAn/HUMAnN", "trend": "微生物组从关联到因果；2026年活体生物药临床推进" }, { "id": "BINF-027", "name": "AI药物发现平台", "type": "AI工具", "description": "AI驱动的端到端药物发现：靶点识别→分子设计→优化→临床试验设计", "application": "新药研发/老药新用/临床试验优化", "tool": "Insilico Medicine/Recursion/Exscientia/Relay Therapeutics", "trend": "AI设计药物2026年多个进入临床II期；从概念验证到疗效验证" }, { "id": "BINF-028", "name": "空间组学临床转化2026", "type": "分析平台", "description": "空间组学从研究到临床转化：空间转录组/空间蛋白质组进入诊断应用", "application": "肿瘤诊断/药物开发/精准医疗", "tool": "10x Visium/MERFISH/CosMx", "trend": "空间组学2026年临床转化加速；从科研工具到诊断平台" }, { "id": "BINF-029", "name": "AI对齐监管框架生物技术", "type": "AI工具", "description": "AI成为受监管药物开发的一部分，AI对齐监管框架在生物技术领域建立", "application": "药物开发/临床试验/监管提交", "tool": "FDA/EMA AI指南", "trend": "AI从辅助到核心工具；监管框架2026年初步成型" }, { "id": "BINF-030", "name": "Prime editing扩展应用", "type": "基因编辑工具", "description": "Prime editing从早期领先扩展到更广泛应用，精度和效率持续提升", "application": "遗传病治疗/作物改良/功能基因组学", "tool": "Prime Medicine/PTC Therapeutics", "trend": "Prime editing 2026年从罕见病到更广适应症；精度优势明显" }, { "id": "BINF-031", "name": "Nature BME 2026前沿", "type": "学术综述", "description": "Nature BME: 生物医学工程前沿快速重塑转化研究和医学", "application": "全行业", "tool": "多平台", "trend": "生物医学工程从辅助到主导；跨学科融合加速" }, { "id": "BINF-032", "name": "Nature BME 2026生物医学工程前沿", "type": "学术综述", "description": "Nature BME: 生物医学工程前沿快速重塑转化研究和医学，跨学科融合加速", "application": "全行业", "tool": "多平台", "trend": "生物医学工程从辅助到主导；跨学科融合加速", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.nature.com/articles/s41551-026-01611-z", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "BINF-033", "name": "2026生物技术10大突破趋势", "type": "行业趋势", "description": "Atlantis Bioscience: 2026年10大生物技术趋势，从体内编辑和RNA疗法到空间组学和再生医学创新", "application": "全行业", "tool": "多平台", "trend": "体内编辑/RNA疗法/空间组学/再生医学四大热点", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.atlantisbioscience.com/blog/2026-biotech-outlook-10-breakthrough-trends-scientists-need-to-watch", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "BINF-034", "name": "BIOENG-2026 AI时代生物工程", "type": "学术会议", "description": "BIOENG-2026: 以'AI时代的生物工程'为主题，推动生物工程研究前沿", "application": "全行业", "tool": "AI+生物", "trend": "AI+生物工程深度融合；从辅助工具到核心方法", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://sciforum.net/event/BIOENG2026", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "BINF-035", "name": "基因驱动逆转杀虫剂抗性", "type": "基因驱动", "description": "新基因驱动技术逆转害虫杀虫剂抗性，保护作物并大幅减少化学农药使用", "application": "农业/害虫防控", "tool": "基因驱动系统", "trend": "基因驱动从灭虫到恢复敏感性；农业应用前景广阔", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.isaaa.org/kc/cropbiotechupdate/article/default.asp?ID=21109", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "BINF-036", "name": "Science基因驱动技术监管", "type": "政策讨论", "description": "Science讨论：如何监管争议性基因驱动技术，平衡创新潜力和生态风险", "application": "政策/监管", "tool": "N/A", "trend": "基因驱动监管框架从空白到建立；国际治理机制讨论", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.science.org/content/article/how-will-we-keep-controversial-gene-drive-technology-check", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "BINF-037", "name": "基因驱动抗疟疾非洲应用", "type": "公共卫生", "description": "MESA: 基因驱动技术在非洲疟疾消除中的应用，为政策制定者提供指导建议", "application": "疟疾防控", "tool": "基因驱动蚊子", "trend": "基因驱动从实验室到受控释放；非洲疟疾防控新工具", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://mesamalaria.org/resource-hub/application-of-gene-drive-technology-for-malaria-elimination-in-africa", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "BINF-038", "name": "Nature基因驱动疟疾控制替代方案", "type": "学术综述", "description": "Nature发表基因驱动用于媒介控制特别是疟疾的综述：使用和进展讨论", "application": "疟疾防控", "tool": "基因驱动", "trend": "基因驱动疟疾控制从概念到评估；安全性和有效性并行研究", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.nature.com/articles/s41434-024-00468-8", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "BINF-039", "name": "空间组学Spatial Omics 2026", "type": "分析平台", "description": "空间组学2026年进展：在组织原位测量基因表达，保留空间信息，揭示组织微环境", "application": "癌症/发育生物学/神经科学", "tool": "10x Visium/MERFISH/Vizgen", "trend": "空间组学从转录组到多组学；亚细胞分辨率突破", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "BINF-040", "name": "AI蛋白质结构预测2026", "type": "计算工具", "description": "AI蛋白质结构预测2026年进展：AlphaFold3/ESMFold等工具精度持续提升，从结构到功能预测", "application": "药物发现/酶工程/蛋白质设计", "tool": "AlphaFold3/ESMFold/RoseTTAFold", "trend": "从结构预测到功能设计；蛋白质工程加速", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "BINF-041", "name": "多组学数据整合AI 2026", "type": "数据分析", "description": "多组学数据整合AI 2026年进展：基因组/转录组/蛋白质组/代谢组数据整合分析，揭示疾病机制", "application": "精准医学/药物发现", "tool": "多平台AI", "trend": "多组学整合从数据到知识；AI驱动的系统生物学", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "BINF-042", "name": "液体活检ctDNA 2026", "type": "诊断技术", "description": "液体活检ctDNA 2026年进展：循环肿瘤DNA检测灵敏度提升，早期癌症筛查和疗效监测应用扩展", "application": "癌症早筛/疗效监测/复发检测", "tool": "Guardant Health/Grail/Natera", "trend": "液体活检从晚期到早期癌症；多癌种早筛应用", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "BINF-043", "name": "数字病理AI 2026", "type": "诊断技术", "description": "数字病理AI 2026年进展：AI辅助病理诊断精度提升，从组织学到分子分型", "application": "癌症诊断/分级/预后", "tool": "Paige/Proscia/PathAI", "trend": "数字病理从辅助到决策支持；AI+病理标准化", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "BINF-044", "name": "单细胞ATAC-seq表观基因组", "type": "分析平台", "description": "单细胞ATAC-seq表观基因组2026年进展：单细胞水平染色质可及性分析，揭示基因调控机制", "application": "发育生物学/癌症/免疫学", "tool": "10x Genomics/Parse Biosciences", "trend": "单细胞多组学从转录组到表观组；空间+单细胞融合", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "BINF-045", "name": "临床基因组学AI解读2026", "type": "临床应用", "description": "临床基因组学AI解读2026年进展：AI辅助变异解读和临床决策，提升遗传病诊断率", "application": "遗传病诊断/药物基因组学", "tool": "Illumina/Invitae/GeneDx", "trend": "AI基因组解读从研究到临床；诊断率持续提升", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "BINF-046", "name": "BMES 2026年会生物信息学", "type": "学术会议", "description": "BMES 2026年会10月Orlando：工程师赋能人类健康主题，生物信息学相关议题", "application": "全行业", "tool": "多平台", "trend": "生物医学工程+信息学深度融合；跨学科合作加速", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.bmes.org/2026/annualmeeting", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "BINF-047", "name": "Nature生物医学工程前沿2026", "type": "学术综述", "efficiency": "N/A", "cost": "N/A", "maturity": "研究前沿", "companies": [ "多研究机构" ], "description": "Nature Biomedical Engineering 2026前沿：生物医学工程进展快速重塑转化研究和医学前沿", "trend": "生物医学工程从辅助到主导；AI+数据驱动成为核心", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.nature.com/articles/s41551-026-01611-z", "collected_at": "2026-06-03T13:57:41.937Z" } ] }, { "id": "BINF-048", "name": "JHU BME 2026年3月发现", "type": "研究突破", "efficiency": "N/A", "cost": "N/A", "maturity": "研究前沿", "companies": [ "Johns Hopkins University" ], "description": "JHU生物医学工程2026年3月5大发现：VR假肢训练/癌症转移解码/3D骨骼成像/可靠AI", "trend": "BME从单一技术到系统解决方案；AI+VR+3D成像融合", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.bme.jhu.edu/news-events/news/the-research-buzz-bmes-latest-discoveries-2", "collected_at": "2026-06-03T13:57:41.937Z" } ] }, { "id": "BINF-049", "name": "Pittsburgh生物医学工程未来路线图", "type": "学术综述", "efficiency": "N/A", "cost": "N/A", "maturity": "参考", "companies": [ "University of Pittsburgh" ], "description": "Pittsburgh发布生物医学工程未来综合路线图：未来十年变革医学格局的突破性研究", "trend": "BME从技术驱动到需求驱动；跨学科融合加速", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://news.engineering.pitt.edu/a-new-comprehensive-roadmap-for-the-future-of-biomedical-engineering", "collected_at": "2026-06-03T13:57:41.937Z" } ] }, { "id": "BINF-050", "name": "BIOENG 2026 AI时代生物工程", "type": "行业会议", "efficiency": "N/A", "cost": "N/A", "maturity": "参考", "companies": [ "多机构" ], "description": "BIOENG 2026第二届国际生物工程会议：AI时代生物工程主题，推动生物工程研究前沿", "trend": "AI成为生物工程核心驱动力；从辅助工具到设计引擎", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://sciforum.net/event/BIOENG2026", "collected_at": "2026-06-03T13:57:41.937Z" } ] }, { "id": "BINF-051", "name": "Atlantis Bioscience 2026十大生物技术趋势", "type": "行业趋势", "efficiency": "N/A", "cost": "N/A", "maturity": "参考", "companies": [ "Atlantis Bioscience" ], "description": "2026年十大生物技术趋势：体内编辑/RNA治疗/空间组学/再生医学创新等", "trend": "生物技术从体外到体内；从单一到多组学整合", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.atlantisbioscience.com/blog/2026-biotech-outlook-10-breakthrough-trends-scientists-need-to-watch", "collected_at": "2026-06-03T13:57:41.937Z" } ] }, { "id": "BINF-052", "name": "AIChE GEAR 2026基因编辑RNA技术", "type": "行业会议", "efficiency": "N/A", "cost": "N/A", "maturity": "参考", "companies": [ "AIChE" ], "description": "AIChE GEAR 2026：CRISPR和新兴基因编辑工具/RNA干扰/mRNA平台/新型递送技术前沿研究", "trend": "基因编辑从CRISPR到多样化工具；RNA治疗平台化", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.aiche.org/sbe/conferences/gene-editing-rna-technologies-gear/2026", "collected_at": "2026-06-03T13:57:41.937Z" } ] }, { "id": "BINF-053", "name": "Pittsburgh BME未来路线图", "type": "学术综述", "description": "Pittsburgh发布生物医学工程未来综合路线图：未来十年变革医学格局的突破性研究", "application": "全行业", "tool": "多平台", "trend": "BME从技术驱动到需求驱动；跨学科融合加速", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://news.engineering.pitt.edu/a-new-comprehensive-roadmap-for-the-future-of-biomedical-engineering", "collected_at": "2026-06-04T14:05:26.379Z" } ] }, { "id": "BINF-055", "name": "Nature BME 2026前沿展望", "type": "学术综述", "description": "Nature BME 2026前沿展望：生物医学工程前沿快速重塑转化研究，多学科交叉加速", "application": "全行业", "tool": "多平台", "trend": "BME前沿从单一技术到系统整合；转化研究加速", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.nature.com/collections/egjifhdgij", "collected_at": "2026-06-04T14:07:22.337Z" } ] }, { "id": "BINF-056", "name": "JHU BME 2026年3月5大发现", "type": "学术突破", "description": "Johns Hopkins BME 2026年3月5大发现：生物医学工程前沿突破性研究", "application": "多领域", "tool": "多平台", "trend": "JHU持续引领BME前沿；月度突破频出", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://engineering.jhu.edu/bme/2026/03/five-bme-discoveries-march-2026", "collected_at": "2026-06-04T14:07:22.337Z" } ] }, { "id": "BINF-056", "name": "2026年AI药物发现权力转移", "type": "行业趋势", "description": "Drug Discovery News 2026：生物技术行业从AI初始兴奋转向更复杂现实，AI权力转移正在进行", "application": "药物发现", "tool": "AI/ML", "trend": "AI药物发现从炒作到务实；权力从IT向生物转移", "sources": [ { "source_type": "web", "source_credibility": "A", "collected_at": "2026-06-04T14:09:22.606Z" } ] }, { "id": "BINF-057", "name": "WEF AI重塑药物发现", "type": "行业分析", "description": "世界经济论坛：AI可帮助药物发现中最困难步骤更快更智能，包括靶点识别/分子生成/临床试验设计", "application": "药物发现", "tool": "AI/ML", "trend": "AI从辅助到主导药物发现；WEF背书加速采纳", "sources": [ { "source_type": "web", "source_credibility": "A", "collected_at": "2026-06-04T14:09:22.606Z" } ] }, { "id": "BINF-058", "name": "Ardigen 2026 AI药物发现趋势", "type": "行业分析", "description": "Ardigen 2026 AI药物发现趋势：自动化/多模态数据/预测模型是关键方向", "application": "药物发现", "tool": "AI/ML", "trend": "AI药物发现从单模态到多模态；自动化加速", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-04T14:09:22.606Z" } ] }, { "id": "BINF-059", "name": "HIMSS AI革命生物信息学", "type": "行业分析", "description": "HIMSS：AI正在革命生物信息学，提供前所未有的精度，大幅削减R&D成本，加速救命药物开发", "application": "生物信息学", "tool": "AI/ML", "trend": "AI从辅助到革命性改变生物信息学；成本和时间大幅降低", "sources": [ { "source_type": "web", "source_credibility": "A", "collected_at": "2026-06-04T14:09:22.606Z" } ] }, { "id": "BINF-060", "name": "AI驱动药物发现Front Line Genomics 2026", "type": "行业会议", "description": "Front Line Genomics 2026年4月AI驱动药物发现在线会议：AI突破重塑药物发现", "application": "药物发现", "tool": "AI/ML", "trend": "AI药物发现从学术到产业；在线会议降低参与门槛", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-04T14:09:22.606Z" } ] }, { "id": "BINF-061", "name": "Atlantis Bioscience: 2026十大生物技术趋势", "type": "行业预测", "description": "Atlantis Bioscience 2026十大生物技术趋势：体内编辑、RNA治疗、空间组学、再生医学创新", "application": "多领域", "tool": "多技术", "trend": "生物技术从单一到融合；体内编辑和空间组学是热点", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.atlantisbioscience.com/blog/2026-biotech-outlook-10-breakthrough-trends-scientists-need-to-watch", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "BINF-062", "name": "Nature BME: 2026生物医学工程前沿", "type": "学术前沿", "description": "Nature BME 2026生物医学工程前沿：快速重塑转化研究和医学前沿的进展", "application": "生物医学工程", "tool": "多技术", "trend": "BME从辅助到引领；转化研究加速", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.nature.com/articles/s41551-026-01611-z", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "BINF-063", "name": "CellGS: 2026生物医学趋势", "type": "行业分析", "description": "CellGS 2026生物医学趋势：工程细胞因子、胞外囊泡、基因治疗等成熟平台碰撞", "application": "生物医学", "tool": "多平台", "trend": "成熟平台碰撞产生新机会；工程细胞因子和EV是焦点", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.cellgs.com/blog/biomedical-trends-in-2026.html", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "BINF-064", "name": "JHU BME: 2026年3月最新发现", "type": "学术发现", "description": "JHU BME 2026年3月5大突破：VR假肢训练、解码癌症转移、3D骨成像、可靠AI", "application": "多领域", "tool": "VR/AI/3D成像", "trend": "BME从传统到数字；VR和AI赋能新发现", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.bme.jhu.edu/news-events/news/the-research-buzz-bmes-latest-discoveries-2", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "BINF-065", "name": "空间组学2026技术突破", "type": "技术突破", "description": "2026年空间组学技术突破：从转录组到多组学空间分析，分辨率和通量大幅提升", "application": "组织分析", "tool": "空间组学", "trend": "空间组学从转录组到多组学；分辨率和通量双提升", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "BINF-066", "name": "单细胞多组学2026整合分析", "type": "技术进展", "description": "2026年单细胞多组学整合分析进展：同时测量转录组、表观基因组和蛋白质组", "application": "细胞异质性", "tool": "单细胞多组学", "trend": "单细胞从单组学到多组学；整合分析揭示细胞状态全貌", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "BINF-067", "name": "AI蛋白质结构预测2026新进展", "type": "AI应用", "description": "2026年AI蛋白质结构预测新进展：从静态结构到动态构象，药物设计应用扩展", "application": "药物设计", "tool": "AI/AlphaFold", "trend": "蛋白质预测从静态到动态；药物设计从辅助到核心", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "BINF-068", "name": "液体活检2026临床应用扩展", "type": "诊断技术", "description": "2026年液体活检临床应用扩展：从癌症早筛到治疗监测，多癌种覆盖", "application": "癌症诊断", "tool": "ctDNA/CTC", "trend": "液体活检从单一到多癌种；早筛到全病程管理", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "BINF-069", "name": "生物信息学云计算2026平台化", "type": "基础设施", "description": "2026年生物信息学云计算平台化：从自建集群到云原生分析，降低计算门槛", "application": "多领域", "tool": "云计算", "trend": "生物信息学从本地到云端；平台化降低使用门槛", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "BINF-070", "name": "多组学数据整合AI 2026框架", "type": "AI框架", "description": "2026年多组学数据整合AI框架：深度学习整合基因组、转录组、蛋白质组数据", "application": "系统生物学", "tool": "深度学习", "trend": "多组学整合从简单拼接到深度学习；系统生物学新范式", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "name": "AlphaFold", "type": "AI System", "technology": "Deep Learning / Neural Networks", "application": "Protein 3D Structure Prediction", "status": "Active and Widely Adopted", "description": "AlphaFold is an advanced artificial intelligence system developed by Google DeepMind designed to predict the three-dimensional structure of proteins from their amino acid sequences. It achieved breakthrough accuracy that was recognized as Science's 2021 Breakthrough of the Year. The system utilizes novel neural network architectures and training procedures to significantly improve upon previous methods. Its predictions have become a cornerstone resource for biological and medical research worldwide.", "id": "BINF-071" }, { "name": "AlphaFold Protein Structure Database (AFDB)", "type": "Database", "technology": "Open Access Repository", "application": "Structural Biology Data Storage", "status": "Publicly Available", "description": "The AlphaFold Protein Structure Database provides open access to hundreds of millions of high-accuracy predicted protein structures generated by the AlphaFold model. Hosted primarily through the European Bioinformatics Institute (EBI), it serves as a central hub for researchers needing structural data. The database enables scientists to bypass time-consuming experimental structure determination for many proteins. It supports broad investigations into protein function, evolution, and drug discovery.", "id": "BINF-072" }, { "name": "AlphaFold 3", "type": "AI Model Version", "technology": "Transformer-based AI / Deep Learning", "application": "Multi-molecule Structure Prediction", "status": "Released / In Use", "description": "AlphaFold 3 represents the latest iteration of the AlphaFold suite, offering transformative capabilities beyond static protein structures. It enables researchers to model dynamic protein conformations and interactions with other molecules such as DNA and RNA. Recent studies highlight its significant impact on accelerating biomedical research and understanding complex biological mechanisms. The model continues to refine accuracy in predicting intricate molecular assemblies.", "id": "BINF-073" }, { "name": "RoseTTAFold", "type": "AI System", "technology": "Deep Learning / Neural Networks", "application": "Protein Structure and Complex Prediction", "status": "Active Research Tool", "description": "RoseTTAFold is a competing AI-driven method for protein structure prediction developed by researchers at Washington University and others. It is capable of predicting the structures of proteins and protein complexes with high accuracy. The tool has been used to predict structures for billions of proteins, expanding the coverage of known protein space. It offers an alternative approach utilizing three-track neural networks for efficient computation.", "id": "BINF-074" }, { "name": "Protein Structure Prediction", "type": "Scientific Field / Task", "technology": "Computational Biology / AI", "application": "Drug Discovery / Functional Annotation", "status": "Rapidly Advancing", "description": "Protein structure prediction involves determining the native 3D shape of a protein based on its amino acid sequence using computational methods. This field has been revolutionized by AI breakthroughs, allowing for the prediction of thousands of structures quickly and accurately. It plays a critical role in understanding protein function, designing new drugs, and elucidating disease mechanisms. The field continues to evolve with new models improving reliability and scope.", "id": "BINF-075" } ], "biomanufacturing": [ { "id": "BM-001", "name": "生物铸造厂Biofoundry", "type": "自动化平台", "description": "自动化设计-构建-测试-学习(DBTL)循环的生物实验平台", "application": "菌株工程/酶优化/代谢通路设计", "companies": [ "Ginkgo Bioworks", "Amyris", "Zymergen(Ginkgo)", "Emerald Cloud Lab" ], "maturity": "商用", "trend": "Ginkgo Bioworks全球最大生物铸造厂；自动化降低合成生物学开发门槛" }, { "id": "BM-002", "name": "精密发酵Precision Fermentation", "type": "发酵工程", "description": "工程微生物精确生产目标分子(蛋白/脂肪/化学品)", "application": "无动物乳蛋白/特殊脂肪/食品原料/工业化学品", "companies": [ "Perfect Day", "Motif FoodWorks", "Geltor", "EVERY Company" ], "maturity": "商用", "trend": "Perfect Day无动物乳清蛋白已上市；成本持续下降；替代蛋白市场增长" }, { "id": "BM-003", "name": "气体发酵Gas Fermentation", "type": "碳利用", "description": "工程微生物利用CO/CO₂/H₂等气体为碳源/能源生产化学品", "application": "废气制乙醇/碳回收/可持续航空燃料", "companies": [ "LanzaTech", "Arcadia eFuels", "Cemvita Factory" ], "maturity": "商用(乙醇)/开发中(其他产品)", "trend": "LanzaTech中国钢厂废气制乙醇运营中；扩展到航空燃料和化学品" }, { "id": "BM-004", "name": "细胞培养肉Cultured Meat", "type": "食品生物制造", "description": "动物细胞体外培养生产肉类，无需屠宰", "application": "牛肉/鸡肉/海鲜/宠物食品", "companies": [ "Upside Foods", "GOOD Meat", "Mosa Meat", "Believer Meats" ], "maturity": "商用初期", "trend": "美国/新加坡批准销售；成本从$330K/汉堡降至$10-50范围；规模化挑战" }, { "id": "BM-005", "name": "生物基材料Biobased Materials", "type": "材料生物制造", "description": "生物法生产塑料/纤维/橡胶等材料替代石油基产品", "application": "生物塑料(PHA/PLA)/生物纤维/生物橡胶", "companies": [ "Genomatica", "Zymergen", "Newlight Technologies", "Danimer Scientific" ], "maturity": "商用/扩产", "trend": "Genomatica生物BDO规模化生产；PHA可生物降解塑料需求增长" }, { "id": "BM-006", "name": "无细胞生物制造Cell-Free Biomanufacturing", "type": "无细胞合成", "description": "无活细胞条件下的生化合成，避免细胞生长限制", "application": "药物蛋白/有毒蛋白/快速原型/按需生产", "companies": [ "Sutro Biopharma", "Tierra Biosciences", "Synthex" ], "maturity": "商用", "trend": "Sutro卵巢癌药luvelta III期；24小时设计到蛋白；与AI蛋白设计结合" }, { "id": "BM-007", "name": "酶工程Enzyme Engineering", "type": "催化剂设计", "description": "AI/定向进化设计高效稳定酶催化剂", "application": "工业催化/药物合成/食品加工/洗涤剂", "companies": [ "Codexis", "Arzeda", "Novozymes(诺维信)", "BASF" ], "maturity": "商用", "trend": "AI设计酶加速；Codexis CodeEvolver平台；定向进化(Nobel 2018)与AI结合" }, { "id": "BM-008", "name": "合成生物学规模化放大", "type": "工艺工程", "description": "从实验室到工业规模的生物工艺放大", "application": "发酵放大/下游纯化/连续生物工艺", "companies": [ "Ginkgo Bioworks", "DSM", "Lonza", "Catalent" ], "maturity": "商用", "trend": "连续生物工艺替代批次生产；数字化/自动化工厂；AI工艺优化" }, { "id": "BM-009", "name": "生物制造法规与标准", "type": "政策/标准", "description": "生物制造产品的安全评估/质量标准/监管框架", "application": "食品安全/环境释放/药品GMP", "companies": [ "FDA/EFSA/各国监管机构" ], "maturity": "持续演进", "trend": "培养肉监管框架建立中；生物基产品认证标准；合成生物学产品审批路径" }, { "id": "BM-010", "name": "AI+生物制造", "type": "跨领域融合", "description": "AI驱动的生物制造全流程优化，从设计到生产", "application": "代谢通路设计/发酵优化/质量控制/供应链", "companies": [ "Ginkgo Bioworks", "Recursion", "Asimov" ], "maturity": "快速崛起", "trend": "Asimov AI设计基因电路；Ginkgo AI优化菌株；2025-2026年最热趋势" }, { "id": "BM-011", "name": "Nature BME 2025年度回顾", "type": "行业趋势", "description": "Nature BME 2025年终编辑：生物医学工程在广泛学科取得进展，2026年趋势展望", "application": "再生医学/组织工程/神经工程/纳米医学", "companies": [ "学术界" ], "maturity": "参考", "trend": "跨学科融合加速；AI+生物工程成为核心驱动力", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.nature.com/articles/s41551-026-01611-z", "collected_at": "2026-05-30T13:30:00Z" } ] }, { "id": "BM-012", "name": "JHU BME 2026突破", "type": "研究突破", "description": "JHU生物医学工程2026年3月突破：VR假肢训练/解码癌症转移/3D骨成像/可靠AI", "application": "假肢/癌症/骨科/AI", "companies": [ "Johns Hopkins University" ], "maturity": "研究阶段", "trend": "VR+神经接口/单细胞追踪转移/3D成像诊断", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.bme.jhu.edu/news-events/news/the-research-buzz-bmes-latest-discoveries-2", "collected_at": "2026-05-30T13:30:00Z" } ] }, { "id": "BM-013", "name": "生物制造规模化2000L+", "type": "产能扩展", "description": "生物制造产能扩展，2000L+生物反应器安装，从实验室到工业规模", "application": "生物制药/工业酶/食品蛋白", "companies": [ "各生物制造企业" ], "maturity": "商用扩张", "trend": "连续生物工艺替代批次；数字化/自动化工厂；模块化生物工厂", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://omanhealthexpo.com/newfront/news/the-future-of-bioengineering", "collected_at": "2026-05-30T13:30:00Z" } ] }, { "id": "BM-014", "name": "基因驱动技术进展", "type": "基因驱动", "description": "基因驱动技术快速推进，为公共卫生和生物保护提供新工具", "application": "疟疾控制/入侵物种/农业害虫", "companies": [ "Target Malaria/ISAAA" ], "maturity": "野外试验/监管审查", "trend": "Gene Drive Monitor追踪2025-2026进展；非洲疟疾基因驱动试验推进", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.isaaa.org/webinars/2025/genedrive/default.asp", "collected_at": "2026-05-30T13:30:00Z" } ] }, { "id": "BM-015", "name": "2026细胞基因治疗预测", "type": "行业趋势", "description": "2026年细胞和基因治疗领域预测：可衡量的进展和成熟化", "application": "基因治疗/细胞治疗/体内编辑", "companies": [ "全行业" ], "maturity": "参考", "trend": "从突破到成熟的过渡期；监管路径清晰化；制造工艺标准化", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.cellgenetherapyreview.com", "collected_at": "2026-05-30T13:30:00Z" } ] }, { "id": "BM-016", "name": "AI驱动生物工艺优化", "type": "数字化", "description": "AI优化发酵/纯化/放大工艺参数，减少实验次数，加速工艺开发", "application": "发酵优化/纯化工艺/放大生产", "companies": [ "AspenTech", "Sartorius", "Cytiva" ], "maturity": "商用初期", "trend": "数字孪生+AI优化成为生物工艺标配；2026年快速渗透" }, { "id": "BM-017", "name": "连续生物制造CBM", "type": "制造模式", "description": "从批次生产到连续生产，提高产率/降低成本/减少占地面积", "application": "生物药/疫苗/细胞治疗", "companies": [ "Cytiva", "Sartorius", "Merck KGaA" ], "maturity": "示范/早期商用", "trend": "FDA鼓励连续制造；2026年生物药连续生产项目增多" }, { "id": "BM-018", "name": "mRNA制造平台", "type": "制造平台", "description": "mRNA疫苗/药物规模化制造平台，体外转录+LNP封装", "application": "mRNA疫苗/mRNA治疗/个性化新抗原疫苗", "companies": [ "Moderna", "BioNTech", "CureVac" ], "maturity": "大规模商用", "trend": "从COVID疫苗到肿瘤/罕见病mRNA疗法；2026年产能持续扩张" }, { "id": "BM-019", "name": "基因治疗载体制造AAV", "type": "制造平台", "description": "腺相关病毒(AAV)载体大规模制造，基因治疗的核心瓶颈", "application": "基因治疗/体内基因编辑递送", "companies": [ "Catalent", "Thermo Fisher", "Lonza", "Andelyn" ], "maturity": "商用扩张", "trend": "AAV产能2026年大幅扩张；新载体设计降低剂量需求" }, { "id": "BM-020", "name": "3D生物打印", "type": "制造技术", "description": "生物3D打印组织/器官模型，用于药物筛选和再生医学", "application": "药物筛选/组织工程/个性化医疗", "companies": [ "Organovo", "CELLINK", "Aspect Biosystems" ], "maturity": "研究/早期商用", "trend": "2026年3D打印组织模型替代动物实验；器官打印仍需5+年" }, { "id": "BM-021", "name": "类器官Organoid制造", "type": "制造技术", "description": "体外培养3D微型器官，模拟人体器官结构和功能", "application": "药物筛选/疾病模型/个性化治疗", "companies": [ "Hubrecht Organoid Technology", "Emulate", "Cellesce" ], "maturity": "研究/商业化初期", "trend": "2026年类器官从研究到药物开发标准工具；Baby KJ CRISPR治疗验证类器官价值", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://capitalcell.com/it/decoding-2035", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "BM-022", "name": "合成生物学规模化放大", "type": "工艺", "description": "从实验室摇瓶到工业发酵罐的规模化放大，AI辅助缩小实验与生产差距", "application": "生物制造/精密发酵/工业生物技术", "companies": [ "Ginkgo Bioworks", "Amyris", "Zymergen" ], "maturity": "商用", "trend": "AI+自动化缩小放大差距；2026年DBTL循环时间缩短50%+" }, { "id": "BM-023", "name": "细胞治疗GMP制造", "type": "制造平台", "description": "CAR-T/TCR-T等细胞治疗的GMP级制造，自动化封闭系统降低成本", "application": "CAR-T/TCR-T/TIL细胞治疗", "companies": [ "Lonza", "Catalent", "Thermo Fisher", "Miltenyi" ], "maturity": "商用", "trend": "自动化封闭系统替代开放操作；2026年制造成本下降30%+" }, { "id": "BM-024", "name": "生物制造市场$295B→$347B", "type": "市场数据", "description": "全球生物工程市场规模2025年2952.8亿美元，2026年预计3470.4亿美元，CAGR约17.5%", "application": "全行业", "companies": [ "全行业" ], "maturity": "参考", "trend": "生物制造从利基到主流制造范式；AI+自动化驱动增长", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.precedenceresearch.com/bioengineering-market", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "BM-025", "name": "生物医学工程Nature 2026展望", "type": "行业报告", "description": "Nature BME 2026展望：2025年生物医学工程各领域进展，2026年前沿方向", "application": "生物医学工程全领域", "companies": [ "Nature" ], "maturity": "参考", "trend": "跨学科融合加速；AI+生物+工程三位一体", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.nature.com/articles/s41551-026-01611-z", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "BM-026", "name": "Baby Kj CRISPR首例婴儿治疗", "type": "里程碑", "description": "全球首例婴儿CRISPR基因编辑治疗成功案例，标志基因治疗新纪元", "application": "遗传病/基因编辑治疗", "companies": [ "多机构合作" ], "maturity": "里程碑", "trend": "从成人到婴儿的基因治疗扩展；2026年更多儿科基因编辑治疗", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://capitalcell.com/it/decoding-2035", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "BM-027", "name": "单克隆抗体AI设计", "type": "AI+生物制造", "description": "AI从头设计单克隆抗体，Chai-2实现16%成功率，大幅缩短抗体药物开发周期", "application": "抗体药物/蛋白治疗/诊断试剂", "companies": [ "Chai Discovery", "Absci", "Generate Biomedicines" ], "maturity": "实验室/早期开发", "trend": "AI抗体设计从概念到管线；2026年AI设计抗体进入临床", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://setr.stanford.edu/sites/default/files/2026-01/SETR2026_02-Biotech_web-260109.pdf", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "BM-028", "name": "生物制造ESG与可持续性", "type": "可持续性", "description": "生物制造的ESG维度：低碳足迹/绿色化学/循环经济，替代石化路线的环保优势", "application": "全行业", "companies": [ "全行业" ], "maturity": "持续改进", "trend": "ESG驱动生物制造投资决策；2026年碳足迹量化标准化" }, { "id": "BM-029", "name": "CellGS 2026生物医学趋势", "type": "行业趋势", "description": "CellGS: 2026年生物医学由成熟平台碰撞驱动：工程细胞因子/细胞外囊泡/基因治疗", "application": "全行业", "companies": [ "CellGS" ], "maturity": "参考", "trend": "成熟平台碰撞产生新机会；基因治疗制造平台化" }, { "id": "BM-030", "name": "2026生物技术制造展望", "type": "行业展望", "description": "2026年生物技术制造展望：Resilience新制造平台服务基因治疗/细胞治疗/疫苗/蛋白质药物", "application": "基因治疗/细胞治疗/疫苗", "companies": [ "Resilience" ], "maturity": "扩张期", "trend": "CDMO平台化制造；模块化工厂降低门槛" }, { "id": "BM-031", "name": "JHU BME 2026突破", "type": "学术突破", "description": "JHU BME 2026年3月突破：VR假肢训练/解码癌症转移/3D骨成像/可靠AI", "application": "假肢/癌症/骨科/AI", "companies": [ "Johns Hopkins" ], "maturity": "研究前沿", "trend": "VR+假肢训练改善康复；AI解码癌症转移机制" }, { "id": "BM-032", "name": "BMES 2026年会", "type": "学术会议", "description": "BMES 2026年会10月21-24日Orlando，主题：工程师赋能人类健康", "application": "全行业", "companies": [ "BMES" ], "maturity": "参考", "trend": "生物医学工程从学科到产业；跨学科合作加速" }, { "id": "BM-033", "name": "Nature BME 2026生物医学工程前沿", "type": "学术综述", "description": "Nature BME: 生物医学工程前沿快速重塑转化研究和医学", "application": "全行业", "companies": [ "多机构" ], "maturity": "参考", "trend": "生物医学工程从辅助到主导；跨学科融合加速", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.nature.com/articles/s41551-026-01611-z", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "BM-034", "name": "2026生物技术10大突破趋势制造", "type": "行业趋势", "description": "Atlantis Bioscience: 2026年10大生物技术趋势，体内编辑/RNA疗法/空间组学/再生医学创新", "application": "全行业", "companies": [ "多公司" ], "maturity": "多阶段", "trend": "体内编辑/RNA疗法/空间组学/再生医学四大热点", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.atlantisbioscience.com/blog/2026-biotech-outlook-10-breakthrough-trends-scientists-need-to-watch", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "BM-035", "name": "BIOENG-2026 AI时代生物工程制造", "type": "学术会议", "description": "BIOENG-2026: AI时代的生物工程，推动生物制造研究前沿", "application": "生物制造", "companies": [ "多机构" ], "maturity": "参考", "trend": "AI+生物制造深度融合；自动化和智能化加速", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://sciforum.net/event/BIOENG2026", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "BM-036", "name": "NEBEC2026东北生物工程会议", "type": "学术会议", "description": "NEBEC2026: 癌症工程/生物材料和组织工程/神经工程等议题", "application": "多领域", "companies": [ "Temple University" ], "maturity": "参考", "trend": "生物工程从学科到产业；跨学科合作加速", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://sites.temple.edu/nebec2026", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "BM-037", "name": "连续生物制造Continuous Bioprocessing", "type": "制造技术", "description": "连续生物制造2026年进展：从批次到连续生产，提升产率和质量一致性", "application": "生物药/疫苗/细胞治疗", "companies": [ "Cytiva/Sartorius/Pall" ], "maturity": "商用初期", "trend": "连续制造从概念到实施；监管框架逐步完善", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "BM-038", "name": "AI驱动生物工艺优化", "type": "数字化", "description": "AI驱动生物工艺优化2026年进展：机器学习优化发酵条件/纯化工艺/质量控制", "application": "生物药/酶/化学品", "companies": [ "多公司" ], "maturity": "商用初期", "trend": "AI+生物工艺从试点到规模化；数据驱动决策", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "BM-039", "name": "模块化生物工厂2026", "type": "工厂设计", "description": "模块化生物工厂2026年进展：预制模块化生物制造设施，缩短建设周期降低投资门槛", "application": "生物药/疫苗/细胞治疗", "companies": [ "多公司" ], "maturity": "示范项目", "trend": "模块化从概念到落地；分布式制造模式兴起", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "BM-040", "name": "无细胞合成生物学制造", "type": "无细胞系统", "description": "无细胞合成生物学制造2026年进展：无需活细胞的蛋白质/化学品生产，速度更快灵活性更高", "application": "蛋白质/疫苗/化学品", "companies": [ "Sutro Biopharma/Tierra Biosciences" ], "maturity": "商用初期", "trend": "无细胞系统从利基到主流；快速响应和灵活性优势", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "BM-041", "name": "3D生物打印组织2026", "type": "生物打印", "description": "3D生物打印组织2026年进展：从简单结构到功能性组织，血管化和成熟度提升", "application": "组织工程/药物筛选/移植", "companies": [ "Organovo/CELLINK/Bioprinting Solutions" ], "maturity": "研发/中试", "trend": "3D生物打印从结构到功能；血管化是关键突破", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "BM-042", "name": "合成生物学规模化放大2026", "type": "工艺放大", "description": "合成生物学规模化放大2026年进展：从实验室到工业规模的挑战和解决方案", "application": "化学品/材料/食品", "companies": [ "Ginkgo Bioworks/Amyris/LanzaTech" ], "maturity": "商用扩张", "trend": "规模化从经验到工程；DBTL循环加速放大", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "BM-043", "name": "生物制造质量控制PAT", "type": "质量控制", "description": "生物制造过程分析技术PAT 2026年进展：实时监测和控制生物制造过程，提升产品质量", "application": "生物药/疫苗", "companies": [ "多公司" ], "maturity": "商用", "trend": "PAT从可选到必须；实时放行检测趋势", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "BM-044", "name": "细胞治疗GMP制造2026", "type": "GMP制造", "description": "细胞治疗GMP制造2026年进展：自动化封闭系统/模块化洁净室/数字化批次记录", "application": "CAR-T/TCR-T/TIL", "companies": [ "Lonza/Catalent/Thermo Fisher" ], "maturity": "商用扩张", "trend": "GMP制造从手工到自动化；成本下降推动可及性", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "BM-045", "name": "生物制造供应链韧性2026", "type": "供应链", "description": "生物制造供应链韧性2026年进展：地缘政治影响/本土化生产/多元化供应策略", "application": "全行业", "companies": [ "多公司" ], "maturity": "战略调整", "trend": "供应链从全球化到区域化；韧性优先于成本", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "BM-046", "name": "mRNA制造平台2026", "type": "mRNA制造", "description": "mRNA制造平台2026年进展：从疫苗到药物，mRNA制造工艺标准化和产能扩张", "application": "疫苗/药物/基因治疗", "companies": [ "Moderna/BioNTech/CureVac" ], "maturity": "商用扩张", "trend": "mRNA制造从应急到常态；平台化生产模式成熟", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "BM-047", "name": "基因治疗载体制造2026", "type": "载体制造", "description": "基因治疗载体(AAV/慢病毒)制造2026年进展：产量提升/成本下降/新型载体开发", "application": "基因治疗", "companies": [ "Spark/Bluebird Bio/UniQure" ], "maturity": "商用扩张", "trend": "载体制造从瓶颈到产能；新型载体平台涌现", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "BM-048", "name": "生物制造可持续发展2026", "type": "可持续发展", "description": "生物制造可持续发展2026年进展：绿色工艺/碳中和工厂/循环经济模式", "application": "全行业", "companies": [ "多公司" ], "maturity": "战略目标", "trend": "可持续发展从口号到行动；碳中和生物工厂兴起", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "BM-049", "name": "2026精密发酵工业化元年", "type": "产业趋势", "efficiency": "N/A", "cost": "持续下降", "maturity": "量产加速", "companies": [ "全行业" ], "description": "2026年 poised to be the year of industrialization in the food sector，精密发酵从潜力到现实转化", "trend": "精密发酵从实验室到工厂；2026年工业化关键年", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.linkedin.com/posts/henrikmgh_2026-is-poised-to-be-the-year-of-industrialization-activity-7440396353131806720-Vion", "collected_at": "2026-06-03T13:57:41.937Z" } ] }, { "id": "BM-050", "name": "iFAB生物制造峰会2026", "type": "行业会议", "efficiency": "N/A", "cost": "N/A", "maturity": "参考", "companies": [ "iFAB Tech Hub" ], "description": "2026 iFAB生物制造峰会：聚焦生物制造和精密发酵，动态小组讨论/创新展示/产业对接", "trend": "生物制造从分散到集群化；iFAB Tech Hub推动区域生态", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.imec.org/event/2026-ifab-biomanufacturing-summit", "collected_at": "2026-06-03T13:57:41.937Z" } ] }, { "id": "BM-051", "name": "Eden Brew无动物酪蛋白", "type": "产品创新", "efficiency": "N/A", "cost": "中", "maturity": "商业化", "companies": [ "Eden Brew" ], "description": "Eden Brew通过精密发酵生产无动物酪蛋白，创造与牛奶功能相同的乳制品，无需奶牛", "trend": "精密发酵乳蛋白从概念到产品；无动物乳制品市场开启", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://futurefoodtechsf.com/articles/breakthrough-innovators-shaping-s-next", "collected_at": "2026-06-03T13:57:41.937Z" } ] }, { "id": "BM-052", "name": "精密发酵2026趋势/初创/专利", "type": "行业分析", "efficiency": "N/A", "cost": "持续下降", "maturity": "参考", "companies": [ "Linknovate" ], "description": "Linknovate 2026精密发酵分析：不再是小众实验室实验，而是跨多行业的生物铸造厂规模化平台", "trend": "精密发酵从食品到多行业扩展；生物铸造厂模式兴起", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://blog.linknovate.com/precision-fermentation-trends-startups-patents", "collected_at": "2026-06-03T13:57:41.937Z" } ] }, { "id": "BM-053", "name": "精密发酵肽化妆品生物技术2026", "type": "产品创新", "efficiency": "N/A", "cost": "中", "maturity": "商业化", "companies": [ "Grand Ingredients" ], "description": "精密发酵肽快速变革化妆品生物技术，2026年角色持续扩展", "trend": "精密发酵从食品到化妆品跨界；肽类活性成分定制化", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://grandingredients.com/precision-fermentation-peptides-2026", "collected_at": "2026-06-03T13:57:41.937Z" } ] }, { "id": "BM-054", "name": "上海精密发酵论坛", "type": "行业会议", "efficiency": "N/A", "cost": "N/A", "maturity": "参考", "companies": [ "SynBioBeta" ], "description": "上海精密发酵论坛：先进生物技术和AI集成有潜力通过精密发酵革命化工业流程", "trend": "中国精密发酵产业加速；AI+发酵优化成为热点", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.synbiobeta.com/read/a-vision-for-the-future-of-biomanufacturing-highlights-from-shanghais-precision-fermentation-forum", "collected_at": "2026-06-03T13:57:41.937Z" } ] }, { "id": "BM-055", "name": "ScienceDirect精密发酵下一代食品配料", "type": "学术综述", "efficiency": "N/A", "cost": "持续下降", "maturity": "参考", "companies": [ "多研究机构" ], "description": "ScienceDirect综述：精密发酵是传统发酵的先进形式，微生物(细菌/真菌/酵母)经基因工程改造生产特定配料", "trend": "精密发酵技术从概念到标准化；下一代食品配料多样化", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.sciencedirect.com/science/article/pii/S2666833525002096", "collected_at": "2026-06-03T13:57:41.937Z" } ] }, { "id": "BM-056", "name": "基因驱动逆转杀虫剂抗性", "type": "基因驱动", "efficiency": "N/A", "cost": "N/A", "maturity": "实验室", "companies": [ "多研究机构" ], "description": "新基因驱动技术可逆转害虫的杀虫剂抗性，有潜力保护作物并大幅减少化学农药使用", "trend": "基因驱动从灭蚊到农业应用扩展；可持续农业新工具", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.isaaa.org/kc/cropbiotechupdate/article/default.asp?ID=21109", "collected_at": "2026-06-03T13:57:41.937Z" } ] }, { "id": "BM-057", "name": "Science基因驱动监管挑战", "type": "政策/伦理", "efficiency": "N/A", "cost": "N/A", "maturity": "政策讨论", "companies": [ "Science" ], "description": "Science探讨如何监管争议性基因驱动技术：基因扩散方法旨在消灭入侵害虫或减少疾病传播，但风险需审慎评估", "trend": "基因驱动技术监管框架建设；科学界呼吁审慎推进", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.science.org/content/article/how-will-we-keep-controversial-gene-drive-technology-check", "collected_at": "2026-06-03T13:57:41.937Z" } ] }, { "id": "BM-058", "name": "基因驱动抗疟疾应用非洲", "type": "应用场景", "efficiency": "N/A", "cost": "N/A", "maturity": "政策推进", "companies": [ "MESA" ], "description": "MESA为政策制定者提供基因驱动技术应用于非洲疟疾消除的建议，指导基因驱动技术用于疟疾控制", "trend": "基因驱动从实验室到非洲实地应用；公共卫生驱动政策推进", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://mesamalaria.org/resource-hub/application-of-gene-drive-technology-for-malaria-elimination-in-africa", "collected_at": "2026-06-03T13:57:41.937Z" } ] }, { "id": "BM-059", "name": "2026精密发酵工业化元年确认", "type": "产业趋势", "description": "2026年被确认为精密发酵工业化元年：从潜力到现实转化，食品行业大规模应用启动", "application": "食品/材料/化学品", "companies": [ "全行业" ], "maturity": "量产加速", "trend": "精密发酵从实验室到工厂；2026年工业化关键年", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-04T14:05:26.379Z" } ] }, { "id": "BM-060", "name": "Eden Brew无动物酪蛋白商业化", "type": "产品创新", "description": "Eden Brew通过精密发酵生产无动物酪蛋白，创造与牛奶功能相同的乳制品，无需奶牛", "application": "乳制品替代", "companies": [ "Eden Brew" ], "maturity": "商业化", "trend": "精密发酵乳蛋白从概念到产品；无动物乳制品市场开启", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://futurefoodtechsf.com/articles/breakthrough-innovators-shaping-s-next", "collected_at": "2026-06-04T14:05:26.379Z" } ] }, { "id": "BM-061", "name": "Linknovate精密发酵趋势/初创/专利分析", "type": "行业分析", "description": "Linknovate 2026精密发酵分析：不再是小众实验室实验，而是跨多行业的生物铸造厂规模化平台", "application": "多行业", "companies": [ "Linknovate" ], "maturity": "参考", "trend": "精密发酵从食品到多行业扩展；生物铸造厂模式兴起", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://blog.linknovate.com/precision-fermentation-trends-startups-patents", "collected_at": "2026-06-04T14:05:26.379Z" } ] }, { "id": "BM-062", "name": "Nature BME 2026生物制造前沿", "type": "学术综述", "description": "Nature BME 2026生物制造前沿：生物工程前沿快速重塑转化研究和制造", "application": "多行业", "companies": [ "多机构" ], "maturity": "参考", "trend": "生物制造从实验室到工业化；Nature关注领域", "sources": [ { "source_type": "web", "source_credibility": "A", "collected_at": "2026-06-04T14:07:22.337Z" } ] }, { "id": "BM-063", "name": "BMES 2026生物医学工程年会", "type": "行业会议", "description": "BMES 2026年会：展示前沿工程和转化研究，推动下一代生物制造技术发展", "application": "多行业", "companies": [ "BMES" ], "maturity": "参考", "trend": "生物医学工程年会聚焦转化；制造技术是重点", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.bmes.org/bmes2026", "collected_at": "2026-06-04T14:07:22.337Z" } ] }, { "id": "BM-064", "name": "生物工程市场95B→47B增长", "type": "市场数据", "description": "全球生物工程市场规模2025年2952.8亿美元，预计2026年增至3470亿美元，持续高速增长", "application": "全行业", "companies": [ "全行业" ], "maturity": "市场增长", "trend": "生物工程市场持续扩大；2026年突破3470亿美元", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-04T14:07:22.337Z" } ] }, { "id": "BM-064", "name": "下一代精密发酵食品配料", "type": "技术突破", "description": "精密发酵是传统发酵的先进版本，微生物被基因工程改造生产特定食品配料", "application": "食品配料", "companies": [ "多公司" ], "maturity": "量产加速", "trend": "精密发酵从概念到食品配料量产", "sources": [ { "source_type": "web", "source_credibility": "A", "collected_at": "2026-06-04T14:09:22.606Z" } ] }, { "id": "BM-065", "name": "低成本原料下一代生物制造", "type": "技术突破", "description": "下一代生物制造从低成本原料到无细胞方法：精密发酵原料成本降低/无细胞合成新路径", "application": "多行业", "companies": [ "多公司" ], "maturity": "技术突破", "trend": "生物制造从高成本原料到低成本替代；无细胞方法兴起", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-04T14:09:22.606Z" } ] }, { "id": "BM-066", "name": "EPA 2026食品生物制造细胞农业会议", "type": "行业会议", "description": "EPA 2026细胞农业会议：培养肉/精密发酵/生物工艺规模化", "application": "食品/农业", "companies": [ "EPA" ], "maturity": "参考", "trend": "细胞农业从实验室到规模化；监管框架完善", "sources": [ { "source_type": "web", "source_credibility": "A", "collected_at": "2026-06-04T14:09:22.606Z" } ] }, { "id": "BM-067", "name": "iFAB 2026生物制造峰会", "type": "行业会议", "description": "iFAB Tech Hub 2026生物制造峰会：聚焦生物制造和精密发酵，动态小组/创新展示", "application": "多行业", "companies": [ "iFAB" ], "maturity": "参考", "trend": "生物制造峰会从学术到产业；精密发酵是焦点", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-04T14:09:22.606Z" } ] }, { "id": "BM-068", "name": "GFI精密发酵微生物制造食品", "type": "行业分析", "description": "GFI分析：细胞农业通过微生物精密发酵生产真正的动物蛋白，无需动物参与", "application": "食品", "companies": [ "GFI" ], "maturity": "参考", "trend": "精密发酵从替代到主流；GFI推动行业认知", "sources": [ { "source_type": "web", "source_credibility": "A", "collected_at": "2026-06-04T14:09:22.606Z" } ] }, { "id": "BM-069", "name": "生物工程市场295B→347B 2026增长", "type": "市场数据", "description": "全球生物工程市场2025年2952.8亿美元，2026年预计3470.4亿美元，持续高速增长", "application": "多行业", "companies": [ "Precedence Research" ], "maturity": "市场数据", "trend": "生物工程市场持续高速增长；多行业应用扩展", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.precedenceresearch.com/bioengineering-market", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "BM-070", "name": "BMES 2026年会: 下一代治疗和设备", "type": "行业会议", "description": "BMES 2026年会：前沿工程和转化研究驱动下一代治疗、医疗设备开发", "application": "多领域", "companies": [ "BMES" ], "maturity": "参考", "trend": "BME从研究到转化；下一代治疗和设备是焦点", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.bmes.org/2026/annualmeeting", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "BM-071", "name": "精密发酵2026规模化生产", "type": "精密发酵", "description": "2026年精密发酵规模化生产：从替代蛋白到特种化学品，产能大幅扩张", "application": "食品/化工", "companies": [ "多公司" ], "maturity": "规模化", "trend": "精密发酵从替代到规模化；产能扩张降低成本", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "BM-072", "name": "细胞农业2026商业化里程碑", "type": "细胞农业", "description": "2026年细胞农业商业化里程碑：培养肉从实验室到小规模生产，监管批准增加", "application": "食品", "companies": [ "多公司" ], "maturity": "早期商业化", "trend": "细胞农业从实验室到市场；监管批准是关键推动力", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "BM-073", "name": "生物制造自动化2026进展", "type": "自动化", "description": "2026年生物制造自动化进展：实验室自动化、AI优化发酵参数、数字孪生工厂", "application": "多行业", "companies": [ "多公司" ], "maturity": "部署中", "trend": "生物制造从手工到自动化；AI和数字孪生提升效率", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "BM-074", "name": "NEBEC 2026: 癌症材料与太空生物新生物材料", "type": "学术会议", "description": "NEBEC 2026(4月16-17日)：研究癌症新生物材料和太空生物组织材料", "application": "生物材料", "companies": [ "多机构" ], "maturity": "参考", "trend": "生物材料从医疗到太空；新应用场景拓展", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://sites.temple.edu/nebec2026", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "BM-075", "name": "合成生物学规模化制造2026挑战", "type": "行业分析", "description": "2026年合成生物学规模化制造挑战：从实验室到工厂的放大难题、一致性控制、成本优化", "application": "多行业", "companies": [ "多公司" ], "maturity": "参考", "trend": "规模化是合成生物学最大挑战；从克级到吨级", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "BM-076", "name": "生物制造连续生产2026趋势", "type": "生产模式", "description": "2026年生物制造连续生产趋势：从批次到连续，提高产率和降低成本", "application": "生物制药", "companies": [ "多公司" ], "maturity": "转型中", "trend": "生物制造从批次到连续；产率提升成本下降", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "BM-077", "name": "微生物细胞工厂2026设计优化", "type": "细胞工厂", "description": "2026年微生物细胞工厂设计优化：AI辅助代谢通路设计、高通量筛选、动态调控", "application": "多行业", "companies": [ "多公司" ], "maturity": "研发中", "trend": "细胞工厂从试错到设计；AI辅助代谢工程", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "BM-078", "name": "生物制造供应链2026韧性建设", "type": "供应链", "description": "2026年生物制造供应链韧性建设：多元化原料来源、本地化生产、库存优化", "application": "多行业", "companies": [ "多公司" ], "maturity": "建设中", "trend": "供应链从效率到韧性；本地化和多元化", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "name": "Digital Twins", "type": "Technology", "technology": "Digital Twin Simulation", "application": "Bioprocess Automation and Optimization", "status": "Emerging", "description": "Digital twins are virtual replicas of bioprocesses that allow for simulation and optimization in a controlled environment. They provide a framework to bridge the gap between traditional bioprocessing methods and modern digital transformation initiatives. By integrating real-time data, they enable predictive maintenance and process adjustments before issues arise in physical operations.", "id": "BM-079" }, { "name": "Artificial Intelligence (AI)", "type": "Technology", "technology": "Machine Learning Algorithms", "application": "Smart Manufacturing and Decision Systems", "status": "Adopting", "description": "AI is reshaping pharmaceutical production by integrating with advanced analytics and automated systems to enhance operational efficiency. It supports intelligent decision-making processes across various stages of biomanufacturing, from discovery to scale-up. The integration of AI helps in managing complex datasets to optimize yield and quality control.", "id": "BM-080" }, { "name": "Precision Fermentation", "type": "Biotechnological Process", "technology": "Genetically Engineered Microorganisms", "application": "Food Ingredients Production", "status": "Commercializing", "description": "Precision fermentation utilizes genetically engineered microorganisms like yeast, fungi, and bacteria to produce specific compounds. It allows for the cost-effective creation of novel food ingredients, including animal-free dairy and eggs. This technology represents a significant shift towards sustainable and efficient production methods in the food industry.", "id": "BM-081" }, { "name": "Continuous Biomanufacturing", "type": "Manufacturing Process", "technology": "Continuous Processing Equipment", "application": "Pharmaceutical Production", "status": "Expanding", "description": "Continuous biomanufacturing involves the uninterrupted production of biological products, contrasting with traditional batch processing methods. It offers potential benefits such as increased efficiency, reduced facility footprint, and consistent product quality. As part of Biomanufacturing 4.0, it is gaining traction for its ability to streamline operations and lower costs.", "id": "BM-082" }, { "name": "Perfusion Technologies", "type": "Bioprocessing Equipment", "technology": "Cell Culture Perfusion Systems", "application": "Biopharmaceutical Manufacturing", "status": "Evaluating", "description": "Perfusion technologies involve continuously supplying fresh media to cell cultures while removing waste products, enhancing productivity. A significant percentage of bioprocessing facilities are planning to evaluate these technologies to improve their manufacturing capabilities. This approach is seen as a key innovation driving advancements in the biomanufacturing sector.", "id": "BM-083" }, { "id": "BM-084", "name": "精密发酵动物蛋白", "type": "精密发酵", "applications": [ "替代蛋白", "食品原料" ], "companies": [ "Perfect Day", "Motif FoodWorks", "Every Company" ], "maturity": "商业化", "description": "精密发酵技术利用合成生物学工具生产动物蛋白和其他产品，无需动物即可实现蛋白质生产", "trend": "精密发酵从实验室走向商业化食品生产" }, { "id": "BM-085", "name": "SynBioBeta 2026 AI+生物", "type": "行业会议", "applications": [ "AI生物交叉", "产业对接" ], "companies": [ "SynBeta" ], "maturity": "N/A", "description": "SynBioBeta 2026大会(5月4-7日圣何塞)聚焦AI与生物学交叉，展示细胞培养、发酵平台和放大策略进展", "trend": "AI驱动生物制造成为核心趋势" }, { "id": "BM-086", "name": "微生物发酵代谢工程", "type": "代谢工程", "applications": [ "化学品生产", "药物合成" ], "companies": [ "Ginkgo Bioworks", "Zymergen" ], "maturity": "商业化", "description": "微生物发酵与合成生物学、代谢工程交叉研究展示前沿进展，优化微生物细胞工厂生产效率", "trend": "微生物细胞工厂替代化工生产" }, { "id": "BM-087", "name": "国家学院合成生物制造研讨", "type": "学术研讨", "applications": [ "政策制定", "技术路线图" ], "companies": [ "National Academies" ], "maturity": "N/A", "description": "2025年7月美国国家学院召开研讨会，审视合成生物学科学进展并探索生物制造的预测性工程", "trend": "政府层面推动合成生物制造战略" }, { "id": "BM-088", "name": "AI驱动蛋白质设计", "type": "AI生物", "applications": [ "酶工程", "蛋白质设计" ], "companies": [ "DeepMind", "Generate Biomedicines", "Profluent" ], "maturity": "研发阶段", "description": "AI驱动的蛋白质设计(如AlphaFold3后续)正在革命性地改变生物制造，可设计全新酶和蛋白质", "trend": "AI+生物制造是下一代工业革命" } ], "synbio": [ { "id": "SB-001", "name": "CRISPR-Cas9", "type": "基因编辑", "applications": [ "基因治疗", "作物改良" ], "companies": [ "Editas", "CRISPR Therapeutics" ], "maturity": "临床阶段" }, { "id": "SB-002", "name": "碱基编辑", "type": "基因编辑", "applications": [ "遗传病治疗" ], "companies": [ "Beam Therapeutics" ], "maturity": "临床阶段" }, { "id": "SB-003", "name": "先导编辑", "type": "基因编辑", "applications": [ "复杂突变修复" ], "companies": [ "Prime Medicine" ], "maturity": "临床前" }, { "id": "SB-004", "name": "mRNA疗法", "type": "核酸药物", "applications": [ "疫苗", "蛋白替代", "癌症" ], "companies": [ "Moderna", "BioNTech" ], "maturity": "已上市" }, { "id": "SB-005", "name": "CAR-T", "type": "细胞治疗", "applications": [ "血液肿瘤" ], "companies": [ "诺华", "吉利德", "传奇生物" ], "maturity": "已上市" }, { "id": "SB-006", "name": "生物制造", "type": "合成生物", "applications": [ "生物塑料", "食品蛋白" ], "companies": [ "Ginkgo", "华熙生物" ], "maturity": "商用" }, { "id": "SB-007", "name": "AI生成基因组Evo 2", "type": "AI+合成生物", "applications": [ "全基因组设计", "蛋白质工程" ], "companies": [ "Arc Institute", "Rice University" ], "maturity": "实验室突破", "description": "Evo 2模型2025年扩展至9.3万亿碱基对，实现全基因组设计；Rice University 2026年1月宣布AI生成基因组突破", "trend": "AI从辅助工具到基因组设计核心引擎；后达尔文时代基因设计", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.academicjobs.com/higher-education-news/first-ai-generated-genomes-breakthrough-or-synthetic-biology-2026-1728", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "SB-008", "name": "Chai-2抗体设计", "type": "AI蛋白质设计", "applications": [ "抗体药物", "蛋白治疗" ], "companies": [ "Chai Discovery" ], "maturity": "实验室验证", "description": "Chai-2 2025年7月实现从头设计抗体16%成功率，AI驱动的蛋白质设计重大突破", "trend": "AI蛋白质设计从概念到实用；SETR 2026报告重点技术", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://setr.stanford.edu/sites/default/files/2026-01/SETR2026_02-Biotech_web-260109.pdf", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "SB-009", "name": "Genyro后达尔文基因设计", "type": "合成生物", "applications": [ "基因组工程", "新物种设计" ], "companies": [ "Genyro" ], "maturity": "早期研发", "description": "Genyro提出'后达尔文时代'基因组设计愿景，百万分之一突破性设计策略", "trend": "从自然选择到理性设计；SynBioBeta 2026重点讨论", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.synbiobeta.com", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "SB-010", "name": "iGEM 2025合成生物创新", "type": "合成生物", "applications": [ "环境修复", "AI治疗", "生物材料" ], "companies": [ "iGEM参赛团队" ], "maturity": "概念验证", "description": "iGEM 2025展示前沿创新：吃塑料植物、AI引导治疗、新型生物材料等", "trend": "合成生物学从学术竞赛到产业转化加速；学生创新推动前沿", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.labiotech.eu/trends-news/igem-2025-synthetic-biology-highlights", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "SB-011", "name": "SynBioBeta 2026大会", "type": "行业会议", "applications": [ "AI+生物", "精准医学", "长寿" ], "companies": [ "全行业" ], "maturity": "参考", "description": "SynBioBeta 2026(5月4-7日圣何塞)：AI驱动治疗、精准医学、长寿成为核心议题", "trend": "AI与生物学深度融合；投资从工具平台向治疗应用转移", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.syntheticbiologysummit.com/human-health-2", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "SB-012", "name": "SEED 2026合成生物会议", "type": "行业会议", "applications": [ "合成生物工程", "进化", "设计" ], "companies": [ "全行业" ], "maturity": "参考", "description": "SEED 2026：合成生物学领先技术会议，覆盖从基础到商业应用全链条", "trend": "合成生物从工程化到进化设计；商业化路径多元化", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://synbioconference.org/2026", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "SB-013", "name": "先导编辑Prime Editing", "type": "基因编辑", "applications": [ "精准基因修正", "遗传病治疗" ], "companies": [ "Prime Medicine", "PTC Therapeutics" ], "maturity": "临床I期", "description": "先导编辑实现任意碱基替换/插入/删除，比CRISPR-Cas9更精准，无需双链断裂", "trend": "2026年多个先导编辑疗法进入临床；体内递送是关键突破点", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "SB-014", "name": "表观遗传编辑", "type": "基因编辑", "applications": [ "基因调控", "长寿", "癌症" ], "companies": [ "Tune Therapeutics", "Epic Bio" ], "maturity": "临床前", "description": "不改变DNA序列，通过表观修饰(甲基化/乙酰化)调控基因表达，可逆且更安全", "trend": "2026年表观编辑成为基因编辑新前沿；可逆性是关键优势", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "SB-015", "name": "DNA数据存储", "type": "合成生物应用", "applications": [ "数据存储", "归档" ], "companies": [ "Catalog", "Twist Bioscience", "Iridia" ], "maturity": "概念验证", "description": "用合成DNA作为超高密度数据存储介质，1克DNA可存储215PB数据", "trend": "读写成本快速下降；2026年微软/Catalog原型系统演示", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "SB-016", "name": "细胞工厂Cell Factory", "type": "生物制造", "applications": [ "化学品", "燃料", "材料" ], "companies": [ "Ginkgo Bioworks", "Zymergen", "Amyris" ], "maturity": "商用", "description": "工程化微生物作为微型化工厂，精确生产目标分子，替代石化路线", "trend": "从专用菌株到通用平台；AI加速DBTL循环", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "SB-017", "name": "合成生物学安全与治理", "type": "政策/伦理", "applications": [ "生物安全", "监管" ], "companies": [ "WHO", "NSABB", "各国家监管机构" ], "maturity": "持续完善", "description": "合成生物学快速发展带来的生物安全/双用性/知识产权等治理挑战", "trend": "2026年全球生物安全框架持续完善；AI+生物交叉领域监管加强", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "SB-018", "name": "无细胞合成生物学", "type": "合成生物", "applications": [ "快速原型", "诊断", "生物传感" ], "companies": [ "Sutro Biopharma", "Tierra Biosciences", "Synthelis" ], "maturity": "商用初期", "description": "无活细胞系统进行转录翻译，快速原型验证，避免细胞毒性限制", "trend": "从研究工具到商业化产品；现场诊断/生物传感应用", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "SB-019", "name": "生物传感器Biosensor", "type": "合成生物应用", "applications": [ "环境监测", "医疗诊断", "食品安全" ], "companies": [ "Synlogic", "Ginkgo Bioworks" ], "maturity": "临床/商用", "description": "工程化生物体感知特定分子并输出信号，用于疾病诊断/环境监测/食品安全", "trend": "活体生物传感器从概念到产品；2026年多个临床项目推进", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "SB-020", "name": "SynbiCITE 2026趋势", "type": "行业趋势", "applications": [ "合成生物产业化" ], "companies": [ "SynbiCITE" ], "maturity": "参考", "description": "SynbiTECH 2025揭示2026年合成生物学趋势：AI驱动、可持续性、监管成熟化", "trend": "从技术突破到产业规模化的过渡期；英国合成生物创新中心引领", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "SB-021", "name": "SETR 2026生物技术报告", "type": "行业报告", "applications": [ "AI+生物", "合成生物", "基因编辑" ], "companies": [ "Stanford" ], "maturity": "参考", "description": "Stanford SETR 2026报告：AI增强生物科学、可扩展个性化医学、超越CRISPR的编辑工具", "trend": "三大技术将塑造2026年生物技术：AI+生物、精准医学、新一代基因编辑", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://setr.stanford.edu/sites/default/files/2026-01/SETR2026_02-Biotech_web-260109.pdf", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "SB-022", "name": "Nature七技术2026", "type": "行业报告", "applications": [ "量子计算", "mRNA治疗", "基因编辑" ], "companies": [ "Nature" ], "maturity": "参考", "description": "Nature 2026年七项值得关注技术：从量子计算到mRNA治疗，基因驱动技术入选", "trend": "跨学科融合加速；基因驱动从实验室到受控释放的关键年", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.nature.com/articles/d41586-026-00188-6", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "SB-023", "name": "碱基编辑Base Editing", "type": "基因编辑", "applications": [ "遗传病", "血液病", "代谢病" ], "companies": [ "Beam Therapeutics", "Verve Therapeutics" ], "maturity": "临床I/II期", "description": "精确转换单个碱基(C→T, A→G)而不产生双链断裂，更安全的基因编辑方式", "trend": "Verve VERVE-101降胆固醇疗法临床数据积极；2026年更多适应症", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "SB-024", "name": "合成基因组学", "type": "合成生物", "applications": [ "最小基因组", "新物种", "工业菌株" ], "companies": [ "JCVI", "Ginkgo Bioworks" ], "maturity": "实验室", "description": "从零合成完整基因组，设计最小基因组生物体，创建自然界不存在的生物系统", "trend": "Sc2.0合成酵母基因组项目接近完成；AI加速基因组设计", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "SB-025", "name": "工程化活体材料ELM", "type": "合成生物应用", "applications": [ "自修复材料", "生物建筑", "智能材料" ], "companies": [ "多所大学研究组" ], "maturity": "实验室", "description": "工程化活体微生物制造的功能材料，可自修复/自组装/响应环境", "trend": "从概念到原型；建筑/航天/医疗应用探索", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "SB-026", "name": "合成生物学投资趋势2026", "type": "投资/市场", "applications": [ "融资", "IPO", "并购" ], "companies": [ "全行业" ], "maturity": "参考", "description": "2026年合成生物学投资从工具平台向治疗应用转移，AI+生物成为投资热点", "trend": "资本从Ginkgo模式(平台)向精准治疗模式转移；AI驱动估值重估", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "SB-027", "name": "生物计算Biocomputing", "type": "合成生物+计算", "applications": [ "生物计算", "智能决策" ], "companies": [ "多所大学研究组" ], "maturity": "概念验证", "description": "利用生物分子/DNA/细胞进行信息处理和计算，与电子计算互补", "trend": "DNA计算/细胞逻辑门/类器官智能；2026年基础研究突破", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "SB-028", "name": "CRISPR诊断CRISPR-Dx", "type": "合成生物应用", "applications": [ "快速诊断", "POCT", "传染病检测" ], "companies": [ "Mammoth Biosciences", "Sherlock Biosciences" ], "maturity": "已上市/临床", "description": "CRISPR用于核酸检测，快速/低成本/现场部署，替代传统PCR", "trend": "SHERLOCK/DETECTR平台商业化；2026年POCT市场快速增长", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-05-31T13:35:00Z" } ] }, { "id": "SB-029", "name": "合成生物学市场预测2026-2033", "type": "市场数据", "applications": [ "全行业" ], "companies": [ "全行业" ], "maturity": "快速增长", "description": "合成生物学市场2026年68.7亿，预计2033年达125.1亿，CAGR 22.7%", "trend": "AI+合成生物深度融合；从概念验证到规模化生产", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.coherentmarketinsights.com/market-insight/synthetic-biology-market-1", "collected_at": "2026-06-01T13:42:00Z" } ] }, { "id": "SB-030", "name": "2026生物技术10大突破趋势", "type": "行业趋势", "applications": [ "全行业" ], "companies": [ "多公司" ], "maturity": "参考", "description": "Atlantis Bioscience 2026年10大生物技术趋势：体内编辑/RNA治疗/空间组学/再生医学创新", "trend": "体内基因编辑从罕见病到常见病；RNA治疗从疫苗到通用平台", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.atlantisbioscience.com/blog/2026-biotech-outlook-10-breakthrough-trends", "collected_at": "2026-06-01T13:42:00Z" } ] }, { "id": "SB-031", "name": "BioTechniques 2026生物技术发展", "type": "行业趋势", "applications": [ "全行业" ], "companies": [ "多公司" ], "maturity": "参考", "description": "BioTechniques 2026年生物技术发展：监管更新/重点领域/新兴技术", "trend": "监管框架适应新技术；人类相关测试模型替代动物实验", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.biotechniques.com/company-news/biotech-developments-to-watch-in-2026", "collected_at": "2026-06-01T13:42:00Z" } ] }, { "id": "SB-032", "name": "Zageno 2026生物技术突破", "type": "行业趋势", "applications": [ "全行业" ], "companies": [ "多公司" ], "maturity": "参考", "description": "Zageno 2026年生物技术突破：AI对齐监管框架/人类相关测试模型/下一代基因编辑", "trend": "AI成为受监管药物开发的一部分；Prime editing扩展应用", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://go.zageno.com/blog/whats-new-in-biotech-2026", "collected_at": "2026-06-01T13:42:00Z" } ] }, { "id": "SB-033", "name": "基因驱动2025研究回顾", "type": "基因驱动", "applications": [ "疟疾防控", "入侵物种管理", "农业" ], "companies": [ "UCMI", "Imperial College", "CSIRO" ], "maturity": "受控释放前", "description": "2025年基因驱动研究：科学进展+战略合作+政策里程碑，从实验室走向受控释放", "trend": "基因驱动从概念到受控释放；治理框架逐步完善", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://genedrivenetwork.org/blog/looking-back-at-2025-gene-drive-research-highlights", "collected_at": "2026-06-01T13:42:00Z" } ] }, { "id": "SB-034", "name": "Imperial基因驱动抗疟蚊子", "type": "基因驱动", "applications": [ "疟疾防控" ], "companies": [ "Imperial College", "UCMI" ], "maturity": "受控释放前", "description": "Imperial College基因驱动蚊子项目接近现实，与UCMI合作推进受控释放", "trend": "基因驱动蚊子从实验室到受控释放；疟疾根除新工具", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.imperial.ac.uk/news/articles/natural-sciences/life-sciences/2025/imperial-led-project-brings-gene-drive-mosquitoes-closer-to-reality", "collected_at": "2026-06-01T13:42:00Z" } ] }, { "id": "SB-035", "name": "基因驱动治理挑战", "type": "基因驱动", "applications": [ "治理", "政策" ], "companies": [ "ISAAA", "USDA" ], "maturity": "政策讨论", "description": "基因驱动面临长期资金激励质疑和治理挑战，AJTMH发表讨论文章", "trend": "基因驱动技术成熟但治理框架滞后；国际共识待形成", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.ajtmh.org/view/journals/tpmd/113/4/article-p728.xml", "collected_at": "2026-06-01T13:42:00Z" } ] }, { "id": "SB-036", "name": "SynbiTECH 2025→2026趋势", "type": "行业趋势", "applications": [ "全行业" ], "companies": [ "SynbiCITE" ], "maturity": "参考", "description": "SynbiTECH 2025揭示2026年合成生物学趋势：AI+生物融合/规模化生产/监管适应", "trend": "合成生物学从实验室到工厂；AI加速DBTL循环", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.synbicite.com/news/2026-trends-in-synthetic-biology", "collected_at": "2026-06-01T13:42:00Z" } ] }, { "id": "SB-037", "name": "SynBioBeta 2026 AI+生物学", "type": "行业会议", "applications": [ "全行业" ], "companies": [ "多公司" ], "maturity": "参考", "description": "SynBioBeta 2026: AI+生物学主题，可编程RNA药物/虚拟细胞模型/AI设计酶/替代糖蛋白", "trend": "AI驱动的生物设计成为主流；可编程RNA药物新赛道", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.syntheticbiologysummit.com", "collected_at": "2026-06-01T13:42:00Z" } ] }, { "id": "SB-038", "name": "AI生成基因组突破", "type": "AI+合成生物", "applications": [ "基因组设计", "合成生物学" ], "companies": [ "Rice University", "Arc Institute" ], "maturity": "研究前沿", "description": "Evo 2模型扩展到9.3万亿碱基对，Rice University 2026年1月宣布AI生成基因组突破", "trend": "AI从蛋白质设计到全基因组设计；后达尔文时代生物工程", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.academicjobs.com/higher-education-news/first-ai-generated-genomes-breakthrough", "collected_at": "2026-06-01T13:42:00Z" } ] }, { "id": "SB-039", "name": "iGEM 2025合成生物学未来", "type": "学生竞赛", "applications": [ "全行业" ], "companies": [ "iGEM" ], "maturity": "参考", "description": "iGEM 2025亮点：吃塑料植物/AI引导治疗/合成生物学创新定义未来", "trend": "下一代合成生物学家关注环境+健康；AI工具降低入门门槛", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.labiotech.eu/trends-news/igem-2025-synthetic-biology-highlights", "collected_at": "2026-06-01T13:42:00Z" } ] }, { "id": "SB-040", "name": "SETR 2026生物技术与合成生物", "type": "学术报告", "applications": [ "全行业" ], "companies": [ "Stanford SETR" ], "maturity": "参考", "description": "Stanford SETR 2026报告：Chai-2抗体设计16%成功率；AI设计抗体进入临床", "trend": "AI抗体设计从概念到管线；2026年AI设计抗体进入临床", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://setr.stanford.edu/sites/default/files/2026-01/SETR2026_02-Biotech_web-260109.pdf", "collected_at": "2026-06-01T13:42:00Z" } ] }, { "id": "SB-041", "name": "GESDA后合成生物学时代", "type": "前沿概念", "applications": [ "全系统设计" ], "companies": [ "GESDA" ], "maturity": "概念阶段", "description": "GESDA高级科学预测会议探讨后合成生物学时代：超越基因编辑，设计整个生物系统", "trend": "从基因编辑到系统设计；合成生物学进入新范式", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.gesda.global/a-post-synthetic-biology-era-explored-at-the-next-gesdas-high-level-science-anticipation-meeting", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "SB-042", "name": "SEED 2026合成生物学会议", "type": "学术会议", "applications": [ "全行业" ], "companies": [ "SEED" ], "maturity": "参考", "description": "SEED 2026合成生物学工程/进化/设计会议：合成生物学领域领先技术会议，从基础到商业应用", "trend": "合成生物学从学术到产业；工程化思维深入", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://synbioconference.org/2026", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "SB-043", "name": "合成生物学市场2026-2033", "type": "市场数据", "applications": [ "全行业" ], "companies": [ "全行业" ], "maturity": "市场增长", "description": "合成生物学市场2026年268.7亿美元，预计2033年达1125.1亿美元，CAGR 22.7%", "trend": "合成生物学市场高速增长；DNA测序成本下降和AI进步驱动", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.coherentmarketinsights.com/market-insight/synthetic-biology-market-112", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "SB-044", "name": "SynBioBeta 2026 AI与生物学", "type": "行业会议", "applications": [ "AI+生物" ], "companies": [ "SynBioBeta" ], "maturity": "参考", "description": "SynBioBeta 2026: AI与生物学交叉，可编程RNA药物/虚拟细胞模型/AI设计酶/替代糖蛋白质等前沿", "trend": "AI+生物学深度融合；可编程RNA和AI设计酶成为热点", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.syntheticbiologysummit.com", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "SB-045", "name": "Xaira AI药物设计进展", "type": "AI药物", "applications": [ "药物发现" ], "companies": [ "Xaira" ], "maturity": "临床前", "description": "SynBioBeta 2026: Xaira生命科学负责人和CEO展示AI药物设计领域进展和剩余挑战", "trend": "AI药物设计从概念到管线；计算生物学加速药物发现", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.synbiobeta.com", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "SB-046", "name": "Nature合成生物学2020-2030六产品", "type": "学术综述", "applications": [ "全行业" ], "companies": [ "多公司" ], "maturity": "参考", "description": "Nature综述合成生物学2020-2030年六个商业化产品：从食品到材料到药物的全面转型", "trend": "合成生物学商业化产品持续增加；从实验室到货架", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.nature.com/articles/s41467-020-20122-2", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "SB-047", "name": "MIT Technology Review 2026三大生物技术", "type": "行业趋势", "applications": [ "全行业" ], "companies": [ "多公司" ], "maturity": "多阶段", "description": "MIT Technology Review: 2026年三大塑造生物技术的技术：AI增强生物科学/可扩展个性化医学/超越CRISPR", "trend": "AI+生物科学融合加速；个性化医学规模化；基因编辑工具多元化", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.facebook.com/technologyreview/posts/three-technologies-that-will-shape-biotech-in-2026", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "SB-048", "name": "Wellcome合成生物学健康可持续", "type": "学术会议", "applications": [ "健康/可持续" ], "companies": [ "Wellcome" ], "maturity": "参考", "description": "Wellcome Genome Campus 2026年3月会议：合成生物学改善人类健康和可持续性", "trend": "合成生物学从工业到健康；可持续发展应用增长", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://coursesandconferences.wellcomeconnectingscience.org/event/synthetic-biology-for-health-and-sustainability-20260311", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "SB-049", "name": "全球合成生物学市场研究2026-2036", "type": "市场研究", "applications": [ "全行业" ], "companies": [ "全行业" ], "maturity": "市场增长", "description": "DNA测序成本下降和AI进步推动合成生物学创新，尤其在制药领域药物发现应用", "trend": "测序成本下降+AI进步双驱动；制药领域合成生物学应用领先", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://finance.yahoo.com/news/global-synthetic-biology-market-research-103000956.html", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "SB-050", "name": "DDW全球合成生物学进展", "type": "行业综述", "applications": [ "药物发现" ], "companies": [ "多公司" ], "maturity": "参考", "description": "Drug Discovery World: 全球合成生物学创新精选，及其在药物发现中的潜力", "trend": "合成生物学在药物发现中应用扩展；从靶点到先导化合物", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.ddw-online.com/global-advances-in-synthetic-biology-20471-202211", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "SB-051", "name": "可编程RNA药物", "type": "RNA疗法", "applications": [ "基因治疗/疫苗" ], "companies": [ "多初创公司" ], "maturity": "临床前/临床", "description": "SynBioBeta 2026亮点：可编程RNA药物平台，精确调控基因表达，治疗遗传病和癌症", "trend": "RNA疗法从疫苗到药物；可编程性提升治疗精准度", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "SB-052", "name": "虚拟细胞模型", "type": "计算生物学", "applications": [ "药物筛选/疾病建模" ], "companies": [ "多初创公司" ], "maturity": "研发中", "description": "虚拟细胞模型：AI驱动的全细胞计算模拟，预测药物反应和疾病进展", "trend": "虚拟细胞从概念到工具；AI+多组学数据驱动", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "SB-053", "name": "AI设计酶", "type": "蛋白质工程", "applications": [ "工业催化/药物合成" ], "companies": [ "多公司" ], "maturity": "研发/中试", "description": "AI设计酶：利用深度学习设计全新酶催化剂，催化自然界不存在的反应", "trend": "AI蛋白质设计从结构到功能；定制化酶催化新化学", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "SB-054", "name": "替代糖蛋白质", "type": "食品科技", "applications": [ "食品/甜味剂" ], "companies": [ "多初创公司" ], "maturity": "商业化初期", "description": "合成生物学开发替代糖的蛋白质甜味剂，解决糖健康问题同时保持甜味体验", "trend": "合成生物学食品应用从概念到产品；健康甜味剂市场需求大", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "SB-055", "name": "合成生物学细胞工厂", "type": "代谢工程", "applications": [ "化学品/材料/燃料" ], "companies": [ "Ginkgo Bioworks", "Zymergen" ], "maturity": "商用扩张", "description": "合成生物学细胞工厂：工程化微生物作为微型化工厂，精确生产目标分子", "trend": "细胞工厂从单一产品到平台化；自动化DBTL循环加速", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "SB-056", "name": "合成生物学标准化2026", "type": "标准", "applications": [ "全行业" ], "companies": [ "多机构" ], "maturity": "制定中", "description": "合成生物学标准化进展：生物元件标准化/数据格式统一/安全规范制定", "trend": "标准化推动合成生物学工程化；从艺术到工程", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "SB-057", "name": "合成生物学生物安全2026", "type": "安全", "applications": [ "全行业" ], "companies": [ "多机构" ], "maturity": "持续关注", "description": "合成生物学生物安全2026年进展：双用途研究监管/生物安全框架/国际治理机制", "trend": "生物安全从被动到主动；AI+合成生物学双用途风险关注", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "SB-058", "name": "合成生物学教育人才培养2026", "type": "教育", "applications": [ "人才培养" ], "companies": [ "iGEM", "多大学" ], "maturity": "扩张期", "description": "合成生物学教育和人才培养2026年进展：iGEM竞赛扩大/大学课程增设/跨学科培养", "trend": "合成生物学人才需求增长；跨学科教育模式推广", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-02T13:42:00Z" } ] }, { "id": "SB-061", "name": "SEED 2026合成生物学技术会议", "type": "行业会议", "efficiency": "N/A", "cost": "N/A", "maturity": "参考", "companies": [ "SEED" ], "description": "SEED 2026合成生物学工程/进化/设计会议：涵盖从基础到商业应用的全领域", "trend": "合成生物学从学术到产业转化加速；工程化设计成为核心", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://synbioconference.org/2026", "collected_at": "2026-06-03T13:57:41.937Z" } ] }, { "id": "SB-063", "name": "Xaira AI+生物学进展", "type": "技术趋势", "efficiency": "N/A", "cost": "N/A", "maturity": "前沿", "companies": [ "Xaira" ], "description": "SynBioBeta 2026上Xaira展示AI+生命科学进展：AI公司生命科学负责人和Xaira CEO阐述领域进展和挑战", "trend": "AI驱动的药物发现加速；AI+生物学投资持续升温", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.synbiobeta.com", "collected_at": "2026-06-03T13:57:41.937Z" } ] }, { "id": "SB-064", "name": "Wellcome合成生物学健康可持续会议", "type": "行业会议", "efficiency": "N/A", "cost": "N/A", "maturity": "参考", "companies": [ "Wellcome" ], "description": "Wellcome Genome Campus 2026年3月11-13日举办合成生物学健康与可持续会议，线上线下同步", "trend": "合成生物学应用从医疗扩展到可持续发展；全球协作加速", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://coursesandconferences.wellcomeconnectingscience.org/event/synthetic-biology-for-health-and-sustainability-20260311", "collected_at": "2026-06-03T13:57:41.937Z" } ] }, { "id": "SB-065", "name": "FII Priority AI+合成生物学", "type": "前沿趋势", "efficiency": "N/A", "cost": "N/A", "maturity": "前沿", "companies": [ "FII" ], "description": "FII Priority Miami 2026：未来十年风投回报将来自高速封闭创新生态系统，AI+合成生物学是核心", "trend": "AI+合成生物学成为风投热点；封闭创新生态系统模式兴起", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.youtube.com/watch?v=VbBF7eDkxfc", "collected_at": "2026-06-03T13:57:41.937Z" } ] }, { "id": "SB-067", "name": "合成生物学2026最变革技术", "type": "行业趋势", "applications": [ "全行业" ], "companies": [ "多公司" ], "maturity": "参考", "description": "2026年合成生物学代表最具变革性技术之一：工程细菌代谢塑料废物/合成细胞设计用于药物递送/AI设计酶", "trend": "合成生物学从实验室到实际应用加速；AI+生物深度融合", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-04T14:05:26.379Z" } ] }, { "id": "SB-068", "name": "Nature合成生物学六产品2020-2030", "type": "学术综述", "applications": [ "全行业" ], "companies": [ "多公司" ], "maturity": "参考", "description": "Nature综述合成生物学2020-2030年六个商业化产品：从食品到材料到药物的全面转型", "trend": "合成生物学商业化产品持续增加；从实验室到货架", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.nature.com/articles/s41467-020-20122-2", "collected_at": "2026-06-04T14:05:26.379Z" } ] }, { "id": "SB-069", "name": "SynBioBeta 2026 AI+生物学大会", "type": "行业会议", "applications": [ "AI+生物" ], "companies": [ "SynBioBeta" ], "maturity": "参考", "description": "SynBioBeta 2026大会主题AI和生物学：展示可编程RNA药物/虚拟细胞模型/AI设计酶/可编程生物", "trend": "AI+生物学成为合成生物学核心主题；可编程生物时代", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://synbiobeta.com/conference", "collected_at": "2026-06-04T14:07:22.337Z" } ] }, { "id": "SB-070", "name": "Chai-2抗体设计16%成功率突破", "type": "AI药物设计", "applications": [ "抗体设计" ], "companies": [ "Chai Discovery" ], "maturity": "工具突破", "description": "Chai Discovery发布Chai-2：AI抗体设计16%成功率，从序列到结构预测，大幅超越传统方法", "trend": "AI抗体设计从概念到实用；成功率大幅提升", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-04T14:07:22.337Z" } ] }, { "id": "SB-071", "name": "Rice University AI生成基因组突破", "type": "AI+生物", "applications": [ "基因组设计" ], "companies": [ "Rice University" ], "maturity": "实验室突破", "description": "Rice University利用Evo 2等AI模型实现基因组设计突破，AI可生成功能性基因组序列", "trend": "AI从分析到设计基因组；合成生物学新范式", "sources": [ { "source_type": "web", "source_credibility": "A", "collected_at": "2026-06-04T14:07:22.337Z" } ] }, { "id": "SB-072", "name": "合成生物学市场6.87B→12.51B预测", "type": "市场数据", "applications": [ "全行业" ], "companies": [ "全行业" ], "maturity": "市场预测", "description": "合成生物学市场2026年估值268.7亿美元，预计2033年达1125.1亿美元，CAGR 22.4%", "trend": "合成生物学市场高速增长；从利基到主流", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-04T14:07:22.337Z" } ] }, { "id": "SB-072", "name": "基因驱动逆转害虫杀虫剂抗性", "type": "基因驱动", "applications": [ "农业" ], "companies": [ "多研究机构" ], "maturity": "实验室突破", "description": "新基因驱动技术可逆转害虫杀虫剂抗性，保护作物并大幅减少化学农药使用", "trend": "基因驱动从疾病防控到农业应用；逆转抗性是新方向", "sources": [ { "source_type": "web", "source_credibility": "A", "collected_at": "2026-06-04T14:09:22.606Z" } ] }, { "id": "SB-073", "name": "Transmission Zero基因驱动新方法", "type": "基因驱动", "applications": [ "疟疾防控" ], "companies": [ "Transmission Zero" ], "maturity": "实验室开发", "description": "Transmission Zero开发新基因驱动方法：结合抑制和修饰策略，防止蚊子传播疟疾", "trend": "基因驱动从单一策略到组合策略；安全性和有效性兼顾", "sources": [ { "source_type": "web", "source_credibility": "A", "collected_at": "2026-06-04T14:09:22.606Z" } ] }, { "id": "SB-074", "name": "最大蚊子遗传研究揭示杀虫剂抗性传播", "type": "学术研究", "applications": [ "疟疾防控" ], "companies": [ "多研究机构" ], "maturity": "参考", "description": "最大规模蚊子遗传研究揭示杀虫剂抗性传播机制，发现基因驱动对大多数蚊子基因可能无效", "trend": "基因驱动局限性被认识；需要更精准的靶点选择", "sources": [ { "source_type": "web", "source_credibility": "A", "collected_at": "2026-06-04T14:09:22.606Z" } ] }, { "id": "SB-075", "name": "合成生物学市场26.87B→112.51B预测", "type": "市场数据", "applications": [ "多行业" ], "companies": [ "Coherent Market Insights" ], "maturity": "市场预测", "description": "合成生物学市场2026年估值268.7亿美元，预计2033年达1125.1亿美元，CAGR 22.7%", "trend": "合成生物学市场高速增长；从利基到主流", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.coherentmarketinsights.com/market-insight/synthetic-biology-market-112", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "SB-076", "name": "GESDA: 后合成生物学时代探索", "type": "学术前沿", "applications": [ "多领域" ], "companies": [ "GESDA" ], "maturity": "概念阶段", "description": "GESDA高级科学预测会议探索后合成生物学时代：从编辑基因到设计整个生物系统", "trend": "从基因编辑到系统设计；后合成生物学时代来临", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.gesda.global/a-post-synthetic-biology-era-explored-at-the-next-gesdas-high-level-science-anticipation-meeting", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "SB-077", "name": "SynBioBeta 2026: AI与生物学融合", "type": "行业会议", "applications": [ "多领域" ], "companies": [ "SynBioBeta" ], "maturity": "参考", "description": "SynBioBeta 2026(5月4-7日圣何塞)：可编程RNA药物、虚拟细胞模型、AI设计酶、替代糖蛋白质", "trend": "AI+生物学从概念到产品；可编程RNA和虚拟细胞是热点", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.syntheticbiologysummit.com", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "SB-078", "name": "Nature: 合成生物学2020-2030六大商业产品", "type": "学术综述", "applications": [ "食品", "材料", "医药" ], "companies": [ "多公司" ], "maturity": "参考", "description": "Nature综述合成生物学2020-2030六大商业可用产品：改变食物、材料、医药来源", "trend": "合成生物学从实验室到货架；六大产品类别商业化", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.nature.com/articles/s41467-020-20122-2", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "SB-079", "name": "DDW: 全球合成生物学进展", "type": "行业分析", "applications": [ "药物发现" ], "companies": [ "多公司" ], "maturity": "参考", "description": "Drug Discovery World精选近期合成生物学创新及其药物发现潜力", "trend": "合成生物学赋能药物发现；从工具到平台", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.ddw-online.com/global-advances-in-synthetic-biology-20471-202211", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "SB-080", "name": "FII Priority Miami 2026: AI+合成生物学投资", "type": "行业会议", "applications": [ "投资" ], "companies": [ "多投资机构" ], "maturity": "参考", "description": "FII Priority Miami 2026: 下一个十年风投回报来自高速封闭创新生态系统，AI+合成生物学是核心", "trend": "AI+合成生物学成为风投焦点；封闭创新生态系统模式", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.youtube.com/watch?v=VbBF7eDkxfc", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "SB-081", "name": "BioIVT: 2026生命科学重大影响领域", "type": "行业预测", "applications": [ "多领域" ], "companies": [ "BioIVT" ], "maturity": "参考", "description": "BioIVT 2026生命科学预测：NAMs、AI驱动R&D、液体活检进展、细胞和基因治疗新兴创新", "trend": "NAMs和AI驱动R&D变革；多领域交叉创新", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://bioivt.com/blogs/2026-areas-of-major-impact-across-life-sciences", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "SB-082", "name": "Reddit: 合成生物学突破在哪里", "type": "社区讨论", "applications": [ "多领域" ], "companies": [ "Filipe Pereira Lab" ], "maturity": "参考", "description": "Reddit r/biotech讨论合成生物学突破：Filipe Pereira Lab被认为是真正合成生物学愿景的代表", "trend": "社区对合成生物学突破的期待；从概念到实际应用", "sources": [ { "source_type": "web", "source_credibility": "C", "article_url": "https://www.reddit.com/r/biotech/comments/1qoqu51/where_are_the_breakthroughs_of_synthetic_biology", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "SB-083", "name": "SynBioBeta: AI公司生命科学负责人与Xaira CEO对话", "type": "行业对话", "applications": [ "AI+生物学" ], "companies": [ "Xaira" ], "maturity": "参考", "description": "SynBioBeta 2026: AI公司生命科学负责人和Xaira CEO讨论AI+生物学进展和剩余挑战", "trend": "AI+生物学从兴奋到务实；挑战仍然巨大", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.synbiobeta.com", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "SB-084", "name": "SEED 2025合成生物学工程进化设计会议", "type": "行业会议", "applications": [ "多领域" ], "companies": [ "多机构" ], "maturity": "参考", "description": "SEED是合成生物学领先技术会议，覆盖从基础到商业应用", "trend": "合成生物学从基础到商业全链条；SEED连接学术和产业", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://synbioconference.org/2025", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "SB-085", "name": "基因驱动逆转昆虫抗药性", "type": "基因驱动", "applications": [ "农业", "害虫防控" ], "companies": [ "多研究机构" ], "maturity": "实验室开发", "description": "新基因驱动技术可逆转害虫杀虫剂抗性，保护作物并大幅减少化学农药使用", "trend": "基因驱动从传播到逆转；农业应用新方向", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.isaaa.org/kc/cropbiotechupdate/article/default.asp?ID=21109", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "SB-086", "name": "Science: 基因驱动技术如何监管", "type": "监管讨论", "applications": [ "多领域" ], "companies": [ "多机构" ], "maturity": "参考", "description": "Science杂志讨论基因驱动技术监管：如何控制这种争议性基因扩散方法", "trend": "基因驱动监管从空白到框架；争议性技术需要审慎治理", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.science.org/content/article/how-will-we-keep-controversial-gene-drive-technology-check", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "SB-087", "name": "MESA: 基因驱动技术用于非洲疟疾消除", "type": "政策建议", "applications": [ "疟疾防控" ], "companies": [ "MESA" ], "maturity": "政策建议", "description": "MESA为政策制定者提供基因驱动技术用于非洲疟疾防控的指导建议", "trend": "基因驱动从研究到政策；非洲疟疾防控新工具", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://mesamalaria.org/resource-hub/application-of-gene-drive-technology-for-malaria-elimination-in-africa", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "SB-088", "name": "Nature: 基因驱动技术需要彻底审查", "type": "学术评论", "applications": [ "多领域" ], "companies": [ "多机构" ], "maturity": "参考", "description": "Nature评论：基因驱动技术需要彻底审查，确保安全性和可控性", "trend": "基因驱动安全性审查加强；科学界呼吁审慎推进", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.nature.com/articles/d41586-017-08214-4", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "SB-089", "name": "GEAR 2026基因编辑和RNA技术会议", "type": "行业会议", "applications": [ "基因编辑", "RNA技术" ], "companies": [ "AIChE" ], "maturity": "参考", "description": "GEAR 2026(9月15-17日)：CRISPR和新兴基因编辑前沿研究", "trend": "基因编辑从CRISPR到多元化；RNA技术崛起", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://www.aiche.org/sbe/conferences/gene-editing-rna-technologies-gear/2026", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "SB-090", "name": "第7届基因组编辑治疗峰会2026", "type": "行业会议", "applications": [ "基因治疗" ], "companies": [ "多公司" ], "maturity": "参考", "description": "第7届基因组编辑治疗峰会：联合制药、生物技术和学术领袖加速安全有效基因组编辑疗法开发", "trend": "基因组编辑从工具到疗法；安全性和有效性是焦点", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://genome-editing-therapeutics-summit.com", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "SB-091", "name": "Gene Drive Network: 基因驱动技术健康保护进展", "type": "行业分析", "applications": [ "健康", "保护" ], "companies": [ "Gene Drive Network" ], "maturity": "参考", "description": "Gene Drive Network: 基因驱动技术在健康、保护和治理方面的最新进展", "trend": "基因驱动多领域应用探索；治理框架同步发展", "sources": [ { "source_type": "web", "source_credibility": "B", "article_url": "https://genedrivenetwork.org/fr/blog/gene-drive-technologies-advances-in-health-conservation-and-governance", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "SB-092", "name": "可编程RNA药物2026进展", "type": "RNA技术", "applications": [ "药物开发" ], "companies": [ "多公司" ], "maturity": "临床阶段", "description": "2026年可编程RNA药物进展：从mRNA疫苗到可编程RNA疗法，精准调控基因表达", "trend": "RNA从疫苗到可编程疗法；精准调控基因表达", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "SB-093", "name": "AI设计酶2026突破", "type": "AI蛋白设计", "applications": [ "催化", "工业" ], "companies": [ "多公司" ], "maturity": "实验室阶段", "description": "2026年AI设计酶技术突破：从序列到功能，AI加速酶工程", "trend": "AI从辅助到主导酶设计；催化效率大幅提升", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "SB-094", "name": "替代糖蛋白质2026商业化", "type": "替代蛋白", "applications": [ "食品" ], "companies": [ "多公司" ], "maturity": "商业化早期", "description": "2026年替代糖蛋白质商业化：合成生物学生产的蛋白质替代传统糖，健康和可持续", "trend": "替代蛋白从概念到产品；健康和可持续双驱动", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "SB-095", "name": "虚拟细胞模型2026进展", "type": "计算生物学", "applications": [ "药物发现", "基础研究" ], "companies": [ "多公司" ], "maturity": "早期开发", "description": "2026年虚拟细胞模型进展：AI驱动的细胞模拟从概念到原型，加速生物学理解", "trend": "虚拟细胞从概念到原型；AI+生物学新范式", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "SB-096", "name": "合成基因组学2026里程碑", "type": "合成基因组学", "applications": [ "基础研究", "生物制造" ], "companies": [ "多研究机构" ], "maturity": "实验室阶段", "description": "2026年合成基因组学里程碑：从合成酵母基因组到更复杂生物基因组设计", "trend": "合成基因组学从酵母到更复杂生物；基因组设计能力提升", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "SB-097", "name": "生物计算2026新架构", "type": "生物计算", "applications": [ "计算", "传感" ], "companies": [ "多研究机构" ], "maturity": "概念验证", "description": "2026年生物计算新架构：DNA存储、细胞计算、生物传感器等新范式探索", "trend": "生物计算从概念到架构；DNA存储和细胞计算突破", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "SB-098", "name": "合成生物学监管2026全球趋势", "type": "监管趋势", "applications": [ "多领域" ], "companies": [ "多机构" ], "maturity": "参考", "description": "2026年合成生物学监管全球趋势：各国从各自为政到协调框架，安全与创新平衡", "trend": "监管从碎片化到协调；安全与创新平衡", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "SB-099", "name": "生物固碳合成生物学2026进展", "type": "生物固碳", "applications": [ "碳捕获", "可持续" ], "companies": [ "多公司" ], "maturity": "实验室阶段", "description": "2026年生物固碳合成生物学进展：工程微生物固定CO2，从概念到中试", "trend": "生物固碳从概念到中试；合成生物学赋能碳捕获", "sources": [ { "source_type": "web", "source_credibility": "B", "collected_at": "2026-06-05T14:16:40.000Z" } ] }, { "id": "SB-100", "name": "CRISPR基因与细胞治疗临床多领域突破", "type": "基因编辑临床", "efficiency": "多疾病 promising", "cost": "高", "maturity": "临床推进", "companies": [ "CRISPR Therapeutics", "多研究机构" ], "description": "2025年ScienceDirect综述：CRISPR基因与细胞治疗已进入多疾病临床试验，早期结果令人鼓舞，但关键挑战仍存，包括脱靶效应、递送效率和免疫反应", "trend": "CRISPR疗法从血液病扩展到实体瘤、HIV和自身免疫病；递送技术是关键瓶颈", "sources": [ { "source_type": "web", "source_credibility": "A", "article_url": "https://www.sciencedirect.com/science/article/pii/S2666379125005324", "collected_at": "2026-06-16T22:31:38.000Z" } ] }, { "name": "AlphaGenome", "type": "AI Model", "applications": [ "genome design", "synthetic biology", "personalized medicine" ], "companies": [], "maturity": "Early-stage development", "description": "AlphaGenome is an emerging AI model capable of designing functional genomes, which could revolutionize synthetic biology by accelerating the creation of new forms of life. It represents a significant advancement in bridging AI capabilities with biological engineering. Researchers believe this technology will transform medicine and biotechnology by enabling precise genome manipulation.", "trend": "Rapidly growing research interest", "sources": [ "https://www.instagram.com/reel/DOC9kuZDDRx", "https://www.hpcwire.com/aiwire/2026/03/11/a-new-ai-model-could-help-scientists-design-new-forms-of-life" ], "id": "SB-101" }, { "name": "CRISPR", "type": "Gene Editing Technology", "applications": [ "genome editing", "microbial cell factories", "synthetic gene circuits", "gene regulation" ], "companies": [], "maturity": "Established and widely adopted", "description": "CRISPR has become a cornerstone tool in synthetic biology for programmable genome editing. Recent advancements include expanded CRISPR toolboxes for constructing microbial cell factories and building synthetic gene circuits. Its applications span from basic research to industrial biotechnology, making it one of the most impactful technologies in the field.", "trend": "Continuously expanding applications", "sources": [ "https://www.sciencedirect.com/science/article/pii/S2405805X26000189", "https://pubs.acs.org/doi/10.1021/acssynbio.0c00349" ], "id": "SB-102" }, { "name": "SynBioBeta", "type": "Conference/Community", "applications": [ "industry networking", "knowledge sharing", "biological engineering innovation" ], "companies": [], "maturity": "Established annual event", "description": "SynBioBeta is a global community and conference bringing together biological engineers, entrepreneurs, investors, and innovators. The 2026 event focuses on AI and biology integration, highlighting programmable genome editing systems and other breakthroughs. It serves as a key platform for advancing synthetic biology through collaboration and education.", "trend": "Growing influence in synthetic biology ecosystem", "sources": [ "https://www.syntheticbiologysummit.com/agenda-main", "https://www.synbiobeta.com/watch/bridging-biology-and-ai-for-genome-design" ], "id": "SB-103" }, { "name": "Generative AI for Synthetic Biology", "type": "AI Application Area", "applications": [ "designing biological parts", "biological circuits", "genome design", "high-throughput genetic design space mapping" ], "companies": [], "maturity": "Emerging research field", "description": "Generative AI is being applied to synthetic biology for designing biological parts, circuits, and entire genomes. This approach enables ultra-high throughput mapping of genetic design spaces, significantly accelerating bioengineering workflows. Published research demonstrates its potential to unlock innovations in medicine, agriculture, and sustainability.", "trend": "Fast-growing research and investment area", "sources": [ "https://www.cell.com/cell-systems/abstract/S2405-4712(26)00015-3", "https://www.nature.com/articles/s44385-025-00021-1", "https://pubmed.ncbi.nlm.nih.gov/40553349" ], "id": "SB-104" }, { "name": "AI in Synthetic Biology Market", "type": "Industry Sector", "applications": [ "medicine", "agriculture", "sustainability", "metabolic pathway optimization" ], "companies": [], "maturity": "Early growth phase", "description": "The global AI in synthetic biology market was valued at USD 110.78 million in 2025 and is projected to reach USD 492.73 million by 2035. This rapid growth reflects increasing integration of AI tools across bioengineering workflows. Key application areas include medicine, agriculture, and sustainability initiatives driven by metabolic pathway optimization and biological system design.", "trend": "Strong upward trajectory with 5x projected growth", "sources": [ "https://www.cervicornconsulting.com/artificial-intelligence-in-synthetic-biology-market" ], "id": "SB-105" }, { "name": "AI-driven synthetic biology tools", "type": "Technology Platform", "applications": [ "Metabolic pathway optimization", "High-throughput genome editing", "Biological circuit design" ], "companies": [], "maturity": "Emerging", "description": "These tools leverage artificial intelligence to streamline bioengineering workflows, from designing genetic parts to optimizing metabolic pathways. They are transforming synthetic biology by accelerating innovation across medicine, agriculture, and sustainability sectors.", "trend": "Rapidly growing", "id": "SB-106" }, { "name": "Microbial cell factories", "type": "Bioproduction System", "applications": [ "Industrial biotechnology", "Metabolic engineering", "Sustainable manufacturing" ], "companies": [], "maturity": "Commercializing", "description": "Microbial cell factories are engineered organisms designed to produce valuable compounds such as pharmaceuticals, biofuels, and chemicals. By combining synthetic biology with AI-driven design, these systems are becoming more efficient and scalable for industrial applications.", "trend": "Growing", "id": "SB-107" }, { "id": "SB-108", "name": "CRISPR 250项临床试验", "type": "基因编辑", "applications": [ "基因治疗", "血液病", "遗传病" ], "companies": [ "Vertex", "CRISPR Therapeutics", "Editas", "Beam" ], "maturity": "临床阶段", "description": "截至2026年CRISPR Medicine News监测约250项涉及基因编辑治疗候选药物的临床试验，其中150+项正在进行", "trend": "CRISPR从首个批准走向广泛应用" }, { "id": "SB-109", "name": "Cleveland Clinic CRISPR降脂", "type": "基因编辑", "applications": [ "高胆固醇血症", "心血管疾病" ], "companies": [ "Verve Therapeutics" ], "maturity": "I期临床", "description": "Cleveland Clinic首次人体试验显示CRISPR-Cas9一次性输注可将LDL胆固醇降低50%、甘油三酯降低55%", "trend": "体内CRISPR编辑从罕见病走向常见病" }, { "id": "SB-110", "name": "Casgevy后续扩展", "type": "基因编辑", "applications": [ "镰刀型贫血", "β地中海贫血" ], "companies": [ "Vertex", "CRISPR Therapeutics" ], "maturity": "已上市", "description": "Casgevy 2023年12月获FDA批准治疗SCD后，持续扩展适应症，2024年EMA批准，2025-2026年推进新适应症", "trend": "首个CRISPR疗法进入商业化扩展期" }, { "id": "SB-111", "name": "先导编辑临床推进", "type": "基因编辑", "applications": [ "遗传病治疗", "精准修复" ], "companies": [ "Prime Medicine" ], "maturity": "I期临床", "description": "先导编辑(Prime Editing)可实现大片段精准插入和修复，2025-2026年推进多项I/II期临床试验", "trend": "先导编辑是CRISPR 2.0核心技术" }, { "id": "SB-112", "name": "表观遗传编辑", "type": "表观遗传编辑", "applications": [ "基因调控", "表观治疗" ], "companies": [ "Tune Therapeutics", "Chroma Medicine" ], "maturity": "临床前/早期临床", "description": "表观遗传编辑不改变DNA序列而是调控基因表达，2025-2026年多家公司进入临床阶段", "trend": "非切割型编辑提高安全性" }, { "id": "SYN-110", "name": "Cas9-Guided Endonuclease", "type": "CRISPR", "applications": "Genome editing, gene knockout, gene insertion, gene therapy", "companies": "CRISPR Therapeutics, Editas Medicine, Caribou Biosciences" }, { "id": "SYN-111", "name": "Base Editor System", "type": "CRISPR", "applications": "Precise point mutations, disease modeling, gene correction without double-strand breaks", "companies": "Beam Therapeutics, Prime Medicine, Verve Therapeutics" }, { "id": "SYN-112", "name": "Prime Editing System", "type": "CRISPR", "applications": "Precise gene insertions, deletions, and all 12 base-to-base conversions, correcting disease-causing mutations", "companies": "Prime Medicine, Editas Medicine, Verve Therapeutics" }, { "id": "SYN-113", "name": "CRISPR-Cas13 System", "type": "CRISPR", "applications": "RNA targeting, diagnostics (SHERLOCK), RNA therapeutics, gene knockdown", "companies": "Sherlock Biosciences, Mammoth Biosciences, Caribou Biosciences" }, { "id": "SYN-114", "name": "Synthetic Operon", "type": "Metabolic Engineering", "applications": "Optimizing metabolic pathways, producing biofuels, pharmaceuticals, and fine chemicals", "companies": "Ginkgo Bioworks, LanzaTech, Zymergen" }, { "id": "SYN-115", "name": "Orthogonal Gene Circuit", "type": "Metabolic Engineering", "applications": "Decoupled metabolic pathways, dynamic pathway control, robust bioproduction", "companies": "Ginkgo Bioworks, Amyris, Genomatica" }, { "id": "SYN-116", "name": "Non-Natural Amino Acid Incorporation", "type": "Metabolic Engineering", "applications": "Protein engineering, creating novel biomaterials, developing new therapeutics", "companies": "Ambrx, Synthorx, Ginkgo Bioworks" }, { "id": "SYN-117", "name": "De Novo Pathway Design", "type": "Metabolic Engineering", "applications": "Creating entirely new biosynthetic routes for complex molecules, bio-based manufacturing", "companies": "Zymergen, Ginkgo Bioworks, LanzaTech" }, { "id": "SYN-118", "name": "Cell-Free Protein Synthesis (CFPS)", "type": "Cell-Free", "applications": "Rapid protein production, toxic protein synthesis, point-of-care therapeutics, vaccine development", "companies": "Sutro Biopharma, Ginkgo Bioworks (cell-free division), Catapult Bio" }, { "id": "SYN-119", "name": "Cell-Free Metabolic Engineering Platform", "type": "Cell-Free", "applications": "Biosynthesis of high-value chemicals, pathway screening without cell viability constraints", "companies": "Ginkgo Bioworks, Zymergen, Sutro Biopharma" }, { "id": "SYN-120", "name": "DNA Data Storage System", "type": "Cell-Free", "applications": "Ultra-dense, long-term digital data archival, information storage in DNA molecules", "companies": "Twist Bioscience, Catalog, Microsoft (DNA Storage Research)" }, { "id": "SYN-121", "name": "Biosensor: RNA Aptamer-Based", "type": "Biosensor", "applications": "Detection of small molecules, toxins, and proteins with high specificity, environmental monitoring", "companies": "SomaLogic, Glympse Bio, Molecular Assemblies" }, { "id": "SYN-122", "name": "Biosensor: Electrochemical Whole-Cell", "type": "Biosensor", "applications": "Real-time detection of pollutants, pathogens, or metabolites in water, soil, and food", "companies": "Aclara BioSciences, BioDevice Group, numerous academic spinouts" }, { "id": "SYN-123", "name": "Biosensor: Luciferase Reporter", "type": "Biosensor", "applications": "High-throughput screening, gene expression analysis, in vivo imaging, toxicity testing", "companies": "Promega, PerkinElmer, Eurofins" }, { "id": "SYN-124", "name": "Biosensor: Cell-Free Diagnostic", "type": "Biosensor", "applications": "Rapid, equipment-free pathogen detection, point-of-care diagnostics, CRISPR-based diagnostics", "companies": "Sherlock Biosciences, Mammoth Biosciences, Mammoth Diagnostics" }, { "id": "SYN-125", "name": "CRISPR-Cas9 Variant X", "type": "CRISPR", "applications": "Gene therapy for genetic disorders, targeted cancer therapies, agricultural trait editing", "companies": "Editas Medicine, CRISPR Therapeutics, Caribou Biosciences" }, { "id": "SYN-126", "name": "Methanol-E. coli Chassis", "type": "Metabolic Engineering", "applications": "Sustainable production of biofuels, bioplastics, and other chemicals from methanol feedstock", "companies": "LanzaTech, Ginkgo Bioworks, Genomatica" }, { "id": "SYN-127", "name": "Cell-Free Protein Synthesis (CFPS) Kit Pro", "type": "Cell-Free", "applications": "On-demand therapeutic protein production, rapid prototyping of enzymes, point-of-care diagnostics", "companies": "Sutro Biopharma, Ginkgo Bioworks (Extract), Amano Enzymes" }, { "id": "SYN-128", "name": "Glucose-Responsive Biosensor Array", "type": "Biosensor", "applications": "Continuous glucose monitoring for diabetes management, bioprocess monitoring, food safety testing", "companies": "Dexcom, Abbott Laboratories, Abaxis" }, { "id": "SYN-129", "name": "Base Editing Platform Prime", "type": "CRISPR", "applications": "Precise single-base changes for correcting point mutations, without double-strand breaks", "companies": "Beam Therapeutics, Prime Medicine, Verve Therapeutics" }, { "id": "SYN-130", "name": "Yeast-Cellulose Production Strain", "type": "Metabolic Engineering", "applications": "Conversion of non-food biomass (cellulose) into biofuels and high-value chemicals", "companies": "LanzaJet, Gevo, Amyris" }, { "id": "SYN-131", "name": "Microfluidic Cell-Free System", "type": "Cell-Free", "applications": "High-throughput screening of genetic circuits, accelerated prototyping, personalized medicines", "companies": "Tune Therapeutics, Ginkgo Bioworks, Berkeley Lights" }, { "id": "SYN-132", "name": "Pathogen-Detect RNA Biosensor", "type": "Biosensor", "applications": "Rapid, field-deployable detection of viral and bacterial RNA, pandemic surveillance", "companies": "Mologic, Mammoth Biosciences, Sherlock Biosciences" }, { "id": "SYN-133", "name": "CRISPR-Cas13 Antiviral System", "type": "CRISPR", "applications": "Detection and targeted degradation of specific RNA viruses, broad-spectrum antiviral therapy", "companies": "Sherlock Biosciences, Excision BioTherapeutics, Caribou Biosciences" }, { "id": "SYN-134", "name": "Algae-Based Astaxanthin Strain", "type": "Metabolic Engineering", "applications": "Sustainable, high-yield production of the antioxidant astaxanthin for nutraceuticals and animal feed", "companies": "Cyanotech, Algenuity, Synthetic Genomics" }, { "id": "SYN-135", "name": "Cell-Free Metabolic Pathway Kit", "type": "Cell-Free", "applications": "Rapid assembly and testing of biosynthetic pathways for drug and chemical discovery", "companies": "Ginkgo Bioworks, Sutro Biopharma, Cytiva" }, { "id": "SYN-136", "name": "Heavy Metal Ion Fluorescent Reporter", "type": "Biosensor", "applications": "Environmental monitoring of lead, mercury, and arsenic in water and soil, industrial process control", "companies": "Neogen, Eurofins, Pall Corporation" }, { "id": "SYN-137", "name": "Prime Editing 2.0 System", "type": "CRISPR", "applications": "Versatile gene writing for precise insertions, deletions, and all base-to-base conversions", "companies": "Prime Medicine, Beam Therapeutics, Verve Therapeutics" }, { "id": "SYN-138", "name": "Pseudomonas Denitrification Strain", "type": "Metabolic Engineering", "applications": "Bioremediation of nitrate-contaminated groundwater and wastewater, industrial nitrogen removal", "companies": "Genomatica, LanzaTech, Ginkgo Bioworks" }, { "id": "SYN-139", "name": "Toxin-Responsive Colorimetric Biosensor", "type": "Biosensor", "applications": "Visual detection of foodborne toxins (e.g., aflatoxin), safety screening for raw materials", "companies": "Neogen, Romer Labs, 3M Company" } ], "longevity_tech": [ { "id": "LONG-001", "name": "Senolytics", "type": "Anti-aging therapy", "description": "Drugs that selectively kill senescent ('zombie') cells that accumulate with age and drive inflammation and tissue dysfunction.", "mechanism": "Dasatinib + quercetin, fisetin, navitoclax - induce apoptosis in senescent cells", "status": "Clinical trials; Unity Biotechnology's UBX1325 in Phase 2 for age-related eye disease", "developer": "Unity Biotechnology, Oisín Biotechnologies, Mayo Clinic" }, { "id": "LONG-002", "name": "NAD+ Repletion", "type": "Metabolic enhancement", "description": "Boosting NAD+ levels (critical coenzyme that declines with age) through precursors like NMN and NR. Shown to improve mitochondrial function and metabolism in mice.", "mechanism": "NMN (nicotinamide mononucleotide) or NR (nicotinamide riboside) supplementation boosts NAD+ levels", "status": "NMN/NR supplements widely available; clinical trials ongoing; FDA challenged NMN as supplement in 2023", "developer": "ChromaDex (NR), Metro Biotech (NMN), Elysium Health" }, { "id": "LONG-003", "name": "mTOR Inhibition (Rapamycin)", "type": "Drug-based longevity", "description": "Rapamycin inhibits mTOR, a master growth regulator. In mice, rapamycin extends lifespan 25%+ even when started late in life. The most robust life-extension drug in mammals.", "mechanism": "Inhibits mTORC1, reducing protein synthesis and increasing autophagy; mimics dietary restriction", "status": "Off-label use growing; dog longevity trials (RAPID, TRUTH); human trials planned", "developer": "ResTORbio (now part of EQRx), AgelessRx, University of Washington" }, { "id": "LONG-004", "name": "Epigenetic Reprogramming (Yamanaka Factors)", "type": "Cellular rejuvenation", "description": "Partial reprogramming using OSKM (Oct4, Sox2, Klf4, Myc) factors to reverse epigenetic age without dedifferentiating cells to pluripotency. The most exciting rejuvenation approach.", "mechanism": "Cyclic expression of Yamanaka factors resets epigenetic marks, restoring youthful gene expression patterns", "status": "Altos Labs ($3B funded); Turn Biotechnologies; in vivo mouse studies show rejuvenation of multiple tissues", "developer": "Altos Labs, Turn Bio, AgeX, Ovelle Therapeutics" }, { "id": "LONG-005", "name": "Metformin (TAME Study)", "type": "Drug-based longevity", "description": "The diabetes drug metformin is associated with reduced all-cause mortality in diabetics vs non-diabetics. The TAME (Targeting Aging with Metformin) study aims to prove aging can be treated as a condition.", "mechanism": "Activates AMPK, inhibits mitochondrial complex I, reduces inflammation and insulin/IGF-1 signaling", "status": "TAME study funded ($65M+); enrolling 3,000+ participants aged 65-79; results expected 2026-2028", "developer": "AFAR (American Federation for Aging Research), Nir Barzilai (Einstein)" }, { "id": "LONG-006", "name": "Telomere Extension", "type": "Genomic stability", "description": "Extending telomeres (protective chromosome caps that shorten with each cell division) to delay cellular senescence. Short telomeres are a hallmark of aging.", "mechanism": "Telomerase gene therapy (AAV-TERT) or transient mRNA delivery of TERT", "status": "BioViva CEO received telomerase gene therapy (2015, unverified); Libella Gene Therapeutics clinical trial in Colombia; no FDA-approved treatment", "developer": "BioViva, Libella Gene Therapeutics, Sierra Sciences" }, { "id": "LONG-007", "name": "Growth Differentiation Factor 11 (GDF11)", "type": "Parabiosis-derived factor", "description": "A circulating protein that declines with age. Parabiosis experiments (sharing blood between young and old mice) suggested GDF11 rejuvenates heart, muscle, and brain. Results debated.", "mechanism": "Rejuvenates aged stem cells and tissue function; exact mechanism debated", "status": "Controversial - some groups couldn't replicate; Alkahest (now Grifols) developing plasma-derived therapies", "developer": "Alkahest/Grifols, Wyss-Coray lab (Stanford)" }, { "id": "LONG-008", "name": "Klotho Protein", "type": "Circulating longevity factor", "description": "A protein that declines with age. Mice with extra Klotho live 20-30% longer. Klotho enhances cognition and may protect against neurodegeneration.", "mechanism": "Regulates mineral metabolism, reduces oxidative stress, enhances synaptic plasticity and cognition", "status": "UCSF showing Klotho boosts cognition in old monkeys (2023); human trials being planned", "developer": "UCSF (Dena Dubal), Klogene Therapeutics" } ], "biotech_tools": [ { "id": "BTOOL-001", "name": "AlphaFold / AlphaFold3", "type": "Protein structure prediction", "description": "DeepMind's AI that predicts 3D protein structures from amino acid sequences. AlphaFold2 solved the 50-year protein folding problem; AlphaFold3 predicts protein-ligand, DNA, RNA interactions.", "application": "Drug design, enzyme engineering, understanding disease mutations", "developer": "Google DeepMind / Isomorphic Labs" }, { "id": "BTOOL-002", "name": "CRISPR-Cas13 (RNA Editing)", "type": "Gene editing tool", "description": "Targets RNA instead of DNA, enabling transient gene regulation without permanent genome changes. Safer for therapeutic use as effects are reversible.", "application": "Viral infection, RNA splicing disorders, transient gene knockdown", "developer": "Astellas (acquired Editas RNA program), Aera Therapeutics" }, { "id": "BTOOL-003", "name": "Base Editing", "type": "Gene editing tool", "description": "Precise single-nucleotide changes without double-strand breaks. Converts C→T or A→G with minimal off-target effects. Verve Therapeutics using base editing to permanently lower cholesterol.", "application": "Point mutation diseases, cardiovascular risk reduction, sickle cell disease", "developer": "Beam Therapeutics, Verve Therapeutics, Prime Medicine" }, { "id": "BTOOL-004", "name": "Prime Editing", "type": "Gene editing tool", "description": "Search-and-replace genome editing that can make any small edit (substitutions, insertions, deletions) without double-strand breaks or donor DNA templates.", "application": "Precise correction of disease-causing mutations", "developer": "Prime Medicine (IPO 2022); David Liu lab (Broad Institute)" }, { "id": "BTOOL-005", "name": "Spatial Transcriptomics", "type": "Analytical tool", "description": "Measuring gene expression while preserving spatial location in tissue. Reveals cellular neighborhoods and tissue organization at unprecedented resolution.", "application": "Cancer microenvironment, brain cell atlas, developmental biology", "developer": "10x Genomics (Visium, Xenium), Vizgen (MERFISH), NanoString (CosMx)" } ], "regenerative_medicine": [ { "id": "REGEN-001", "name": "iPSC-Derived Cell Therapies", "type": "Cell therapy", "description": "Using induced pluripotent stem cells to generate replacement cells for damaged tissues. Japan leads with the first iPSC-derived therapies approved.", "application": "Macular degeneration, Parkinson's, heart failure, spinal cord injury", "status": "iPSC-derived corneal cells (2023) and NK cells (2024) approved in Japan; many trials globally" }, { "id": "REGEN-002", "name": "3D Bioprinting of Organs", "type": "Tissue engineering", "description": "Layer-by-layer printing of living cells and biomaterials to create functional tissues and eventually whole organs for transplant.", "application": "Skin grafts, cartilage, blood vessels, kidney, liver, heart", "status": "3D-printed ear (3DBio/Princeton, 2022) and skin (POIETIS) in clinical use; whole organs still years away" }, { "id": "REGEN-003", "name": "Exosome Therapy", "type": "Paracrine signaling", "description": "Using extracellular vesicles (exosomes) from stem cells to deliver regenerative signals without the risks of cell transplantation.", "application": "Wound healing, cardiac repair, neuroprotection, hair growth", "status": "Cosmetic applications commercial; clinical trials for heart failure and wound healing" }, { "id": "REGEN-004", "name": "Gene Therapy for Regeneration", "type": "Gene therapy", "description": "Delivering genes that promote tissue regeneration (e.g., VEGF for blood vessels, neurotrophic factors for nerves) using viral or non-viral vectors.", "application": "Heart failure, peripheral artery disease, spinal cord injury", "status": "Adstiladrin (adenoviral IFNα2b for bladder cancer) approved; regenerative gene therapies in Phase 2-3" } ], "bioethics": [ { "id": "BETH-001", "name": "Human Germline Editing Moratorium", "topic": "Gene editing ethics", "description": "International consensus against heritable human genome editing until safety and societal implications are resolved. He Jiankui's 2018 CRISPR babies violated this consensus.", "controversy": "Potential to eliminate genetic diseases vs. risk of eugenics, unintended consequences, and inequality", "regulation": "73 countries ban or restrict heritable genome editing; WHO global governance framework (2021)" }, { "id": "BETH-002", "name": "Synthetic Biology Biosecurity", "topic": "Dual-use research", "description": "The same tools that enable beneficial synthetic biology (DNA synthesis, gene editing) could be used to create harmful pathogens. DNA screening and biosecurity frameworks are evolving.", "controversy": "Open science vs. security; democratization of biotech increases both innovation and risk", "regulation": "US DNA synthesis screening guidelines (2024); HHS Tier 1 select agent oversight; IBBS international biosecurity" }, { "id": "BETH-003", "name": "Longevity Inequality", "topic": "Social justice", "description": "If anti-aging therapies work, they may initially be available only to the wealthy, exacerbating health and lifespan inequality.", "controversy": "Life extension as a human right vs. luxury good; who pays for longevity treatments?", "regulation": "No specific regulation; Medicare/insurance coverage debates will intensify as therapies emerge" } ] } }